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Abstract 
Despite 30 years of research dedicated to the development of an HIV-1 vaccine, a 
successful candidate capable of elicitation of neutralizing antibodies against the 
virus has not yet emerged. The Env gp120 mutation rate is very rapid, however in 
order to maintain its binding-site towards CD4 receptor, certain crucial residues 
must be conserved within the viral strains, making it an interesting therapeutic 
target. 
This thesis describes the synthesis of discontinuous gp120 epitope mimics with a 
novel cyclisation linker, which was applied to improve the solubility and 
purification of the constructs. For the mimicry of gp120, cyclic peptides mimicking 
the discontinuous epitopes were assembled on a molecular scaffold. The 
synthesized linear and cyclic peptides, and final constructs with cyclic peptides 
assembled on a molecular scaffold were analysed by 1H NMR and CD spectroscopy. 
These spectroscopic methods allowed to gain a deeper understanding of the 
secondary structure of the synthesized compounds. It was found that cyclisation 
constrained the peptides, when compared to their linear counterparts. The NMR 
spectra of the final gp120 mimics were superimposed on each other and it was 
found, that two out of three compounds were almost identical. CD-spectrometry 
confirmed the results obtained by NMR. 
Since binding studies of the synthesised gp120 mimics required access to CD4 and 
gp120 proteins, therefore approaches towards expression, purification and 
characterisation of these proteins were made. However, the challenging refolding 
of CD4D12 resulted in obtaining a heterogenous mixture of properly folded and 
misfolded protein. The expression of gp120 in mammalian cells was low-yielding 
and this protein could not be produced in an amount needed for binding studies. 
A reliable and reproducible technique was needed to evaluate binding of gp120 
mimics to CD4 receptor. SPR was chosen to study the kinetics of the constructs. 
Careful optimisation of the experimental conditions yielded in a highly 
reproducible method for the evaluation of gp120 discontinuous mimics. 
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1 Introduction 
1.1 A brief history of vaccination 
The vaccines developed over the first two hundred years since Jenner’s lifetime 
represent one of the brightest chapters in the history of science. Their striking 
impact on human’s longevity and health is best illustrated by the fact that 
smallpox, once a deadly disease which is estimated to have killed up to 300 million 
people during the 20th century alone, was eradicated in 1979.[1] Global efforts 
towards eradication of polio has reached its final stages, while successful control 
of measles makes it another potential target for eradication.[2][3] Over the course 
of 20th century other vaccines protecting against once fatal diseases, such as 
diphtheria, pertussis, tetanus and several other, were developed.[4] Pasteur’s 
innovative idea of injecting live-attenuated or inactivated pathogens, has been 
further developed and a wide range of new methods and approaches are used 
nowadays. Indeed, the vaccination development has moved away from Pasteur’s 
“three Is paradigm” (isolate, inactivate, inject) towards rational design.[5] Despite 
these achievements, infections such as malaria, tuberculosis and HIV, still pose a 
great threat, and development of vaccines against them have been so far 
unsuccessful. Current challenges include development of novel, effective vaccines 
that would target these complex pathogens, be cost-effective and could be used 
widely enough to achieve their maximum impact.[2] 
1.2 Human Immunodeficiency Virus 
A chronic infection with human immunodeficiency virus-1 (HIV-1) is the main cause 
of the acquired immunodeficiency syndrome (AIDS) - one of the most ravaging 
pandemics in the human history.[6] The HIV epidemic emerged as a result of 
zoonotic transmission of the simian immunodeficiency virus (SIV) from African 
primates. SIVs crossed species from chimpanzees and sooty mangabeys to humans 
and adapted to yield HIV-1 and HIV-2.[7] It is estimated that in 2017 approximately 
37 million people were living with HIV/AIDS worldwide and that more than 40 
million people have died from AIDS-related illnesses since the start of the 
epidemic in the 1980s. In 2017 21.7 million people had access to the antiretroviral 
therapy (ART), resulting in decreased mortality rates globally (numbers based on 
UNAIDS fact sheet 2018).[8] Although, due to ART, it is now possible to live with 
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HIV, the treatment is lifelong, costly and does not eradicate the infection due to 
a latent viral reservoir. Thus, prevention of HIV onset by a prophylactic 
vaccination would be extremely beneficial. Despite enormous worldwide efforts 
directed to the discovery of both preventive and therapeutic vaccines this goal 
still remains elusive. 
1.2.1 HIV entry – the fundamentals 
As any other virus, HIV can reproduce only by employing host cells machinery. The 
replication cycle begins with the adhesion of the virus to the host cell, followed 
by fusion of the cell membrane with the viral envelope (Env) and release of the 
HIV capsid into the cell. This series of complex protein-protein interactions can 
be divided into three phases (Figure 1). 
The entry process begins with binding of the envelope spikes to their primary 
receptor on the surface of T lymphocytes, CD4. Upon binding, gp120 undergoes 
conformational rearrangements of V1/V2 and subsequently V3 that allow binding 
to the co-receptor – either C-C chemokine receptor type 5 (CCR5) or C-X-C 
chemokine receptor type 4 (CXCR4). Moreover, a bridging sheet, a structure 
comprised of two double-stranded β-sheets that were previously spatially 
separated, is formed because of the binding to CD4. Binding of the co-receptor 
then triggers fusion of the cell and viral membranes. During this process, the 
fusion peptide (FP) of gp41 inserts into the host cell membrane, followed by 
6-helix bundle formation that pulls together the membranes of both cells. This 
completes the membrane fusion, and results in the formation of a fusion pore, 
which is followed by the delivery of the viral contents into the host cell 
cytoplasm.[6] 
Once inside the cell, the viral enzyme reverse transcriptase (RT) converts the viral 
RNA into DNA, which then can be fused with the genome of the host (provirus). 
During cell division, both DNA of the host and proviral DNA are replicated. The 
proviral DNA serves as a template for transcription of viral RNA which afterwards 
is translated to yield the viral proteins. A final infectious virion is formed after 
viral-particle budding and release.[6][9][10] 
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Figure 1 HIV-1 entry mechanism. Adapted from [6][10]. 
 
1.2.2 Structure of gp120 
HIV is an enveloped virus, which contains two single-stranded positive-sense RNA 
copies inside of its capsid. The glycoprotein gp120 subunit is a significant part of 
the envelope spikes on the HIV-1 surface.[11] The envelope spikes are formed by 
trimeric heterodimers and consist of three subunits of gp120, a 120 kDa 
glycoprotein present on the outer surface of the virus, and three subunits of the 
transmembrane glycoprotein gp41. The complex is formed by cleavage of a 
polyprotein precursor – gp160.[12] These two Env glycoproteins are essential to 
initiate the infection process of the virus by binding to the CD4 receptor, however, 
it is gp120 that participates in the binding event directly. 
Gp120 is a heavily glycosylated glycoprotein, it is estimated that approximately 
half of its molecular weight is comprising N-linked glycans (20-35 N-glycosylation 
sites) with a small contribution of O-linked sugars. Biochemical and mass 
spectrometry studies have revealed that the majority of these glycans comprise 
the mannose types – Man-5- and Man-9. The glycans contribute to the correct 
folding of the protein and shield the immunogenic epitopes of gp120.[13][14] 
Gp120 contains five relatively conserved domains (C1-C5) which are interspersed 
by five variable loops (V1-V5), named for their relative genetic heterogeneity. 
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Regions V1-V4 form surface-exposed loops comprising disulphide bridges at their 
bases. The variable regions are responsible for co-receptor binding (especially V3) 
and play role in evasion from the immune system. The variable regions V1/V2 and 
V3 shield the conserved CD4-binding site on gp120. The role of V4 and V5 is 
unclear, however V4 region is probably needed for the correct folding of gp120.[15] 
Highly conserved cysteine residues present in the primary structure of gp120 
contribute to the disulphide formation that is crucial to develop the correct 
tertiary structure.[12] Conserved residues, specifically C1, C3 and C4 determinants 
form the CD4 binding-site. Structural studies performed by Kwong et al.[16] have 
identified the amino acid sequences of the discontinuous loops that form the CD4 
binding-site. These are: 454LTRDGGK460, 424INMWQEVGKA433, 365SGDDPEIVT373. The 
high degree of conservation in the CD4 binding-site makes it an attractive target 
for broadly cross-reactive neutralization studies. Mimicry of the recognized 
discontinuous epitopes is an interesting starting point in the design of a potential 
vaccine against HIV-1. 
1.2.3 HIV evasion techniques and epitope design approaches 
Despite extensive global research efforts dedicated to finding an HIV vaccine there 
still have not been any therapeutic advances. The development of a protective 
vaccine is an extremely challenging task due to a variety of genetic and structural 
evasion techniques that HIV employs to escape the host immune system (Figure 
2). These evasion mechanisms include: 
1) the genetic diversity with sequence conservation limited to receptor-binding 
sites;[17] 
2) the highly error-prone replication and remarkable capacity to accumulate 
mutations allow for rapid emergence of escape variants under selection pressure 
of antibodies and drugs;[17] 
3) the receptor-binding site is sterically occluded by variable surface exposed 
loops;[17][18] 
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4) the extensive glycosylation of the envelope restricts access to conserved 
binding-sites (glycan shield);[17][19][20] 
5) the glycan shield allows the virus to masquerade itself as a host protein and 
modulate interactions with the host immune system;[17][19] 
6) the CD4 binding site is available only for a very short period of time as a 
transient intermediate between the epitope being completely shielded and 
displayed just before binding its target. Therefore, antibodies have only a 
relatively narrow “window of opportunity”;[21] 
7) the presence of non-functional envelope spikes, such as gp120-gp41 monomers, 
gp41 stumps or uncleaved gp160 precursors, which may divert the immune 
response from functional targets;[22][23] 
8) the low density of spikes on the HIV-1 Env limits interspike cross-linking by 
antibodies;[24][25] 
9) the conformational masking – the antibodies against the CD4-binding site 
encounter a high energetic barrier not found in any other anti-gp120 antibodies.[26] 
 
Figure 2 Architectural and structural envelope-dependent defensive mechanisms of HIV-1. Adapted 
from [27]. 
 
These elaborative defensive mechanisms impede the design of an effective 
vaccine against HIV because of several reasons. The most evident one is that 
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individuals infected with HIV do not develop the natural immune response, 
therefore vaccines cannot mimic natural immunological mechanism. During the 
course of infection, the antibodies elicited are mostly directed against variable 
and accessible Env loops (immunodominant) rather than less accessible, conserved 
epitopes, such as the receptor and co-receptor binding sites. Since HIV targets 
and infects the immune cells it leads to progressive destruction of the immune 
system. Moreover, the integration of HIV-1 DNA into the host genome results in a 
latent pool of infected cells which conceal the virus from the immune system. The 
different strains of the virus present enormous antigenic variability and the degree 
of antibody affinity maturation required to neutralize HIV-1 is much higher 
compared with antibodies directed at other viruses.[28] Moreover, the vaccine 
candidates are usually designed based on a unique HIV strain, while an ideal 
vaccine should not be strain-specific. 
Traditional approaches have proved unsuccessful due to the fact, that the 
immunodominant viral epitopes are mutable while the conserved epitopes 
necessary for infection are not sufficiently immunogenic.[29] Several different 
strategies were approached to improve the immunogenicity of the epitopes 
recognized by mAbs. One of the approaches in the design of the epitopes include 
hyperglycosylation of HIV gp120 to mask undesired epitopes and direct the 
immune response against conserved epitopes that are important for CD4 
binding.[30] Other strategies are based on amino acid substitutions[31] or 
stabilization of the CD4-bound state by introducing crosslinks or deleting variable 
loops.[32] An interesting strategy includes immunofocusing, e.g. decreasing the 
ability of the CD4 binding-site to bind to non-neutralizing antibodies while 
retaining the capacity to bind to broadly neutralizing mAbs (bnmAbs).[33] 
Apart from these different epitope-design-based approaches, other tactics 
towards a therapeutic HIV vaccine were employed (Table 1), among them: 
1) DNA vaccines - designed to encode antigens, which once produced would 
stimulate an immune response after administration. This approach is safe and has 
demonstrated promising immunogenicity in animal models. These results 
encouraged the development of the DNA-based HIV-1 vaccine PENNVAX. After 
vaccination with PENNVAX with IL-12 plasmid, it was found that most subjects 
developed CD4+ or CD8+ T-cell responses.[34] 
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2) Dendritic cell vaccines – possess an ability to ensure that the antigen reaches 
the cells most able to activate protective immune responses. However, this 
approach has the disadvantage of being time-consuming and expensive. An 
example of dendritic cells vaccine is the DCV2/MANON07-ORVACS which consists 
of autologous dendritic cells pulsed with whole heat-inactivated HIV-1. It 
demonstrated immunogenicity associated with a control of viral replication in a 
phase I clinical trial. After administration of the vaccine the viral load was 
significantly reduced, which was probably a result of increased HIV-1 specific 
T-cell responses.[35] 
3) Subunit vaccines – consist of peptides derived from conserved domains within 
HIV-1, without introduction of the entire viral particles. As an example of this 
approach, the Vacc4X subunit vaccine consists of four modified peptides derived 
from the conserved domains within the HIV-1 p24 group-specific antigen (gag) 
protein containing major histocompatibility complex (MHC) class I and class II 
restricted epitopes. It induced T-cell responses in 90% of patients which were 
associated with reduced viral loads. Seven years after immunization, CD4+ and 
CD8+ T-cell responses were still observed in 95% and 68% of subjects, respectively. 
These studies provided evidence for long-lasting T-cell memory response to a 
peptide-based immunotherapeutic candidate for HIV-1 infected patients.[36] 
4) Viral vector vaccines – especially adenovirus and pox vaccine, created 
considerable interest due to low cost and ease of manufacture. The principle of 
action is based on induction of expression of desired genes encoding for antigens, 
which in consequence would result in prophylactic immunity or T-cell immune 
responses, that may have a therapeutic effect. The flagship example comes from 
a 2009 trial of RV144 canarypox-prime glycoprotein 120 boost vaccine, which 
reported estimated vaccine efficacy of 31.2%. This level of efficacy is insufficient 
for deployment of the vaccine; however it was the first example of such a response 
and encouraged research in this field, as it suggested that a preventive vaccine 
could be made.[37] 
Altogether, above examples demonstrate that the HIV/AIDS therapeutic and 
preventative vaccine field is expanding and that new approaches, which differ 
from traditional methods in the choice of antigen and delivery system are sought. 
The Holy Grail of HIV vaccine research remains to be the development of 
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immunogens capable of induction of broadly neutralizing antibodies that could 
protect against the large number of different strains of HIV circulating globally. 
Protein- and peptide-based vaccines have the advantage of being safe, cheap and 
stable. This would be beneficial as the HIV vaccine would have to be distributed 
among low-and middle-income countries, where they are likely to achieve their 
maximum impact. Moreover, the relatively simple design allows to characterize 
methodically and carefully what impact on the immune system they have 
compared to more complex vaccines that showed several complications that were 
problematic to identify. 
Table 1 Summary of selected anti-HIV therapeutic vaccines in HIV-1 positive and healthy individuals. 
Vaccine (type + 
name) 
Vaccine 
(constituent) 
Immune responses Viral load Year of 
publication 
DNA Vaccine 
PENNVAX 
Three plasmids 
expressing Env, 
Gag and Pol; plus 
plasmid containing 
IL-12 
Developed CD4+ 
and CD8+ T-cell 
responses after 
repeated 
vaccination 
Uninfected 
volunteers 
2013 
DC vaccine 
DCV2/MANON07-
ORVAC 
Autologous DC 
pulsed with whole 
inactivated HIV-1 
Increased HIV-1 
specific T-cell 
responses 
Decrease of 
plasma viral load 
setpoint ≥1 log 
was observed in 
vaccinated groups 
and was 
associated with a 
consistent 
increase in HIV-1 
specific T cell 
responses. 
2013 
Subunit vaccine 
Vacc4X 
Four modified 
peptides from Gag 
protein containing 
MHC class I and II 
restricted 
epitopes 
Delayed-type 
hypersensitivity 
(DTH) reactions. T-
cell responses in 
80-90% of patients 
allowing for 
structured 
treatment 
interruption 
Significantly 
improved viral 
load ratios 
2012 
Viral vector 
vaccine 
RV144 
Recombinant 
canary pox viral 
vector engineered 
to express HIV-1 
Gag and Pro and 
CRF01_AE HIV-1 
gp120 
Weak evidence of 
increased CD4+ T 
cell count upon 
HIV-1 infection 
No overall 
statistically 
significant 
reduction in pre-
ART viral load 
upon HIV-1 
infection 
2009 
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1.2.4 Mimicry of the discontinuous CD4-binding site of HIV-1 gp120 
Despite 30 years of research dedicated to the development of an HIV-1 vaccine, a 
successful candidate capable of elicitation of neutralizing antibodies against the 
virus has not yet emerged. A number of previously discussed evasive mechanisms 
of HIV-1 hampers the discovery of an effective vaccine. The Env gp120 mutation 
rate is very rapid, however in order to maintain its binding-site towards CD4 
receptor, certain crucial residues must be conserved within the viral strains, 
making it an interesting therapeutic target. An ever-growing number of HIV Env 
X-ray crystal structures in conjunction with neutralizing antibodies and the CD4 
receptor, provide detailed structural information, which combined with 
knowledge about previous attempts in the design of a vaccine candidate, can be 
used as a starting point. The key binding sites of the conserved gp120 regions have 
been identified to be three discontinuous peptide sequences. These are: 
Loop 1: 454LTRDGGK460, 
Loop 2: 424INMWQEVGKA433, 
Loop 3: 365SGDDPEIVT373. 
The residues contributing in majority to the binding were identified to be Trp427, 
Asp368 and Glu370.[16] The conserved binding site is buried within a hydrophobic 
core of gp120 and is shielded by variable regions (in particular V1, V2 and V3) from 
efficient antibody recognition. Several studies have shown that during early stages 
of HIV infection the non-neutralizing antibodies are elicited against the more 
accessible V1/V2 region making it an immunodominant epitope (Figure 3).[38][39] 
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Figure 3 X-ray structure of gp120-CD4-antibody complex. 
Gp120 (yellow) binds with its discontinuous epitopes (blue, red and green) to CD4 (cyan). On the 
left-hand side, the antibody (grey and pink) binds to the immunodominant V3 loop. (PDB entry: 
1GC1). 
Due to its high degree of conservation, the CD4 binding-site is an attractive target 
for broadly cross-reactive neutralising antibodies. Such antibodies could be 
elicited by a synthetic mimic (section 1.6) of the gp120 conserved CD4 binding-site 
in which only the important for the binding event residues would be displayed. 
Such a mimic could be made by assembly of the cyclic peptides (section 1.5) on a 
molecular scaffold (section1.4). In this way the viral evasive mechanisms such as 
the variable shielding regions and the glycan shield would be omitted. However, 
reconstruction of the HIV-1 discontinuous epitopes and presenting them in the 
required conformation at the surface of the scaffold is a challenging task. 
The entry of HIV into the cell is dependent on protein-protein interactions (PPIs). 
PPIs are an important feature of cell biology and an interesting target in drug 
discovery and will be discussed in more detail in paragraph 1.3. 
1.3 Protein-protein interactions 
Protein-protein interactions (PPIs) can be defined as the physical contacts 
between two or more proteins that are present in a cell or in a living organism in 
vivo.[40] They are involved in a number of key biological processes such as 
cytoskeletal remodelling, vesicle transport, and signal transduction.[41] It is 
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evident that any dysfunctions in the network of protein interactions might lead to 
numerous pathological conditions[42] e.g. Huntington’s disease, osteoporosis, 
cancer, rheumatoid arthritis, and many other infectious or auto-immune 
diseases.[43][44] Therefore, inhibition or modulation of PPIs provide an attractive 
opportunity for drug discovery. 
1.3.1 Protein binding sites as complex structures 
Proteins use epitopes (hot spots, binding sites), short peptide sequences that are 
well defined in three-dimensional conformation, to bind to their targets and elicit 
biological response. PPIs may occur at the interface of two large protein surfaces 
that possess electrostatic and structural complementarity to one another.[45] The 
sites involved in these interactions are often flat and devoid of deep pockets that 
could be targeted by small molecules, which is one of the reasons why they are so 
difficult to target. The interface area ranges between 1200-2000 Å2,[46] however 
it is important to realise, that within this large surface only a subset of residues 
often clustered in the centre contributes to the binding energy. These hot spots 
are often shielded by residues that are not directly important to the binding event, 
however, they play a significant role in occluding bulk solvent from the hot spot, 
thereby creating suitable dielectric and solvation conditions (‘O-ring’ theory).[47] 
The resulting non-aqueous environment with decreased dielectric constant 
favours non-covalent interactions such as hydrogen bonding, π-π interactions, 
hydrophobic interactions and Van der Waals interactions. Analysis of a large 
protein database of alanine mutants (ASEdb) of heterodimeric protein-protein 
complexes revealed that tryptophan (Trp), arginine (Arg) and tyrosine (Tyr) are 
the most common residues found on the interface of protein dimers.[45][48] These 
three amino acids are capable of making multiple types of these favourable 
interactions (Table 2). 
 
 
12 
 
Table 2 Trp, Tyr and Arg interactions. 
Tryptophan aromatic π-interactions, a hydrogen binding donor, a large 
hydrophobic surface 
Tyrosine aromatic π-interactions, a hydrogen bonding ability, 
hydrophobic surface 
Arginine hydrogen bond network with up to five H-bonds and a salt-
bridge, pseudo-aromatic character, hydrophobic character 
 
Enormous efforts in the pharmaceutical industry and in the academia are being 
directed at targeting PPIs to inhibit or modulate them. However, this task is very 
challenging due to several limiting factors: 1) protein binding sites usually have a 
complex architecture and the crucial interacting residues are often unclear; 2) as 
mentioned before, the surface areas involved in forming PPIs are large, which is 
a serious challenge for small molecules to be competitive – the contact surface 
area they cover is approximately 300-500 Å2[49]; 3) most PPIs occur via 
discontinuous epitopes thus cannot be mimicked by simple synthetic peptides; 4) 
the majority of the protein-protein interfaces are relatively featureless, therefore 
selectivity becomes a difficult task; 5) biological assays that follow enzyme 
activity are not always applicable, therefore in many cases activity must be 
detected via more sophisticated techniques that monitor binding directly, e.g. 
isothermal titration calorimetry (ITC) or surface plasmon resonance (SPR).[50] The 
complex nature of the PPIs inspired researchers to broaden the spectrum of 
investigated molecules that could potentially modulate the protein interface 
which was believed to be ‘undruggable’ for a long time. There are three major 
categories of compounds employed to tackle this problem: fragment-inspired 
small molecules, protein epitope mimetics, and large recombinant 
macromolecules.[42] Inhibition of PPIs by small molecules has been extensively 
studied and successful attempts have increased considerably in the recent years 
with navitoclax and lifitegrast as examples of marketed agents and several other 
drugs being investigated in clinical trials.[49][51] Large recombinant 
macromolecules, due to their large chemical spaces, can mimic protein interface 
easier than typical small molecules, and therefore target a wide variety of 
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different PPIs. However, synthesis and large-scale production of large 
recombinant molecules is often difficult, time consuming and expensive. On the 
other hand, peptides and peptidomimetics are believed to have a great potential 
in modifying PPIs. Rational design based on the identified hot spot sequences allow 
to focus on the residues important for binding. Moreover, peptides can be 
chemically modified to obtain the correct spatial conformation and mimic protein 
structure. An increasing number of peptides and peptidomimetics targeting PPIs 
is reaching clinical trials.[52] A recent example involves a stapled peptide 
ALRN6924 targeting a tumour suppressor protein  p53 via MDMX/MDM2 antagonism. 
MDM2 and MDMX play a major role in oncogenesis as negative regulators of p53 
protein.[53] ALRN6924 is currently in Phase I clinical trial in advanced solid tumours 
and acute myeloid leukaemia.[54] However, the hydrophobic character of both 
peptides and macromolecules, which results in poor solubility and lack of 
intracellular penetration, presents a serious challenge to their application in vivo. 
PPIs occur via complex interactions between proteins and can be classified 
depending on the interaction and structural features of interacting proteins. In 
order to mimic effectively PPIs in the process of drug discovery, it is important to 
consider what type of PPIs is targeted. 
1.3.2 Classification of protein-protein interactions 
Protein-protein interactions can be classified in different ways, depending on the 
category being analysed.[55][56] 
I. Depending on the interacting peptide chains[55][56] 
PPIs may arise as a result of interaction between identical or non-identical 
oligomers, for example: 
a) homomeric, e.g. P22 Arc repressor, 
b) heteromeric, e.g. human cathepsin D, 
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II. Depending on the protomers stability and lifetime[55][56] 
Protein that obtain a quaternary structure are built of protomers. Protomer is a 
subunit of the heterooligomeric protein built of at least two associated 
polypeptides.[57] The protomers vary in their stability and lifetime: 
a) obligate PPIs (strong and long lived) – the protomers are not found as stable 
structures on their own in vivo, e.g. P22 Arc repressor dimer. 
b) non-obligate PPIs (weak and transient) – protomers can exist independently e.g. 
antibody-receptor, enzyme-inhibitor. 
III. Depending on the complexity of the binding epitopes (Figure 4)[49] 
PPIs can be classified by the complexity of the epitope interacting with the target 
protein: 
a) primary structure epitopes – short, continuous, linear peptides, e.g. the linear 
tripeptide Arg-Gly-Asp (RGD – epitope of fibrinogen) binds to the “I-like” domain 
of IIbIIIa;[58] the linear acetylated histone peptide binds to BRD4 bromodomain.[59] 
b) secondary structure epitopes – α-helix, β-sheet, or extended peptide, e.g. 
interactions between α-helix of p53 with MDM2 protein.[60] 
c) tertiary structure epitopes – multiple sequences requiring discontinuous binding 
sites, e.g. binding between interleukin 2 (IL-2) and interleukin 2 receptor α (IL-2-
RA).[61] 
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Figure 4 Classification of epitopes based on their complexity.  
Structures shown are BRD4 (raspberry red) – histone (marine blue) (PDB entry: 2WP1), MDM2 
(palecyan) – p53 (magenta) (PDB entry: 1YCR), IL-2 (orange) – IL-2R (blue) (PDB entry: 1Z92). 
Adapted from [49]. 
IV. Depending on the structural features of interacting proteins (Figure 5)[56] 
Structurally different proteins can participate in PPIs. Moreover, the PPIs can 
induce structural change in the proteins. Therefore, PPIs can be classified 
according to the structural features of interacting proteins: 
a) The interaction via discontinuous epitope between two globular proteins 
proceeds without substantial structural changes (Figure 5 a). 
b) The interaction between two globular proteins involves one or both proteins 
undergoing a substantial conformational change (Figure 5 b). 
c) PPIs involve an interaction between a globular protein and a single peptide 
chain either with a substantial conformational change, or without a substantial 
conformational change (Figure 5 c and d, respectively). 
d) PPIs involve an interaction between two peptide chains (Figure 5 e). 
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Figure 5 Structural classification of protein-protein interactions.  
In the upper part of the figure simplified illustrations are used to represent protein/peptide binding 
partners, and in the lower part the crystal structures of the exemplary interactions are shown. a) an 
interaction via discontinuous epitope between two globular proteins without structural changes (PDB 
entry: 2CCY), b) an interaction between two globular proteins involving conformational change to 
form binding site (PDB entry: 1Z92), c) an interaction of a rigid protein with a flexible peptide chain 
(PDB entry: 2DYH), d) an interaction between a flexible globular protein and a peptide (PDB entry: 
2XA0), e) an interaction between two peptides (PDB entry: 1NKP). Adapted from [56]. 
It is evident, that the main function of proteins is formation of complexes with 
different ligands, such as other proteins or peptides in order to elicit cellular 
processes that are crucial for a living organism. Formation of these complexes can 
be studied by various biophysical methods to characterise PPIs, their role and 
mechanism of action.  
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1.3.3 Biophysical methods for characterizing protein-protein 
interactions 
A variety of experimental methods have been developed to study protein-protein 
interactions, among them biophysical, biochemical or genetic-based assays. An 
overview of the key biophysical methods for detection of PPIs is described in this 
chapter. Each type of a method has its advantages and disadvantages in terms of 
sensitivity, specificity or sample consumption, which were summarised in Table 
3. 
1) Surface plasmon resonance (SPR) 
SPR-is a label-free method commonly used in drug discovery. The phenomenon 
occurs in thin conducting films at the interface between two media (the glass of 
the sensor chip and the sample solution) of different refractive index. One of the 
interaction partners (ligand) is immobilised on the surface of the sensor chip 
(typically a gold chip, Figure 6, top) while the other molecule (analyte) is 
dissolved and injected to flow over the sensor surface. When the chip is 
illuminated with polarized light at a certain angle of incidence, a proportion of it 
penetrates through the metal film as an evanescent wave into the medium of 
lower refraction index. As a result, the energy is absorbed via the evanescent 
wave field, which is observed as a drop in the intensity of reflected light, which 
can be detected at a certain angle (SPR angle, Figure 6, bottom).The interaction 
between the ligand on the chip surface and the analyte in the solution results in 
a change of refractive index at the sensor surface, which is proportional to the 
change in mass concentration. The alteration in the SPR angle can be measured 
over time, providing information about the kinetics and the binding affinity of 
interacting molecules.[62][63] 
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Figure 6 Illustration of a principle of surface plasmon resonance. Adapted from [64]. 
 
2) Fluorescence polarization (FP) 
In FP the movement of fluorescent compounds is observed. Molecules move and 
rotate in a solution, and their rotation rate is highly dependent on the mass. 
Therefore, large molecules or complexes of two interacting molecules rotate 
slower than small molecules or individual binding partners. When a fluorophore is 
excited by polarized light, it emits light with a certain degree of polarization. 
Small molecules capable of fast rotation emit depolarized light, while rotation of 
large molecules/complexes is decreased, therefore the emitted light remains 
polarized. In an FP assay, typically a small molecule is labelled with a fluorophore 
and its association and dissociation rates when binding to a large molecule are 
measured. Complex formation causes an increase in FP signal which can be 
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measured by a microplate reader. By plotting the FP signal against several 
concentrations of the labelled molecule a binding curve can be obtained and the 
dissociation constant (Kd) can be determined from the curve.[64][65] 
3) Isothermal titration calorimetry (ITC) 
All chemical reactions proceed with an endothermic or exothermic change in the 
energy which is detected in ITC. One of the bio-macromolecules (e.g. a protein) 
is present in a sample cell, the temperature of which is controlled and coupled to 
a reference cell. When the ligand of interest is titrated in small aliquots, the heat 
is absorbed or released over the course of titration and can be directly measured. 
The main parameters measured by ITC include: association constant (Ka), 
enthalpy change (∆H), reaction stoichiometry (n), heat capacity change (∆Cp), 
free energy change (∆G) and entropy change (∆S).[66][67] 
4) Nuclear magnetic resonance (NMR) 
Nuclear magnetic resonance is a physical phenomenon - a nucleus that possesses 
spin is placed in a strong magnetic field adopts allowed orientations of different 
energy. Upon application of electromagnetic radiation, the nuclei absorb the 
energy and are promoted to a higher energy level. Once the pulse is finished, the 
nuclei return to its lowest energy level with emission of radiation which can be 
detected. The frequency at which nucleus resonates depends on its chemical 
environment. NMR is a powerful technique which allows characterization of the 
structures of biological macromolecules and to analyse protein-ligand interactions 
by comparing NMR shifts in their free and bound states.[68][69] 
5) Circular Dichroism (CD) 
Circular dichroism spectroscopy is a useful technique for studying secondary 
structure of proteins and peptides, as well as protein-protein interactions. The 
counter-clockwise (left, L) and clockwise (right, R) circularly polarized light is 
passed through a chiral sample and absorbed to different extents. This difference 
can be measured and reported in unit of ellipticity (θ) in degrees. CD spectra can 
be recorded in far UV region (190-250 nm) where absorption arises from the amide 
groups on the protein backbone thus providing information on the secondary 
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structure including an α-helix, a β-sheet and a random coil structures (Figure 7). 
On the other hand, the absorption in the near UV region (260-320 nm) arises from 
the absorption by aromatic amino acids and disulphide bonds, therefore offering 
insight into tertiary structure of the sample of interest. The analysis of the 
differences in the spectra in a free and bound-state provides valuable information 
about conformation changes accompanying PPIs.[70][71] 
 
Figure 7 An illustration of far UV CD spectra, which are typical for various protein secondary 
structures. 
Solid curve – α-helix; long dashes – antiparallel β-sheet; dots – type 1 β-turn; dots and dashes – 
irregular structure. Adapted from [72]. 
6) Microscale Thermophoresis (MST) 
MST is a novel and highly sensitive technique that provides information about 
affinity and thermodynamics (Kd, n, ∆H, ∆S) of the interaction between binding 
molecules. In MST the movement of fluorescent molecules (labelled or intrinsically 
fluorescent) through a microscopic temperature gradient (thermophoresis) is 
monitored. The movement is highly dependent on various molecular properties, 
such as size, charge, hydration shell, conformation.[73] 
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Table 3 Advantages and disadvantages of the described biophysical methods for study of protein-
protein interactions. 
Technique Advantages Disadvantages 
SPR label-free, real time kinetic 
measurement, consumes 
several μg of sample per chip 
immobilisation of the ligand 
might interfere with the 
binding event 
FP relatively inexpensive 
equipment (compared to ITC, 
SPR), simple protocol 
(mix-and-read) 
autofluorescence and light 
scattering, anomalous 
polarisation from 
aggregation-based non-specific 
binding might confound the 
calculations 
ITC a non-destructive technique 
(does not require 
immobilisation or labelling of 
the interacting partners), high-
precision and reproducibility 
(errors typically within 5%) 
long preparation time (samples 
should be dialysed in the same 
buffer to avoid buffer 
mismatch), high sample 
consumption (several hundred 
μg per binding assay) 
NMR high structural resolution experimental time, high sample 
consumption, long time to 
analyse the obtained spectra, 
internal protein labelling 
required, in routine practice 
the method is limited to 
proteins with low molecular 
masses (less than 30 kDa) 
CD label-free, quick assay, non-
destructive technique 
low structural resolution 
MST fast measurement times, low 
sample consumption, 
immobilisation-free 
fluorescent labelling required 
 
The described biophysical methods can also be successfully applied to study the 
activity of the PPI mimics. Such mimics can be made by assembly of the peptides 
corresponding to the protein epitope on a molecular scaffold, that would display 
them in a bioactive spatial conformation. 
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1.4 Molecular scaffolds 
1.4.1 Molecular scaffolds in protein mimicry 
As it was discussed in detail in section 1.3, correct three-dimensional presentation 
of epitopes results in binding to the target protein and elicitation of the biological 
response. Continuous epitopes consist of a linear amino acid sequence, while more 
complicated discontinuous epitopes are built of several peptides strands that are 
relatively far away from each other in the primary structure of a protein, however 
are close to each other in the three-dimensional conformation of the protein 
(Figure 8). 
 
Figure 8 The continuous and discontinuous epitopes. 
 
In theory, the simplest approach for mimicry of discontinuous epitopes is to 
combine different peptide segments into a single construct. However, short linear 
peptide motifs are often flexible and disordered, therefore induction or 
stabilization of the desired secondary structure is required.[52] Utilization of a 
molecular scaffold may represent the best approach to present critical recognition 
functionalities in the proper bioactive spatial conformation and it is a commonly 
used tool (Figure 9). 
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Figure 9 Mimicry of a discontinuous epitope by attachment of the corresponding cyclic peptides onto 
the molecular scaffold. 
 
A plethora of different molecular scaffolds was reported in the recent years. One 
of the first examples was the Template-Assembled Synthetic Protein (TASP) 
scaffold by Mutter et al[74], which was based on a peptide template (Figure 10 a). 
Initially it allowed for introduction of four identical peptides, however, it was 
further developed to introduce three different peptide loops by using three 
different protecting groups (Figure 10 g).[75] This concept was pushed even further 
by Dumy et al.[76] by implementation of four different protecting groups in four 
positions to create the Regioselectively Addressable Functionalised Template 
(RAFT) scaffold, which allowed attachment of a different moiety in each position 
(Figure 10 h). 
In another early example a lysine core extended with peptidic arms has been 
synthesized to create the Multiple Antigenic Peptide (MAP) scaffold (Figure 10 b). 
MAP allows for the introduction of a high density of peptide antigens.[77][78] This 
idea was further explored by Lo-Man et al. who used the lysine core to create a 
dendrimeric Multiple Antigenic Glycopeptide (MAG) template for the attachment 
of glycopeptides (Figure 10 c),[79] which presented high immunogenicity in mice 
and in non-human primates.[80] 
Calix[4]arene is an example of a highly pre-organized non-peptidic scaffold, which 
allows for introduction of four albeit identical peptide loops (Figure 10 d). 
Multiple antigenic units are attached covalently to this multivalent construct, 
resulting in a better immunogenicity compared to the monovalent construct.[81] 
Apart from fully synthetic, organic scaffolds, a growing interest has been observed 
in the utilization of different biomolecules as scaffolds. For example, two 
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oligoguanosine strands were attached at C- and N-terminus of a peptide via click 
chemistry and these conjugates underwent the process of self-assembly in the 
presence of metal ions into a G-quadruplex (Figure 10 e). Dimeric assembly of 
the peptide-oligonucleotide conjugates (POCs) could in principle occur in either 
one or two faces of the complex depending on the parallel or antiparallel direction 
of oligonucleotide strands. However, it was shown that parallel topology is 
selectively formed.[82] Another example making use of biomolecules as scaffolds 
gaining attention is the utilization of miniature proteins – a class of oligopeptides 
characterized by their short sequence lengths and ability to adopt well-folded, 
three-dimensional structures. This class of compounds as potential therapeutic 
agents takes advantage of their small size and can form defined tertiary 
structures. Functional epitopes can be grafted onto the scaffold to obtain 
biomolecular recognition of therapeutically relevant targets.[83] As an illustration 
of this approach Silverman et al.[84] used agouti-related protein (AgRP), a 4 kDa 
cysteine-knot protein that has four disulphide bonds and four solvent-exposed 
loops, as a scaffold grafted with peptides capable of targeting ανβε integrins 
(Figure 10 f). Yeast display was used to generate a library of peptides with an 
RGD-integrin recognition motif that was flanked by randomized residues. In this 
way, the authors successfully designed highly specific miniature proteins that 
bound ανβε with sub-nanomolar affinity. 
Although there are several molecular scaffolds that permit multiple conjugations 
with peptides, in order to mimic discontinuous epitopes correctly, an orthogonally 
protected scaffold which allows for the controlled and stepwise introduction of 
ligands is often needed. 
One of the first examples of this new generation scaffolds were the modified TASP 
and RAFT scaffolds, which are discussed above (Figure 10 g, h). 
The highly pre-organised orthogonal cyclotriveratrylene (CTV) scaffold was 
recently developed in our group (Figure 10 i).[85] It was designed for subsequent 
ligation of three different cyclic peptides in order to achieve protein mimicry. It 
was used lately in the synthesis of highly pre-organised molecules bearing three 
different peptides mimicking complementarity determining regions (CDR) of the 
monoclonal antibody Infliximab. The prepared synthetic antibodies exhibited 
micromolar affinities towards tumour necrosis factor alpha (TNFα) protein. 
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Another example of a novel orthogonally protected scaffold developed in our 
group, which served as a starting point for the synthesis of an HIV vaccine 
candidate containing three different peptide fragments representing 
discontinuous epitopes of HIV-1 gp120, is the TriAzaCyclophane (TAC) scaffold. So 
far, the TAC-scaffold was used successfully in various studies involving papain 
inhibitors,[86] development of a whooping cough vaccine[86] and mimicry of gp120 
discontinuous epitopes.[87][88] Initially it was protected by Alloc, Fmoc and oNBS 
protecting groups, which allowed for a sequential introduction of peptides through 
the formation of amide bonds (Figure 10 j). However, this scaffold required 
utilization of protected amino acids, which might result in difficulties with 
solubility of the construct and further purification. To address these issues, two 
orthogonally protected and one unprotected alkyne moieties replaced previous 
protecting groups (Figure 10 k). This modification allows the application of Cu(I)-
catalyzed azide-alkyne cycloaddition (CuAAC) for the conjugation of unprotected 
peptide chains modified to contain an azide group. TES and TIPS were chosen as 
the protecting groups as these can be removed orthogonal to each other, which 
provides the control over the sequence and position in which peptides are 
attached. 
Recently, a similar approach to the previously mentioned orthogonally protected 
TAC scaffold was by published by Fabre et al (Figure 10 l).[89] At first, the scaffold 
also had a free alkyne arm and two arms protected by TES and TIPS. However, it 
was found that the TES group is unstable in high copper concentrations. Therefore, 
the TES-protecting group was exchanged by an Fmoc-protecting group, which 
allowed for coupling to aldehydes, which are often commercially available and 
are orthogonal with CuAAC chemistry. The final construct can be substituted by 
two different azides and an aromatic aldehyde, which extends the scope 
compared to the trialkyne-based scaffold. However, it was found that aliphatic 
aldehydes cannot be used for coupling, which is a substantial limitation. 
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Figure 10 Examples of (orthogonal) molecular scaffolds used in protein mimicry (PDB entry for 
miniature protein: 1HYK). 
 
1.5 Peptides and their modifications in drug discovery 
Peptides constitute one of the most promising platforms for drug development in 
the field of PPIs due to their bio-compatibility, chemical diversity and 
resemblance to proteins. However, it is well documented that linear peptides 
have certain features undesirable in therapeutic agents, namely: low stability 
towards proteolysis, negligible membrane permeability or oral bioavailability, 
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high clearance and metabolic instability. Moreover, they tend to form a disordered 
structure in water, whereas their binding target usually recognizes a specific 
conformation.[90][91] To tackle these problems, a variety of chemical modifications 
has been employed: cyclisation (increased stability), N-methylation (increased 
membrane permeability and stability), incorporation of unnatural amino acids 
(increased specificity and stability), attachment of polyethylene glycol polymer 
(reduced clearance) assorted structural constraints (e.g. disulphide bonds), 
“stapled” peptides (improved potency and specificity). Chemical modifications of 
peptides resulted in constructs that were less prone to proteolysis and obtained 
higher binding affinities and an entropy advantage in receptor binding compared 
to their more flexible linear counterparts. Reduction of conformational freedom 
enhances metabolic stability, bioavailability and specificity, thus providing 
promising lead compounds for drug development. Moreover, the continuous 
advances in solid-phase peptide synthesis, purification strategies and price 
reduction of amino acids, have enabled further exploration of peptide-based 
epitope mimicry.[91][92] 
Consequently, a growing interest in the peptides was observed in the recent years. 
Year 2017 noted the highest figure of 46 new drugs approved by the US Food and 
Drug Administration (FDA) in the last twenty-five years. Among them were five 
peptides and one peptidomimetic, which together accounted for 13% of the 
accepted drugs.[93] These molecules enable quick access to relatively 
underexploited higher molecular weight chemical matter that is beyond rule-of-
five.[94][95] Peptides can address larger and less hydrophobic surfaces involved in 
many PPIs.  
Short synthetic peptide sequences corresponding to the bioactive protein surface 
do not form thermodynamically stable protein-like structures in water. However, 
peptides can be induced to fold into protein-like bioactive conformations (strands, 
helices, turns) by cyclisation. Such constrained cyclic peptides can have protein-
like biological activities and potencies, enabling their utilization as biological 
probes and for development of leads toward therapeutics, diagnostics and 
vaccines. 
28 
 
1.5.1 Cyclic peptides in protein mimicry 
Most epitope sequences in a protein have a well-defined secondary structure, such 
as loops, α-helices or β-sheets. Several epitopes have effectively been mimicked 
due to cyclisation of the peptides to obtain a better protein-like structure.  
For example, constrained cyclic peptides have been developed to mimic the turn 
conformation of the RGD sequence. The RGD peptidic motif is the most common 
motif present in many matrix proteins and is recognized by integrins (cell adhesion 
proteins). RGD-binding integrins can distinguish between different adhesion 
proteins because the RGD sequence is presented in slightly different ways.[96] On 
this basis, a series of cyclic pentapeptides with the sequence RGDFV were 
synthesized and screened leading to the discovery of Cilenglitide.[97] This drug 
entered Phase III clinical trials for treatment of glioblastomas, however it did not 
get final approval.[98] 
A recent example of protein-protein interactions disruption by a cyclic peptide 
mimic is the inhibition of the YAP-TEAD complex. YAP (Yes-associated-protein) is 
a protein responsible for transcription regulation and is known for its oncogenic 
activity driven by the association with transcription factors from TEAD 
(transcriptional enhancer factor domain) family.[99] In order to inhibit this 
interaction, firstly the epitope of YAP significant for binding to TEAD was 
identified to be 81PQTVPMRLRKLPDSFFKPPE100. Based on the crystal structure, 
residues at positions 87 and 96 were substituted by cysteine and homocysteine 
and formed a disulphide bond. This resulted in a highly potent cyclic peptide 
inhibitor.[100] 
The study by Galsky et al.[101] is an example of targeting G protein-coupled 
receptors (GPCRs) by cyclic peptides. A chemokine receptor, CXCR4 was recently 
co-crystalized with the CVX15 (Figure 11), a 16-residue peptide cyclized by a 
disulphide bridge, previously identified as an HIV-inhibitor and anti-metastatic 
agent.[102] In order to mimic CVX15 peptide, medium throughput screening and 
rational design approach were employed and resulted in the identification of the 
cyclic peptide LY2510924. LY2510924 reached Phase II clinical trials and even 
though it had an acceptable toxicity profile it did not improve the efficacy of the 
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first-line standard of care chemotherapy (carboplatin/etoposide) for 
extensive-disease small cell lung cancer.[103] 
 
Figure 11 CXCR4 chemokine receptor co-crystallised with CVX15 cyclic peptide (PDB entry: 3OE0). 
 
Cyclic peptides are used more often nowadays in drug discovery. Between 2006 
and 2015 nine cyclic peptide drugs were approved by FDA and EMA: four employed 
in bacterial and fungal infections, three oncology drugs and a drug developed to 
treat anaemia, this latter one, however, was withdrawn due to safety concerns.[92] 
These data underline the potential that cyclic peptides possess and which should 
be further explored. 
1.6 Applications of discontinuous epitopes mimics in 
drug design 
While it would be extremely convenient if linear peptides could be used in the 
development of vaccines, unfortunately they are rarely targeted by neutralizing 
antibodies and studies with animals have shown that such antibodies are not 
elicited.[104] The majority of the neutralizing determinants possess quaternary 
structure, therefore more complex constructs, ones that are capable of obtaining 
accurate conformation, could be used in the mimicry.[104] As an example 
supporting this hypothesis, the dengue virus Env protein consists of three domains 
in each protomer. Two protomers form head-to-tail dimers, and a trimer of these 
dimers forms a raft on the surface of the viral particle. It has been shown, that 
the human monoclonal antibody (mAb) 1F4 recognizes only a “bent” conformation 
of the domain I/II region on the dengue Env protein. However, a soluble 
recombinant Env protein, in which the angle of the domain I/II hinge is more 
relaxed, does not bind this neutralizing antibody.[105][106] 
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Since protein-protein interactions, and more precisely discontinuous epitopes 
interactions with proteins, play a crucial role in many diseases, inhibition or 
controlled modulation of undesired PPIs has become an important target in drug 
design.[107][50] 
Peptide-based mimics have gained popularity in recent years as potential 
therapeutics because of their relatively small size, ease of synthesis, and better 
bioavailability when compared to proteins. Moreover, as was previously discussed, 
disruption of PPIs by small molecules is rather difficult. Therefore, utilisation of 
this family of compounds as discontinuous epitopes mimics is highly sought-after. 
1.6.1 Protein mimics in vaccinology 
Protein mimics have found multiple applications in the field of drug discovery. 
They can be used as PPIs inhibitors,[54] synthetic antibodies,[108] anticancer 
therapeutics,[109] antimicrobials,[110] anti-inflammatory agents,[111] and what is 
probably one of their most exciting applications - in vaccinology. Live attenuated 
or killed pathogens, which can be considered as mimics of natural infection, were 
used to elicit antibody responses in vivo and generated many effective vaccines. 
This approach has been utilised for years, however with certain viruses it was 
considered unsafe, because of the risk of permanently integrating proviral DNA 
within host chromosomes, as in the case of HIV.[112] Such pathogens could 
therefore be targeted by careful epitope mimicry in synthetic vaccines. 
Vaccines, by definition, are preventive, however in recent years a growing interest 
was observed in therapeutic vaccines. Prophylactic vaccine is administered to a 
person who is free of the targeted infection, while in case of therapeutic vaccine 
it is administered to a person who has already acquired chronic viral infection, 
against which naturally produced antibodies are ineffective. In such case, the aim 
is to increase the immune system reactivity to such pathogen.[113] Scaffolded 
protein mimics, especially of discontinuous epitopes, are extremely interesting 
approach towards synthetic vaccines. If carefully designed to provide correct 
rigidity and positioning of epitopes and introduce pre-organisation of the peptides 
so that they obtain the same three-dimensional structures as present in mimicked 
template epitopes, this approach could lead to new potent vaccines. 
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1.7 Aim of the project 
The research described in this thesis aims at the development of a method for the 
synthesis of discontinuous gp120 epitope mimics and a reliable and reproducible 
technique to study binding of these constructs to the CD4 protein. Since studies 
of binding between gp120 mimics and its natural ligand CD4 require access to both 
proteins, approaches towards expression of these proteins in mammalian and 
bacterial cells (respectively) are described. Moreover, NMR and Circular Dichroism 
(CD) spectroscopy studies were performed to obtain a deeper insight into the 
structural features of the linear peptides, cyclised peptides and entire constructs 
containing loops mounted on the scaffold. 
For the mimicry of discontinuous epitopes, the TAC scaffold was chosen as a 
platform that should provide the right spatial conformation of the peptides. The 
TAC scaffold was synthesized based on a literature procedure and one of the steps 
in the synthesis was optimised. Based on the previously described linear peptide 
sequences for mimicry of gp120, we describe an optimised synthesis of novel cyclic 
peptides, containing a recently published cyclisation hinge, which was applied to 
improve the solubility and purification of the cyclic peptides. Finally, having all 
the building blocks ready, the cyclic peptides were sequentially introduced on the 
scaffold, resulting in the complete constructs for gp120 mimicry. 
Initially it was decided, that the binding studies of these constructs will be 
conducted using ITC technique. ITC requires large quantities at high 
concentrations of the proteins for each assay and using commercial proteins was 
not financially viable. Therefore, protein expression efforts and their subsequent 
purification were pursued. Unfortunately, it was not possible to obtain enough 
proteins in the required purity, therefore the approach towards the binding 
studies was changed. 
Previous approaches towards binding evaluation in the Liskamp group have shown 
that ELISA assays are highly unreliable and not reproducible.[114] Therefore one of 
the aims of this project was to develop a robust method of evaluation of this class 
of compounds. In order to achieve this goal SPR was chosen to study the kinetics 
of the constructs. Careful optimisation of the experimental conditions yielded in 
a highly reproducible method for the evaluations of gp120 discontinuous mimics. 
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1H-NMR and CD spectroscopy techniques provide valuable information about the 
folding patterns and three-dimensional conformation of studied molecules. 
We describe a first attempt of characterization of the synthesized linear and cyclic 
peptides as well as entire constructs by these spectroscopic methods to gain a 
deeper insight into their structure. The results can inspire the design of future 
constructs to obtain optimised and active compounds.
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2 Protein production and characterisation of 
CD4D12 and gp120 
2.1 Expression of CD4D12 in Escherichia coli (E.coli) 
2.1.1 CD4 – introduction 
The main objective of this thesis was to evaluate binding properties of the gp120 
discontinuous mimics to the natural ligand CD4 receptor, therefore efforts 
towards expression of CD4 and gp120 proteins were made. 
CD4 (cluster of differentiation 4) is a 55 kDa membrane glycoprotein present on 
the surface of immune cells such as T helper cells, monocytes, macrophages, 
Langerhans cells, B lymphocytes, dendritic cells and eosinophils. It plays a major 
role in the response of the acquired immune system. Under physiological 
conditions CD4 is a co-receptor of lymphocyte T receptor (TCR) cells and 
participates in the antigen presentation process. CD4 stabilises the interaction 
between the antigen presenting major histocompatibility class II (MHCII) cells and 
lymphocyte T. It also participates in TCR signalling mitigating lymphocyte 
activation. However, the immune role of CD4 can be corrupted by the HIV-1 virus 
and it can be used as a port of entry into the cell, which allows further infection 
by the virus.[115] HIV binding and fusion with the host cell is mediated by 
interaction with the HIV surface gp120 as was described in Chapter 1. 
The primary sequence of CD4 consists of 435 amino acids, which constitutes a 
N-terminal extracellular domain (residues 1-371), a transmembrane segment 
(residues 373-395) and a C-terminal cytoplasmic tail (residues 396-435).[116] The 
extracellular region is folded into four distinct domains designated D1 to D4. 
Domains D1, D2 and D4 are additionally stabilised by disulphide bridges, while 
domains D3 and D4 contain N-linked glycans. 
Several studies have shown that the gp120 binding site is located in the first two 
domains and the minimum essential region participating in this interaction is 
situated in the first domain (Figure 12).[117] Within the 98 residues of D1 only 19 
have impact on gp120 binding and 13 out of these lie in the region 38-59.[118] The 
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oligosaccharide chains present on domains D3 and D4 have no effect on gp120 
binding.[119] 
One of the aims of this project was to test and evaluate binding properties 
between gp120 discontinuous epitope mimics and CD4, which was supposed to be 
pursued by the ITC. ITC requires relatively large quantities (several hundred μg 
per binding assay)[64] of highly concentrated and purified protein samples thus 
utilisation of commercial proteins was not financially feasible. Therefore, it was 
decided that it would be attempted to express and purify the CD4 protein in our 
laboratory. 
 
Figure 12 The X-ray crystal structure of full length CD4 structure (left; PDB entry: 1WIO) and its first 
two domains (CD4D12), which are participating in the interaction with HIV gp120 (right; PDB entry: 
1GC1). 
 
2.1.2 Overview of CD4D12 expression in E.coli 
Biologically active recombinant proteins have a variety of downstream 
applications, such as identification of protein structure and function, 
characterisation of protein-protein interactions or generation of antibodies. 
Protein expression in mammalian and insect cells results in biologically active 
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proteins that contain post-translational modifications, such as glycosylation or 
phosphorylation.[120] On the other hand, production of recombinant proteins in 
E.coli expression system is frequently preferred due to its inexpensive substrates, 
convenience and high yields.[121][122] However, during protein overexpression in 
E.coli inclusion body (IB) formation is frequently encountered. IBs are insoluble 
products of protein aggregation in a non-native form. While the exact mechanism 
of IB formation is not yet known, it is commonly believed, that the process of 
protein expression is faster than its folding into the native form. Hydrophobic 
regions are exposed on the surface of misfolded or partially folded proteins and 
interact with other alike proteins, which results in formation of insoluble 
aggregates.[123] For years researchers discarded the insoluble aggregates as an 
unwanted product obtained during protein overexpression. However, IBs are 
gaining an increasing attention among researchers due to their mechanical 
stability that allows harsh physical techniques to lyse the cells, several washing 
and purification steps, long-term storage stability without loss of protein 
biological activity and tolerance towards freeze-thawing.[121] The major difficulty 
with proteins being expressed in the form of IBs lies in the solubilisation and 
subsequent refolding steps to obtain the protein in the native and biologically 
active form. In order to purify the protein, it is often solubilised first under 
denaturing conditions (urea, guanidinium chloride - GdnHCl). The high 
concentration of denaturant is responsible for breakage of non-covalent 
interactions between molecules and addition of reducing agent helps with 
prevention of unwanted disulphide bond formation. The most difficult part is the 
protein refolding step, which often is case-specific and requires trial-and-error to 
achieve success.[120] 
Our group contacted professor Varadarajan (Indian Institute of Science, 
Bangalore) in reference to the plasmid used for expression of the first two domains 
CD4-D1 and D2 (Figure 12, right). DNA plasmid peT28a(+)-CD4D12[124] was kindly 
donated to our group. The peT28(+)-CD4D12 is a plasmid that codes for the first 
two domains of CD4 protein linked to a polyhistidine fusion tag (His-tag) (Figure 
13). It is known that CD4D12 is expressed in the form of IBs. Several different 
protocols for protein overexpression, purification and refolding were tested 
throughout this work and are described in this chapter. 
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2.1.3 Results and discussion 
2.1.3.1 CD4D12 expression 
2.1.3.1.1 Structure and restriction enzyme digestion of PET28a(+) CD4D12 
plasmid 
CD4D12 protein expression was carried out using pET expression system as 
supplied (Figure 13). The gene expression in the pET system proceeds by 
utilisation of T7 RNA polymerase and bacteriophage T7 promoter.  
Modified E.coli BL21(DE3) cells which carry the gene coding for T7 RNA polymerase 
under control of the lacUV5 promoter were used since T7 RNA polymerase is not 
naturally present in E.coli. A pET vector typically consists of: 1) a lac operon (site 
of E.coli RNA polymerase binding) with the gene of interest, 2) an origin of 
replication (ORI) and the antibiotic resistance gene (KAN(R)) and 3) the lacI gene 
coding for Lac operon repressor protein. Before induction, the Lac operon 
repressor protein encoded in the E.coli chromosome, inhibits the lacUV5 promoter 
(within lac operon) by prevention of RNA polymerase binding to the lacUV5 
promoter and in consequence halting background expression. During induction, 
isopropyl β-D-1-thiogalactopyranoside (IPTG) binds to the lac repressor protein in 
E.coli and activates the lacUV5 promoter, which is followed by expression of T7 
RNA polymerase. T7 polymerase in presence of IPTG binds to the T7 promoter in 
the pET plasmid and activates the expression of the gene of interest. 
 
Figure 13 Vector map of pET28a(+) CD4D12 plasmid (left) and the amino acid sequence of CD4D12 
(right). 
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Initially, the donated plasmid was analysed by restriction digestion. The PET28a(+) 
CD4D12 plasmid consists of 5845 base pairs (bp) (Figure 13) and possesses two 
restriction sites: SmaI and BlpI. A restriction enzyme digestion was performed as 
described in the Materials and Methods section 6 and samples prior and post the 
digest were analysed by DNA electrophoresis (Figure 14). Prior the restriction 
enzyme digestion (lane B) the plasmid migrated to a height corresponding to 
5,000 bp as expected, however, some bands were visible above, which might be 
due to formation of a super-coiled plasmid. Restriction enzyme digestion of the 
plasmid with enzymes SmaI and BlpI produced two DNA fragments of 1152 bp and 
4963 bp, as predicted. This result confirmed the size of the plasmid. 
 
Figure 14 DNA electrophoresis of restriction enzyme digest of pET28a(+)-CD4D12 plasmid. 
Lane A: 1 Kb Plus DNA ladder, lane B - the plasmid prior to restriction digestion, lane C the cut 
plasmid after restriction digestion. 
2.1.3.1.2 CD4D12 protein expression 
The pET28a(+)-CD4D12 vector was transformed into the DH5α competent cells, 
which were used to replicate the plasmid. Once a sufficient amount of the plasmid 
was prepared and purified, the plasmid was further transformed into BL21(DE3) 
competent cells. The Bl21(DE3) strain of E.coli is more suitable for protein 
expression than DH5α as it is compatible with expression under control of the T7 
promoter. 
Firstly, different media (2×YT, LB, auto-induction LB and TB media) and induction 
times were tested to optimise the bacterial growth. The comparison was made 
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based on the size of the pellet of the bacterial culture after centrifugation. The 
pellets coming from the cultures grown in the auto-induction media and pellets 
from the cultures induced with IPTG and incubated overnight (compared to shorter 
incubation times) resulted in similar sized pellets. Therefore, 2×YT medium with 
manually added IPTG was chosen as the system for protein expression, as it was 
more economical than utilisation of commercial auto-induction media. 
Expression levels after IPTG induction in E.coli were monitored by performing test 
expression. From the inoculated overnight culture, a small sample was collected 
– this was the uninduced sample. Afterwards the bacterial culture was induced 
with IPTG until OD600 reached 7.2 and a further sample was collected – the 
post-induction sample. The uninduced and induced samples were then lysed and 
diluted. A fraction of post-induction sample was further used for preparation of 
following samples: after centrifugation the supernatant (the post-induction 
soluble fraction) was separated from the pellet, which was resuspended in water, 
in this way producing the fourth sample – the post-induction insoluble fraction. All 
these fractions were then analysed by SDS-PAGE. As can be observed on Figure 
15, prior to the IPTG induction, very weak bands of the proteins were visible (lane 
B). This might be due to the leaky expression, which is caused by an incomplete 
repression of the lac promoter leading to low level protein expression prior to the 
induction.[125] After induction many different proteins were expressed (lane C). 
This post-induction total sample was further divided into soluble (lane D) and 
insoluble fractions (lane E). The band corresponding to the CD4D12 can be 
observed in the insoluble post-induction fraction (lane E). The band migrated at 
between 25 and 35 kDa, while the molecular weight of the two-domain CD4D12 is 
21 kDa. The anomalous migration can be caused by the relatively high content 
(10%) of aspartic acid and glutamic acid residues. Examples in the literature show, 
that when above 20% of the amino acids in the sequence are acidic, they might 
repulse the negatively charged SDS, thus migrate slower through the gel, which 
can lead to the molecular weight differences of even up to 50 kDa between where 
the band is predicted to migrate and the actual migration position.[126][127] In case 
of CD4D12 the content of acidic residues was not as high and the band migrated 
only slightly higher than expected. The soluble post-induction fraction did not 
contain any CD4D12, which was in agreement with the hypothesis, that CD4D12 
was overexpressed in the IBs. Moreover, it can be seen that the post-induction 
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insoluble fraction (lane E) was relatively pure compared to the post-induction 
soluble fraction. 
 
Figure 15 SDS-PAGE analysis of test expression levels after induction in E.coli.  
Lane A: molecular weight marker with values in kDa, lane B: pre-induction total sample, lane C: post-
induction total sample, lane D: post-induction soluble fraction, lane E: post-induction insoluble 
fraction. 
2.1.3.2 Purification of CD4D12 
Purification of the CD4D12 protein consists of two steps: cell lysis, harvest of the 
inclusion bodies and solubilisation of inclusion bodies under denaturing conditions, 
followed by Ni2+-affinity chromatography. 
2.1.3.2.1 Cell Lysis and Solubilisation of Inclusion Bodies 
Sonication was employed as a method of cell lysis of all protein samples as 
described in the literature. [124][128] It resulted in cell opening and release of the 
IBs into the cell lysis buffer. Supernatant was removed by decantation after high 
speed centrifugation. Afterwards the pellet of IBs was washed several times with 
a solution of methionine and EDTA. The pellet was washed further with water to 
remove the EDTA which would interfere with Ni2+-affinity chromatography. The 
insoluble protein aggregates were solubilised in a solubilisation buffer containing 
high concentration of a denaturant (GdnHCl) and reducing agent 
(β-mercaptoethanol or TCEP). This process allowed the protein to unfold into its 
primary structure, preventing formation of undesired disulphide bridges, and to 
expose the His-tag, which was otherwise buried in the tertiary structure of the 
protein, which would prevent successful purification. Once the protein was 
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solubilised, a filtration step was required to remove any insoluble cell debris, thus 
creating a lysate that could be applied on the Ni2+-column. 
2.1.3.2.2 Ni2+-Affinity Chromatography 
Ni2+-affinity chromatography is one of the established methods of purification of 
recombinant proteins containing His-tag.[129] It is widely used and highly reliable. 
The method is based on the affinity between the imidazole side chain of the 
histidine tag and nickel ions which are present in the stationary phase. The tagged 
protein is retained on the column while the untagged proteins are eluted. Once 
the impurities are removed, the protein can be eluted with an increasing 
concentration of imidazole (from 20-300 mM), which forces the histidine-tagged 
protein out of coordination to Ni2+. The proteins that have natural affinity towards 
Ni2+ are washed away with 20 mM imidazole prior to elution of the desired protein. 
The buffers (solubilisation, wash and elution) contain NaCl which prevents 
unspecific binding, and a reducing agent which prevents formation of intra- and/or 
intermolecular disulphide bridges. 
Two procedures were developed for purification of CD4D12. The first one, which 
was used initially and was not optimised, involved a two-step purification by 
Ni2+-affinity chromatography followed by a one-step dialysis and size exclusion 
chromatography. Due to limited access to size exclusion chromatography 
equipment only a small batch of the protein was purified in this way. The protein 
purified in this way was used for preliminary studies by ITC, which consumed the 
entire protein stock. The second procedure involved only a one-step Ni2+-affinity 
chromatography and long gradual dialysis in order to obtain correctly refolded 
protein. This procedure aimed at obtaining the protein in high enough purity after 
just one step of the purification and focused on the refolding method. The protein 
produced in this way was used in all characterisation techniques (SDS-PAGE, 
Western Blotting, NMR and CD-spectroscopy) as well as in the SPR binding studies, 
unless stated otherwise. 
Initially, the test purifications by Ni2+ and Co2+-affinity columns were performed 
to compare which method was better. It was found that the purity of the eluted 
CD4D12 was similar, however Ni2+ ions bound the His-tagged protein slightly better 
than Co2+ ions, which resulted in higher amounts of the protein found in the eluted 
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fractions than in the flow-through. The intensity of the CD4D12 peak was 
approximately 5× lower during the purification using the Co2+ resin (200 mAu) than 
when the Ni2+ resin was used (1000 mAu), which is shown in Figure 16. Therefore, 
all the purifications were performed using Ni2+-packed columns thereafter. 
 
Figure 16 Analysis of the impact of different stationary phase during affinity chromatography.  
a) Co2+-packed affinity column. The broad peak on the left was the flow-through, the peak on the 
right - CD4D12. b) Ni2+-packed affinity column. The broad peak on the left – flow-through, the middle 
peak – washes, the peak on the right – CD4D12. 
The purification of non-denatured protein was also attempted, however it was 
unsuccessful. It underlined the necessity of exposing the His-tag, which was 
otherwise buried in the protein and did not bind the resin. 
1. Two-step protein purification for ITC 
Solubilised and filtered protein sample was loaded onto the Ni2+-column and 
washed with 50 mM imidazole wash buffer in order to remove any impurities that 
might have a natural affinity for Ni2+. The protein was then eluted with 500 mM 
imidazole buffer supplemented with a high concentration of denaturant. After 
purification, a one-step dialysis to remove GdnHCl was performed. Because of a 
rapid change of concentration of denaturing agent in the protein sample, 
formation of a considerable precipitate was observed (Figure 17). 
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Figure 17 Protein precipitation observed during dialysis. 
 
The precipitate was removed by filtration and the soluble fraction of the protein 
was concentrated and analysed by SDS-PAGE. It was observed, that CD4D12 was 
already of good purity. Since CD4D12 elution was observed already at the washing 
step, it was concluded that in future purifications, the imidazole concentration in 
the wash buffer should be decreased (Figure 18 a). Finally, CD4D12 sample was 
purified by size exclusion chromatography which yielded highly pure protein 
(Figure 18 b), however the amount of CD4D12 produced in this way was very low 
due to the loss of large part of the sample during the dialysis step. 
a 
 
b 
 
 
Figure 18 SDS-PAGE analysis of CD4D12 purification.  
Left: SDS-PAGE after the first step purification and dialysis of the protein to remove GdnHCl. Lane 
A: flow-through, lanes B-E: washes, lanes F-I: elutions of the protein. Right: SDS-PAGE of CD4D12 
after size exclusion chromatography. Lane A: molecular weight marker with values in kDa, B: purified 
CD4D12 under reducing conditions. 
This method could be optimised by gradual dialysis of the protein sample after 
the affinity chromatography step, which would circumvent the loss of the protein 
due to precipitation. Size exclusion chromatography was much preferred as a final 
purification step as it yielded protein of high purity and it should be pursued in 
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the future. Refolding of the protein by dialysis was studied in more detail and is 
described below. 
2. One-step purification of CD4D12 
Solubilised and filtered CD4D12 sample was loaded onto a Ni2+-affinity 
chromatography column and washed with 20 mM imidazole wash buffer and eluted 
with 300 mM imidazole, as it was observed that CD4D12 eluted at approximately 
150 mM imidazole. Purification of the protein was monitored by UV as well as dot 
blot analysis with an anti-CD4 antibody. This second method was used as a quick 
test to confirm presence or absence of the CD4D12 in the samples, as SDS-PAGE 
analysis could not be carried out prior to removal of GdnHCl by dialysis. Dot blot 
analysis of all the eluted fractions (flow-through, washes, elution fractions) 
revealed that CD4D12 eluted in all the fractions (Figure 19). This might be due to 
a high concentration of CD4D12 in the lysate and saturation of the Ni2+-column. 
The purest fractions according to the chromatogram were chosen for further 
steps. This method of purification together with the refolding method described 
below was used for preparation of protein samples for NMR and CD-spectrometry 
and SPR binding studies unless stated otherwise. 
 
Figure 19 Analysis of a one-step CD4D12 purification followed by dot blot and UV. 
a) dot blot analysis of all the fractions prior (lysate) and obtained after purification (flow-through, 
washes, elutions); b) the chromatogram obtained after the affinity purification. 
2.1.3.3 Refolding 
Several approaches were utilised in protein refolding to retrieve its native 
structure and biological activity. One of the traditional methods of refolding which 
was used in this work is dialysis.[120] In a typical procedure, the process of refolding 
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from the unfolded, primary structure of the protein into its folded, active form is 
accomplished by removal of denaturing agent. Removal of the denaturant can be 
performed in one step from high to low concentration of denaturant or in several 
steps by decreasing the concentration via intermediate concentrations of 
denaturant. During one step dialysis, the longer the dialysis, the more the 
concentration of denaturant in the protein sample is decreased and the refolding 
rate of the protein is increased. However, as the hydrophobic surfaces of the 
protein are rapidly exposed interactions with each other may cause aggregation 
of the protein. The rate of misfolding of the protein increases with the number of 
protein aggregates contacting each other and other protein molecules in the 
process of refolding. In stepwise dialysis, this problem can be circumvented by 
gradual removal of the denaturant, so the folding process is slower, and the 
number of misfolded proteins is decreased. In this way properly-folded protein 
can be obtained. During the course of this project both techniques were 
evaluated. 
2.1.3.3.1 Refolding of CD4D12 
Following the one-step purification, the refolding of the protein via gradual 
dialysis was performed. This process was performed according to a slightly 
modified published procedure.[130] After purification, CD4D12 was present in the 
highest concentration of the denaturant – 6 M GdnHCl. Pure fractions were then 
dialysed overnight against 3 M GdnHCl buffer, which also contained 10% sucrose 
as a stabilising agent in the process of refolding, and a redox system consisting of 
1 mM reduced L-Glutathione (GSH)/0.1 mM oxidised L-Glutathione (GSSG). The 
presence of the redox system in the refolding buffer facilitates process of 
disulphide shuffling, which allows the disulphide bonds to be reduced and oxidised 
repeatedly until correct folding of the protein is achieved.[123] 
The next step was to remove the denaturing agent entirely from the buffer and 
place the protein in the refolding buffer with agents facilitating proper refolding: 
10% sucrose, 0.1 mM GSH/0.01 mM GSSG and Na2CO3 to keep the pH at 9.6. High 
pH is also beneficial in the formation of disulphide bridges, while addition of 
sucrose stabilizes protein by enhancement of interactions between the additive 
and the hydrophobic side chains of the denatured protein.[120] When changing the 
refolding buffer from the intermediate concentration of denaturing agent to the 
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buffer devoid of the denaturant some precipitation was observed. When compared 
to the one step dialysis, the precipitation in this case occurred to a lesser extent. 
However, the pH used during refolding was close to the calculated theoretical pI 
of the protein (9.18, as calculated by the online program 
https://web.expasy.org/compute_pi/), which meant that the protein net charge 
was close to 0, and the protein was prone to aggregation. This aggregation was 
not observed during previous steps, because the buffer was supplemented with 
denaturing agent, which prevented aggregation and precipitation. However, when 
the denaturant was removed, the protein started to aggregate and precipitated 
out of the solution. Future wise, it would be beneficial to lower the pH of the 
refolding buffers by at least 1 pH unit, so the pH would be still high enough for 
the bridge disulphide formation, but the protein would be still charged and soluble 
in the solution. 
The last step was an extensive dialysis against PBS buffer at pH 7.4, which was 
the final buffer in which the protein was stored. No precipitation was observed at 
this point. The purity of the protein purified in this way was analysed by SDS-PAGE 
(Figure 20). Using this method, (2-3 mg of purified CD4D12 was obtained per 1 L 
of bacterial cell culture). 
 
dimer of CD4D12 
CD4D12 
 
impurities 
 
Figure 20 SDS-PAGE analysis of one-step CD4D12 purification.  
Lane A: molecular weight marker with values in kDa, Lanes B, C – fraction 1. of the CD4D12 under 
reducing conditions at concentrations 1 μg∙ml-1 and 2.5 μg∙ml-1, respectively. Lane D: fraction 1. of 
the CD4D12 under non-reducing conditions at 2.5 μg∙ml-1. Lanes E-G and H-J represent fractions 2. 
and 3., respectively, presented as fraction 1. 
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2.1.4 Confirmation of identity of CD4D12 
Upon production of CD4D12 it was needed to confirm that the protein that had 
been over-expressed was definitely CD4D12, and that it had folded correctly. This 
was achieved by several methods: Western Blotting, mass analysis after in-gel 
trypsin digestion, 1D 1H-NMR and CD spectrometry. Western Blotting is a commonly 
used technique to detect specific proteins. SDS-PAGE is used to separate proteins 
in the sample by mass and then they are transferred from the gel to a membrane. 
The membrane is firstly incubated with a solution of a primary specific antibody 
that targets the desired protein, which is followed by incubation with a secondary 
antibody that targets the primary antibody and is conjugated to an enzyme 
horseradish peroxidase (HRP). When multiple secondary antibodies bind to one 
primary antibody, the signal is amplified which allows visualisation. 
SDS-PAGE and Western Blotting carried out with a monoclonal anti-CD4 antibody 
showed that the overexpressed protein was indeed CD4D12. Under reducing 
conditions, a single band corresponding to CD4D12 was observed (Figure 21, a) 
lanes B-D; b) lane A). However, under non-reducing conditions (Figure 21, a) lanes 
E-G; b) lane B), some binding was also detected at almost twice the mass of the 
protein , which corresponds to the bands observed by SDS-PAGE. 
 
Figure 21 a) SDS-PAGE and b) Western Blot analysis of the purified CD4D12. 
a) Lane A: molecular weight marker with values in kDa, Lanes B-D: CD4D12 under reducing 
conditions at 1.0 μg, 2.5 μg and 4.0 μg in a sample, respectively. Lanes E-G: CD4D12 under 
non-reducing conditions at 1.0 μg, 2.5 μg and 4.0 μg in a sample, respectively. b) Lane A: CD4D12 
under reducing-conditions, lane B: CD4D12 under non-reducing conditions. 
These results indicated, that the protein under non-reducing conditions formed 
intermolecular disulphide bridges. In the overall sequence of CD4D12, there are 
four cysteine residues and in the native form two disulphide bridges should be 
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formed: one in the first domain D1, and one in the second domain D2 (Figure 22). 
Since the upper bands were visible both in the SDS-PAGE and in the Western Blot, 
it suggested that at least a fraction of the entire protein might have formed 
intermolecular disulphide bonds rather than form into its native conformation. 
The upper bands were less intense compared to the bands corresponding to the 
CD4D12. 
 
Figure 22 Crystal structure of CD4D12 (PDB entry: 1GC1).  
The overall structure of the protein is shown in red. The two disulphide bridges present in the first 
domain D1 (lower part), and in the second domain D2 (upper part) are shown in yellow. 
The next method to confirm the identity of CD4D12 performed with the assistance 
of Dr. Emma Carrick (Institute of Cardiovascular & Medical Sciences, University of 
Glasgow) was the in-gel trypsin digest followed by protein mass spectrometry. In 
the protein mass spectrometry, the protein was initially analysed by SDS-PAGE, 
the band corresponding to the protein of interest was separated and digested, and 
the resulting sample was analysed. The peptide sequences were then compared 
with all human proteins in the UniProt database. Five unique peptide sequences 
that corresponded to the sequence of the entire 4-domain CD4 protein (UniProt, 
P01730) were identified: 
- NSNQIKILGNQGSFLTK 
- KGDTVELTCTASQK 
- IDIVVLAFQ 
48 
 
- ILGNQGSFLTK 
- KSIQFHWK 
These peptides covered 10.70% of the full length CD4 (Figure 23, also see 
Appendix Figure 97). All these peptides correspond to regions of the full-length 
protein that are also present in CD4D12. Thus, the overexpressed protein was 
CD4D12. 
 
Figure 23 Amino acid sequence of the full length CD4 protein (UniProt: #P01730). 
5 unique peptide sequences were found within the sequence of the entire CD4 protein. These 
sequences are highlighted by different colours, moreover one sequence found within a longer peptide 
is written in red. The underlined sequence corresponds to CD4D12 part of the entire CD4 protein. 
Samples of CD4D12 coming from three different purified batches were analysed 
by CD-spectrometry (see Introduction, section 1.3.3) with the assistance of Dr. 
Sharon Kelly (Institute of Molecular, Cell and System Biology, University of 
Glasgow). Samples were at different concentrations: sample 1: 0.505 mg∙mL-1, 
sample 2: 0.237 mg∙mL-1, and sample 3: 2.855 mg∙ml-1 in a PBS buffer at pH 7.5. 
Far UV CD measurements were measured in 0.02 cm pathlength cuvette. Presence 
of chloride ions present in samples 1 and 2 precluded measurements below 195 nm 
for far UV CD spectra. Sample 3 was however 6-fold diluted into H2O (final 
concentration 0.476 mg∙mL-1), which allowed to obtain data below 195 nm. 
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Figure 24 Far UV CD spectra of expressed CD4D12.  
Sample 1 (blue), sample 2 (red) and sample 3 (green). All spectra have been corrected for protein 
concentration and cell pathlength. 
Negative minima were found to be at different wavelengths in each spectrum: 
sample 1: ~215 nm, sample 2: ~212 nm, sample 3: ~210 nm (Figure 24). These 
shifts correspond to the shifts found in the literature of ellipticity minima, which 
were at 212-214 nm for CD4D12.[115][130] However, the differences between the 
shifts may reflect conformational differences between the samples, differences 
in oxidation states or the presence of contaminating proteins. This would be in 
accordance with the bands migration on SDS-PAGE and Western Blot. 
In the near UV CD measurements peaks in the range of 280-305 nm are 
characteristic for aromatic amino acid side chains (Figure 25, a). Aromatic amino 
acids: tyrosine (Tyr 99), tryptophan (Trp 45, 79, 174) and phenylalanine (Phe 43, 
60, 84, 115, 187, 196) are relatively far away from each other in the primary amino 
acid sequence (Figure 25, b, c). Based on the results from the near UV CD 
measurements, there was spectral evidence that at least some of the aromatic 
residues were held rigidly in an asymmetric environment, which indicated that 
the protein is folded in the region around these residues (Figure 25). 
Secondary structure estimates were obtained for sample 3, since data could be 
collected down to 190 nm. The protein was estimated to contain around 35% 
β-sheet, ~23% turns, ~33% unordered structure and less than 10% helical structure 
(Table 4). These data indicated, that one third of the sample had an unordered 
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structure, which might be coming from the previously mentioned dimers of 
CD4D12, which were not in their native conformation. Disulphide bridges formed 
randomly with other CD4D12 molecules prevented the protein from obtaining its 
native, correct conformation, therefore the folding process ceased, and some 
parts of the protein were misfolded. This demonstrated that the refolding 
procedure was crucial to obtaining a correctly folded protein. 
 
Figure 25 Analysis of secondary structure of expressed CD4D12. 
a) Near UV CD spectrum of CD4D12 sample 3, b) crystal structure of CD4D12 (red, PDB entry: 
1GC1) with shown aromatic residues: green - Trp, blue – Phe, cyan – Tyr, c) amino acid sequence 
of the overexpressed CD4D12 with highlighted aromatic residues as in b. 
Table 4 Secondary structure estimates – closest matching solution with all proteins. The goodness 
of fits as judged by NRMSD value (0.055) was favourable. Method used: Contin-LL (Provencher & 
Glockner method).[131] 
Helix Strand Turns Unordered Total 
0.096 0.338 0.230 0.336 1 
 
1D 1H NMR (see Introduction, section 1.3.3) of CD4D12 measurements were 
performed with the assistance of Dr. Brian Smith (Institute of Molecular, Cell and 
Systems Biology, University of Glasgow). Although 1D NMR alone cannot be used 
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for the identification of the protein, it allowed to draw conclusions of how well 
folded the protein was in solution. In 1D 1H NMR spectrum several regions 
indicated whether the protein was ordered or in a random coil form.[132][133] Well 
dispersed signals in the aliphatic region (-1.0-1.0 ppm) indicate a folded protein, 
in contrast to a sharp signal at approximately 1 ppm, indicating an unfolded 
protein. Large, broad peaks in the region of 8.3 ppm are a fingerprint of the amide 
backbone in a random coil configuration. Conversely, well dispersed peaks in this 
region indicate a folded protein. Another indication of a folded protein are 
dispersed peaks in the region of 8.5-11 ppm. 
The purified protein sample in PBS buffer, pH 7.5, was supplemented with D2O to 
a final concentration of 5% and the 1D NMR spectrum was recorded (Figure 26). 
Well dispersed peaks especially in the CH3 region (-0.5-1.0 ppm) as well as peaks 
present downfield, characteristic to CH2 and α C-H protons in the region between 
1-4.5 ppm, indicate hydrophobic interactions present in the proteins that has a 
rigid secondary structure. The region between 6.5-8.5 ppm corresponds to 
aromatic CHs as well as backbone amide protons. This region is well dispersed, 
although three characteristic peaks at 6.77, 7.65 and 8.37 ppm are distinct. These 
are possibly protons of the imidazole ring present in histidines. The overexpressed 
CD4D12 protein has nine histidines and six out of them are within the His-tag at 
the N-terminus. It was also observed, that the protons corresponding to the indol 
ring in tryptophans are not visible. This might be caused by rapid exchange of 
protons with the solvent when the indol protons are not protected by other 
residues. 
Several broader peaks are also visible in the spectrum at 1.1, 1.60 and 2.92 ppm. 
The overall pattern of the 1D 1H NMR indicats, that the protein is a mixture of 
both properly folded protein with a smaller fraction of misfolded protein. 
One of the possibilities to confirm the folding pattern of the protein would be to 
record additionally the 1D spectrum of this protein in the presence of denaturant. 
In this way it would be possible to compare the spectra of unfolded and folded 
protein. 
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Figure 26 1D 1H NMR of CD4D12 protein.  
Scale in ppm. The water signal at 4.5 ppm was supressed. Blue box indicates imidazole ring present 
in histidines. Green box indicates well dispersed peaks of the aliphatic region. 
Another method to confirm whether the protein was in the correctly folded form, 
which is biologically active, is to evaluate its binding properties towards a known 
ligand and to compare the obtained values with the literature data. This has been 
described in the chapter 4.2.1 in which evaluation of the CD4D12 activity was 
performed by SPR. 
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2.2 Expression of HIV-gp120 in mammalian cells 
2.2.1 HIV-gp120 
Gp120 protein was required as a positive control for binding experiments, thus 
efforts towards its expression and purification were undertaken. 
The structure of gp120 and the mechanism of binding to CD4 followed by viral 
entry of HIV into the cell have been described in Chapter 1. 
2.2.2 Overview of protein production in mammalian cells 
As previously discussed in section 2.1.2 protein overexpression in eukaryotic cells 
has the advantage of production of biologically active proteins folded into their 
native form and equipped with post-translational modifications, such as 
glycosylation or phosphorylation.[120] Protein expression can be performed in a 
variety of different cell lines, among the most frequently used ones: HeLa, Baby 
Hamster Kidney (BHK) cells, Human Embryonic Kidney (HEK293) cells or Chinese 
Hamster Ovary (CHO) cells. The most common applications of the mammalian 
expression system include: expression of complex proteins, virus and antibody 
production, functional assays. However, this expression system is also highly 
challenging due to low yields in protein production by adherent cells, demanding 
culture conditions, high costs of tissue culture and potential contaminations of 
the cells.[134]  
Gp120 is a highly glycosylated protein and glycans are required for the correct 
folding of the protein,[13][14] therefore HEK293 cells were chosen as the expression 
system, which was described previously for the obtained plasmid.[128] 
2.2.3 Overview of gene transfection 
Transfection is the introduction of the foreign genetic information into eukaryotic 
cells in order to change properties of the cell to either produce recombinant 
protein of interest or inhibit gene expression. Transfection can be broadly 
classified into two general types: transient and stable transfection. In transient 
transfection the introduced genetic information is not integrated into the genome 
of the host cell and therefore is present in the cell only for a limited period of 
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time. Dividing cells do not pass the introduced genetic material to the next 
generations the introduced genetic material. The advantage of this approach is 
that the material is transfected in a high copy number which results in high 
expression levels of the protein. In the stable expression strategy, the introduced 
genetic material is integrated into the host genome, which allows its passage to 
the next generations during cell division. On the other hand, the number of copies 
of the transfected material is kept low, which results in lower yields of expressed 
protein when compared to transiently transfected genes.[135] 
The cell membrane carries negative charge on its outer surface which prevents 
entry of similarly charged nucleic acids into the cell. Therefore, chemical, 
biological and physical methods were developed for gene delivery to the cell. 
Chemical methods are based on neutralisation of the negative charge of the 
nucleic acid by carrier molecules. Biological methods employ genetically 
engineered viruses to transfer the gene of interest into the cell. Physical methods 
aim at creation of transient pores in the cell membrane, for transfer of the nucleic 
acid to pass into the cell. 
Once the genetic material is transfected into the eukaryotic cell, after integration 
in cellular genome, it will be transcribed in nucleus to produce messenger RNA 
(mRNA) and translated to give the desired protein which will be 
post-translationally modified to produce a functional protein.[136] 
2.2.4 Results and discussion 
2.2.4.1 Restriction enzyme digestion of the V1Jnstpagp120 plasmid 
Our group has contacted professor Varadarajan (Indian Institute of Science, 
Bangalore, India) with respect to the plasmid used for expression of the full length 
gp120. DNA plasmid V1Jnstpagp120[128] was kindly donated to our group. 
Initially, the donated plasmid was analysed by restriction enzyme digestion. The 
V1Jnstpagp120 plasmid consists of 6391 base pairs (Figure 27) and possesses 
restriction sites: SspI and BlpI. Restriction enzyme digestion was performed as 
described in the Materials and Methods section 6 and samples prior and post 
digestion were analysed by DNA electrophoresis. Prior to the restriction digest 
(lane C) the plasmid migrated above 5,000 bp. Restriction enzyme digestion of the 
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plasmid with enzymes SspI and BlpI produced two DNA fragments of 1818 bp and 
4573 bp, as predicted (lane B). This result confirmed the size of the plasmid. 
 
Figure 27 a) DNA electrophoresis of restriction enzyme digest of V1Jnstpagp120 plasmid.  
Lane A: 1 Kb Plus DNA ladder, lane B - the cut plasmid after restriction enzyme digestion, lane C - 
the plasmid prior to restriction digest. b) Vector map of V1Jnstpagp120 plasmid, c) the amino acid 
sequence of gp120. 
2.2.4.2 Plasmid transfection and protein expression 
The transfection method was altered from the original method described in the 
literature by Varadarajan et al.[128] A polymer transfection reagent jetPRIME™ 
reagent was used in order to deliver the plasmid into the cells. 
Test expression and purification of gp120 showed several challenges. Firstly, 
SDS-PAGE of all obtained samples was performed (Figure 28). It revealed that 
three different populations of gp120 were expressed: nonglycosylated monomer, 
glycosylated monomer and glycosylated dimer. As can be observed, quite a large 
portion of the expressed protein was expressed in the nonglycosylated form. Also, 
the band corresponding to the dimer of gp120 seemed more distinct than its 
monomeric form. Secondly, binding conditions during the purification should be 
optimised, because a large portion of proteins was eluted in the flow-through. The 
bands corresponding to the glycosylated monomer of the gp120 were not migrating 
exactly at 120 kDa, which could have been caused by heterogeneity in protein 
glycosylation.[137] 
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Figure 28 SDS-PAGE analysis of gp120 expression in HEK293 cells.  
Lanes A: molecular weight marker with values in kDa, lane B: tissue culture supernatant after 24 h 
post-transfection, lane C: flowthrough, lanes D-F: washes with wash buffer, lands G-H: washes with 
binding buffer, lane I-L: elution fractions of the gp120 protein, lane M: resin beads post-purification, 
lane N: filtrate post-concentration, lane O: concentrated eluted fractions, lane P: empty, lane R: tissue 
culture supernatant after 48 h post-transfection, lane S: tissue culture supernatant after 72 h 
post-transfection, lane T: tissue culture supernatant after 72 h post-transfection in Optimem-reduced 
medium. 
The difference in expression level of gp120 can be compared by analysis of bands 
corresponding to the tissue culture supernatant coming from the samples 24, 48, 
and 72 h after transfection (Figure 28, lanes B, R, S, T). The expression time 
seemed to be insignificant, however, it was later shown by Western Blot analysis 
with anti-gp120 antibody, that the nonglycosylated form of the gp120 was formed 
mostly inside the cell and was not secreted into the tissue supernatant. The 
amount of glycosylated form varied especially between 24 h and 48 h after 
induction. It could be observed that the longer the plasmid was incubated with 
the cells, the more of the glycosylated protein was produced. There was a small 
increase in gp120 production after 72 h, however when the cells were incubated 
in serum reduced medium, the amount of the produced protein decreased (Figure 
29). The observation that gp120 was secreted into the tissue culture supernatant 
is in accordance with the fact, that gp120 contains in the sequence a signal 
peptide (residues 1-31), which allows the protein to be secreted into the tissue 
culture supernatant.[138] From thereafter, the cells were incubated for 72 h 
post-transfection. 
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Figure 29 Western Blot analysis of the gp120 expression post-induction after 24, 48, 72 h.  
Lane A: tissue supernatant after 24 h, lane B: tissue supernatant after 48 h, lane C: cell lysate after 
48 h, lane D: tissue supernatant after 72 h, lane E: cell lysate after 72 h, lane F: tissue supernatant 
after 72 h in serum reduced medium, lane G: cell lysate after 72 h in serum reduced medium. 
2.2.4.3 Overview of gp120 purification 
As was described in the Chapter 1, gp120 is a heavily glycosylated glycoprotein 
present on the surface of the HIV virus. N-linked glycans contribute to 
approximately half of the molecular weight of the entire glycoprotein. The 
majority of the glycans are mannoses: Man-5 and Man-9.[13][14] This structural 
feature of the gp120 structure can be used during the protein purification because 
sugar residues present in the glycoproteins can bind to carbohydrate-binding 
proteins, that is lectins. Lectins are present on the stationary phase of the column 
and bind glycoproteins selectively, enabling their isolation from a cell lysate. Once 
the impurities are washed away, the glycoprotein is eluted with 
methyl-α-D-mannopyranoside (MMP). Detergent is added to the solubilisation, 
wash and elution buffers to reduce non-specific binding to the column. 
2.2.4.3.1 Purification of gp120 
Purification was performed either by batch method using Galanthus nivalis (GNL) 
lectin-bound agarose beads or by column packed with Lentil Lectin resin, followed 
by size exclusion chromatography. Purification of the collected supernatant after 
transfection was performed according to a slightly modified literature 
procedure.[139] The first step of the purification which employed lectin beads was 
used to isolate glycoproteins present in the tissue culture supernatant from all the 
other proteins produced by the cells. This step yielded relatively pure protein, 
however it was observed that the monomer and dimer species eluted almost 
together, as the resin does not distinguish between them (Figure 30 a, b). Size 
exclusion chromatography allowed to obtain highly pure protein separated from 
dimeric species (Figure 30, c, lane K), but the purified gp120 was obtained in low 
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yield and was highly unstable, as it precipitated out of the solution. In the future, 
it would be worth considering adding another step to the purification, such as 
dialysis, to remove detergent from the protein sample prior to size exclusion 
chromatography. ITC measurements for binding studies of discontinuous mimics 
required large volumes of highly concentrated gp120 as a positive control. To 
obtain gp120 in these quantities, the expression would have to be immensely 
scaled up and optimised, which would be extremely time-consuming. Therefore, 
work on gp120 expression and purification was discontinued. 
 
Figure 30 Progress of purification of gp120 by SDS-PAGE and UV. 
a) and b) upper:SDS-PAGE analysis of the first step purification of gp120 by Lentil-Lectin column: 
Lane A: molecular weight marker with values in kDa, Lane B: flowthrough, Lane C-D washes, Lane 
E-H: eluted fractions of gp120; lower: chromatograms of the performed purification. c) upper SDS-
PAGE analysis after size exclusion chromatography. Lanes I-K: eluted fractions of gp120; lower: 
chromatogram of the performed purification. 
2.2.4.4 Confirmation of identity of gp120 
As was discussed in section 2.2.4.2, the Western Blot analysis performed with a 
polyclonal anti-gp120 antibody identified that the overexpressed protein was 
indeed gp120. However, it was observed that the antibody bound also the 
nonglycosylated form of the glycoprotein. 
Samples of gp120 coming from two different purified batches were analysed by 
CD-spectrometry with the assistance of Dr. Sharon Kelly (Institute of Molecular, 
Cell and Systems Biology, University of Glasgow). Samples were at different 
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concentrations: sample 1: 267 μg∙mL-1 and sample 2: 296 μg∙mL-1 in a PBS buffer 
at pH 7.5. Presence of chloride ions present in samples 1 and 2 precluded 
measurements below 195 nm for far UV CD spectra, therefore only far UV spectra 
were recorded. The spectra appeared to be very similar in intensity and shape and 
suggested that the protein in each fraction was folded (Figure 31). Negative 
minima were found at approximately 210 nm and the overall shape of the 
spectrum resembled closely the CD spectra found in the literature.[128][140] 
 
Figure 31 Far UV spectra of gp120 samples: sample 1 (blue), sample 2 (red). 
 
Another method to confirm whether the protein is in the correctly folded form, 
which is biologically active, is to evaluate its binding properties towards a known 
ligand and to compare the obtained values with the literature data. An ITC 
experiment was performed between the expressed, purified gp120 and expressed 
and purified CD4D12. However, the concentrations of the samples were by far too 
low to detect any binding, therefore it could not be concluded whether gp120 was 
expressed in the biologically active form. 
2.3 Conclusions 
Efforts towards expression, purification and characterisation of CD4D12 and gp120 
proteins were made. 
60 
 
CD4D12 was a challenging protein to express in E.coli, refold and purify. It could 
be produced on a large scale and the scale-up was feasible. It was characterised 
by various methods including: SDS-PAGE, Western Blot, 1D 1H-NMR and 
CD-spectroscopy, and protein mass spectroscopy. All these techniques confirmed 
that CD4D12 protein was expressed and the majority of it was properly folded. 
However, finding refolding conditions to obtain correctly folded, biologically 
active protein was an extremely challenging task. Several refolding methods were 
tested, yet optimisation is still required in order to avoid formation of the 
improper dimeric species coming probably from the incorrectly formed 
intermolecular disulphide bridges. 
The glycoprotein gp120 was transiently expressed in mammalian cells, which was 
confirmed by SDS-PAGE and Western Blot. Gp120 requires at least a two-step 
purification, and future wise it would benefit from introduction of an intermediate 
step to remove the detergent from the sample. Since the expression in the current 
setup is rather low yielding, a scale up of the procedure would be required. A 
possible remedy would be to employ Vaccinia Virus as a tool for gene expression 
in mammalian cells[139] or protein in baculovirus-infected insect cells.[141] 
ITC studies planned for evaluation of binding properties would require initial 
optimisation of the experimental conditions, which only then could be followed 
by the actual experiments. Low-yielding expression of gp120 and requirement of 
large volume of highly concentrated sample for the ITC studies resulted in 
discontinuation of gp120 expression. Thus, it was decided, that the binding studies 
should be evaluated by SPR, which consumes less proteins. 
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3 Synthesis of the gp120 discontinuous epitope 
mimics 
3.1 Introduction 
After 30 years of major global efforts towards the discovery of a HIV-1 vaccine, a 
successful candidate capable of prevention of the viral infection has thusfar not 
been identified. Research in this field is an intriguing challenge. HIV-1 and its 
interactions with the CD4 receptor and CCR5 and CXR4 co-receptors, as well as its 
impact on the immune system are very well documented and studied. The 
abundance of the literature on the topic indicates that plentiful ideas and 
scientific approaches have already been investigated, however, without success. 
Breakthroughs in this area require exceptionally creative and innovative 
approaches. 
Previous research carried out in our group towards the design and synthesis of a 
HIV-1 vaccine served as a good starting point for further optimisation and 
evaluation of the constructs.[142][143][144][145] The TAC scaffold developed in our 
group was chosen as a platform for attachment of the cyclic peptides because of 
the well-developed synthetic route and the ease of preparation of the scaffold on 
a large scale. Moreover, Werkhoven et al.[88] have shown that orthogonally 
protected alkynes present on the TAC scaffold allowed the introduction of three 
different cyclic peptides bearing an azide handle with a control over positioning 
of the loops. Introduction of the cyclic peptides onto such scaffold allowed to 
display them in a pre-organised fashion mimicking the discontinuous site of gp120. 
The peptide sequences selected for the mimicry of gp120 were based on the 
established conserved amino acids corresponding to the CD4-binding site found in 
gp120.[16] These are: loop 1: 454LTRDGGK460, loop 2: 424INMWQEVGKA433 and loop 3: 
365SGGDPEIVT373 (Figure 32). The cyclisation of the peptides was performed to 
improve their stability as well as induce a loop conformation, which should 
improve the mimicry of the naturally occurring conformation in gp120 when 
compared to the linear peptides. Moreover, Meuleman at al.[146] have recently 
shown, that cyclic peptides mimic epitopes more closely than their linear 
counterparts and have improved specificity. 
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Introduction of the peptide loops was performed by copper catalysed azide-alkyne 
cycloaddition (CuAAC, also click). The CuAAC method of ligation is a 
stereoselective reaction between a terminal azide and alkyne moieties catalysed 
by copper (I) species. The product of this reaction is a 1,4-disubstituted 
1,2,3-triazole. The versatility of its applications is the main cause why the click 
reaction is frequently employed for conjugation of peptides and biomolecules. 
The reaction can be performed in various solvents and is insensitive to pH and 
temperature. CuAAC is well documented to be bio-compatible, efficient, robust, 
and fast. Moreover, it allows the introduction of unprotected peptides. For these 
reasons CuAAC was chosen as the method of introduction of cyclic peptides 
representing discontinuous epitopes of gp120 onto the TAC scaffold, which 
orthogonally protected alkyne handles are compatible with CuAAC 
chemistry.[147][148] 
 
Figure 32 X-ray crystal structure of gp120-CD4-antibody complex (PDB entry: 1GC1). 
Left: gp120 (yellow) binds CD4 (cyan) via the loops present in the conserved CD4-binding site (blue, 
red and green). The antibody (grey and pink) interacts with the variable V1/V2 region of gp120, which 
is more accessible than the CD4-binding site. Right: zoom of the conserved residues within 
CD4-binding site of gp120. 
The TAC molecular scaffold should position the attached discontinuous epitope 
sequences in the correct spatial conformation, thereby mimicking the gp120 
CD4-binding site. Utilisation of the scaffold allowed omitting the bulk of the entire 
protein and possibly avoid the viral immune evasion mechanisms, such as glycan 
shielding or presentation of the immunodominant epitopes (Figure 33). It is known 
that the CD4-binding site is conserved among different HIV-1 strains.[149] 
Therefore, a mimic of this conserved region in a vaccine would not only be broadly 
applicable to different HIV-1 strains but would also be resistant against emergence 
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of new viral mutants. A synthetic mimic of the gp120 discontinuous epitopes 
synthesized in this way might prove to be an efficacious HIV-1 vaccine candidate. 
 
Figure 33 Attachment of the cyclic peptides onto the scaffold for the mimicry of the discontinuous 
epitopes.  
Peptide sequences analogous to the protein discontinuous epitopes are synthesized and cyclised, 
which is followed by their attachment on to the molecular scaffold. The scaffold serves as a skeleton 
positioning the loops in the right spatial conformation and omits the bulk of the protein. 
The main aim of this project was to synthesize the discontinuous epitope mimics 
of the HIV-1 gp120 by attachment of the corresponding cyclic peptides to the TAC 
scaffold, which is described in this chapter. The process of the synthesis can be 
separated into three parts: synthesis of the TAC scaffold, synthesis of the cyclic 
peptides corresponding to the CD4-binding site on gp120 and lastly, attachment 
of the peptidic loops onto the scaffold by the means of CuAAC chemistry.  
Moreover, first attempts of characterisation by NMR and CD-spectroscopy were 
performed on the linear and cyclic peptides as well as the scaffolded cyclic 
peptides to gain further insight into their structural features. The combination of 
these two techniques proved to be a powerful source of information on the 
three-dimensional conformation of the studied molecules. Each compound was 
studied separately to analyse whether it obtained a certain secondary structure 
of or if it was disordered. Afterwards, NMR spectra of the cyclic peptides were 
superimposed on the spectrum of the entire constructs to analyse the shift 
differences. This method allowed to draw conclusions on the structural 
organisation of the molecules and could aid optimisation of their design to obtain 
biologically active compounds. 
Synthesized constructs and cyclic peptide loops described below were tested for 
their biological activity, which will be described in section 4.2.2. 
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3.2 Results and discussion 
3.2.1 Synthesis of TriAzaCyclophane (TAC) scaffold 
Synthesis of the TAC scaffold was performed according to our slightly modified 
literature procedure.[88] The TAC scaffold was equipped with two protected 
alkynes, which are triethylsilyl (TES) and triisopropylsilyl (TIPS) derivatives of 
pentynoic acid. These compounds were synthesized in three steps. Firstly, the 
carboxylic acid moiety of 4-pentynoic acid was protected by conversion to a tert-
butyl ester (Scheme 1). Initially this reaction was performed according to the 
literature procedure by Fischer et al,[150] however, the product was obtained 
consistently in low yields (37%). Tert-butyl-protected pentynoic acid was required 
in large amounts as it was a precursor to obtain TES and TIPS-protected pentynoic 
acid derivatives. To increase the yields, a new method was investigated.[151] 4-
pentynoic acid was reacted with tert-butyl-2,2,2-trichloroacetimidate to afford 
the desired product in an excellent yield of 90%. Moreover, this approach 
benefited from an easy work-up procedure, which was a simple filtration using 
Celite to remove the crystalline side product trichloroacetamide. Due to volatility 
of the obtained compound 2, it was crucial to work with solvents that were easy 
to evaporate during the work-up (DCM), in following reactions and respective 
purifications (Et2O, pentane). The following reactions of TES and TIPS-protection 
had the highest yields when performed in THF (described further below), which 
was present in a small amount. Although it has a higher boiling point than Et2O, it 
could be still evaporated, if care was taken. The purification had to be performed 
in Et2O/pentane. After the purification the product was highly diluted, and it 
could not be recovered if the purification was performed with ethyl acetate and 
hexane or petroleum ether. Upon evaporation of these solvents, the product 
evaporated too. 
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Scheme 1 Synthesis of the tert-butyl protected pentynoic acid 2. 
 
The next step involved the reaction of the afforded tert-butyl ester 2 with an 
appropriate silyl chloride to obtain TES and TIPS-protected alkynes. When the 
reaction was performed according to the published procedure (Table 5, entry 1), 
the product was obtained in a lower yield (Table 5, entry 2), therefore screening 
of the reaction conditions to improve the yield was performed. The alterations 
included changes of the solvent in which the reaction was performed and the 
number of equivalents (equiv.) of added n-BuLi. It was found that an increase in 
the amount of n-BuLi from 1.0 to 1.2 equiv. decreased the yield to 35% (Table 5, 
entry 3). Change of the solvent to Et2O was thought to improve the yield of the 
recovered product after the work-up, since it was found that these compounds 
were volatile. It was observed that this reaction proceeded with formation of a 
milky precipitate, which was not observed previously and the reaction yield 
decreased further down to 13% (Table 5, entry 4). Even though the reported yield 
could not be reproduced, the initial conditions (Table 5, entry 2) were applied in 
TES-protection of tert-butyl 4 pentynoate 3 and enough of the product was 
obtained to proceed. 
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Table 5 Conditions screening for TES-protection. 
 
Entry Solvent nBuLi equiv. Yield 
1.[88] THF anh. 1.0 72% 
2. THF anh. 1.0 59% 
3. THF anh. 1.2 35% 
4. Et2O anh. 1.0 13% 
 
A similar screen of reaction conditions was performed for TIPS-protection of the 
tert-butyl ester. Performance of the reaction under published conditions (Table 
6, entry 1) resulted in a lower yield (Table 6, entry 2). Since it was observed, that 
the starting material was still present at the end of the reaction, the amount of 
n-BuLi was increased up to 1.8 equiv. to increase the deprotonation rate, 
however, the yields under these conditions decreased significantly (Table 6, entry 
3). The impact of dry Et2O as a solvent was investigated also in the TIPS-protection 
reaction. When the reaction was performed under the same conditions as the 
literature reaction with only the solvent changed to Et2O, the yield decreased 
down to 4% (Table 6, entry 4). However, when LDA was used instead of n-BuLi as 
a base in Et2O, the yield increased to 21% (Table 6, entry 5). Moreover, the 
alteration of TIPS-Cl to TIPS triflate was investigated. This reaction also proceeded 
with low yields (Table 6, entry 6). Even though the reported yield could not be 
reproduced, the initial conditions (Table 6, entry 2) were applied in 
TIPS-protection of tert-butyl 4 pentynoate 4 and enough of the product was 
obtained to proceed. 
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Table 6 Conditions screening for TIPS-protection. 
 
Entry Solvent Base (equiv.) 
TIPS source 
(equiv.) 
Yield 
1.[88] THF anh. n-BuLi (1.0) TIPS-Cl (1.2) 68% 
2. THF. anh. n-BuLi (1.0) TIPS-Cl (1.2) 46% 
3. THF anh. n-BuLi (1.8) TIPS-Cl (1.2) 6.6% 
4. Et2O anh. n-BuLi (1.0) TIPS-Cl (1.2) 4% 
5. Et2O anh. LDA (1.0) TIPS-Cl (1.2) 21% 
6. THF anh. n-BuLi (1.1) 
TIPS triflate 
(1.0) 
16% 
 
In a final step of the preparation of TES and TIPS-protected alkynes, the tert-butyl 
ester was removed by treatment with TFA. In the literature procedure[88] 
tert-butyl protected silyl alkynes were treated with 15% TFA/DCM. However, it 
was found that the amount of TFA could be decreased to 10%. These reactions 
proceeded with good yields of 66% (for compound 3) and 57% (for compound 4). 
Scheme 2 summarizes the final conditions for the synthesis of the TES and 
TIPS-protected 4-pentynoic acid derivatives. 
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Scheme 2 Synthesis of the TES and TIPS protected pentynoic acid derivatives. 
 
Synthesis of the TAC scaffold was performed according to the literature procedure 
published recently by Werkhoven et al.[88] The synthesis route is shown in the 
Scheme 3. The first step in the synthesis was protection of 3-bromopropylamine 
with the o-nitrobenzenesulfonyl (oNBS) protecting group to afford oNBS-protected 
bromopropylamine 7 in an excellent yield of 95%. Next, bromopropylamine 7 was 
reacted with 10 equiv. of 1,3-diaminopropane in DMA. After stirring overnight, 
1 equiv. of 4.0 M NaOH was added to deprotonate the amines, followed by 
evaporation of the excess diamine, which had a lower boiling point (140°C) than 
DMA (164.5-166°C). The reaction mixture was co-evaporated with DMA until the 
collected solvent was no longer basic. The crude product 8 was treated with ethyl 
trifluoroacetate to obtain bis-protected triamine 9. 4-pentynoic acid was coupled 
to the secondary amine functionality of triamine 9 in the presence of BOP and 
NMM, which after purification yielded product 10 in the yield of 69% over three 
steps. 
The triple-protected triamine 10 was cyclised with the dibromide 11 in presence 
of Cs2CO3, to obtain the TAC-scaffold skeleton 12 in a yield 44%. The cyclisation 
was performed at a relatively high dilution (12 mM) to prevent formation of the 
dimeric cyclic side product. The next step was the removal of trifluoroacetyl 
protecting group and methyl-ester by hydrolysis with Tesser’s base (15:4:1 
dioxane/MeOH/aqueous NaOH 4 M).[152] This was followed by Fmoc-protection of 
the free amine, which afforded the oNBS,Fmoc-protected TAC 13 scaffold in an 
excellent yield of 95%. 
The scaffold was loaded onto a 2-chlorotrityl resin and the Fmoc group was 
removed by treatment with 20% piperidine/DMF. At this point the TIPS and 
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TES-protected pentynoic acid derivatives were attached to the TAC scaffold one 
after the other. It is known, that the TIPS-protecting group is more stable than 
the TES-protecting group, therefore it was decided, that TIPS will be introduced 
first.[88] The TIPS-protected pentynoic acid 6 was coupled to the scaffold using 
BOP to afford the product 14. Afterwards, the oNBS-group was removed by 
treatment with β-mercaptoethanol and DBU, which was followed by coupling of 
the TES-protected 4-pentynoic acid 5 to the scaffold. Cleavage of the scaffold 
from the resin was accomplished by treatment with HFIP, which afforded the 
orthogonally protected trialkyne TAC scaffold 15 in the yield of 88%. 
 
Scheme 3 Synthesis of the orthogonally protected trialkyne TAC scaffold. 
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3.2.2 Synthesis of the cyclic peptides 
The next step in the preparation of discontinuous epitope mimics was the synthesis 
of the cyclic peptides corresponding to the conserved CD4-binding site of HIV-1 
gp120. The sequences of these epitopes were identified[153] and used successfully 
previously in our group.[144][88][154] However, peptides cyclised with an azido 
di(bromomethyl)benzene (N3-DBMB) (Figure 34, left) handle used in the previous 
studies were facing the problem of poor solubility, which hampered purification, 
attachment to the scaffold and biological assays. Therefore, in order to increase 
the aqueous solubility of the cyclic peptides it was decided to use an azido 
triazinanetris(2-bromoethanone) (N3-TADB) (Figure 34, right) cyclisation handle 
instead of the bisbromobenzylic handle N3-DBMB. The N3-TADB handle was 
recently developed in our group and has shown to significantly increase the 
solubility of the synthesized peptides in aqueous buffers.[155] Three peptide loops 
cyclised with the N3-TADB hinge would mimic the discontinuous epitope in gp120, 
which is also built of three loops (Figure 35). The peptide sequences found in 
gp120 were mimicked by the loops with identical peptide sequences. Moreover, 
cysteine residues were introduced at the N- and C-termini in each of the peptides 
to facilitate cyclisation with N3-TADB hinge. The N3-TADB hinge is also equipped 
with an azide handle, which is required to click the loops onto the orthogonally 
protected trialkyne TAC scaffold. 
 
Figure 34 Structures of cyclisation hinges.  
Left: N3-DBMB cyclisation hinge. Right: N3-TADB polar cyclisation hinge. 
71 
 
 
Figure 35 Synthetic peptide loops for the mimicry of gp120 CD-4 binding site. 
Top left: zoom on the CD4 (cyan) binding to gp120 within the conserved CD4-binding site. Loops 
participating in binding are shown in blue, red and green. Top right and bottom: the structures of the 
cyclic loops used in the mimicry of the gp120 discontinuous epitope. 
The linear peptides were synthesised by means of the standard Solid Phase Peptide 
Synthesis (SPPS). The obtained crude peptides were cleaved off the resin and 
lyophilised. Since the cyclisation reaction of crude linear peptides was known to 
be clean and without formation of any side products, crude peptides were used 
directly in the reaction of cyclisation.[155] The linear peptide was dissolved 
together with N3-TADB linker in acetonitrile to obtain the concentration of 1 mM 
of the peptide. Once dissolved, 20 mM ammonium bicarbonate was added, and 
the cyclisation was monitored by LCMS. It was found that the cyclisation was 
complete after 30 min. Next, the peptide was lyophilised and purified using 
preparative HPLC. Three cyclic peptides corresponding to the gp120 epitope 
sequences were synthesized according to this protocol. The overall yields of the 
synthesized cyclic peptides varied from 10-29%, which corresponds to the average 
yield 91-95% per reaction step (Table 7). 
A fraction of each of the linear peptides was separated and purified for future 
characterisation with 1H-NMR, CD-spectroscopy and MALDI-TOF. 
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Table 7 The synthesized cyclic peptides based on the HIV gp120 epitope sequences and the general 
structure of the cyclised peptide. 
Linear sequence 
Overall yield 
(yield per step) 
 
Ac-CLTRDGGKC-NH2 
(16, Loop 1) 
13% (91%) 
H-CINMWQEVGKAC-NH2 
(17, Loop 2) 
10% (92%) 
Ac-CSGGDPEIVTC-NH2 
(18, Loop 3) 
29% (95%) 
 
3.2.3 Attachment of the cyclic peptides to the TAC scaffold  
With all the building blocks ready, it was possible to assemble the loops on the 
TAC scaffold. 
As it was previously described by van de Langemheen et al.,[144] the cyclophane 
ring of the TAC scaffold is susceptible to ring-flipping, thus the “left” and “right” 
positions in the scaffold are interchangeable. Therefore, a construct 1-2-3 is 
identical to 3-2-1, where numbers indicate the peptide loop number (Figure 35). 
Since the “middle” position defines the final construct, loop 1, 2 or 3 was 
introduced as the first one on to the “middle” position to synthesize constructs in 
all possible combinations. The ligation of the peptides onto the scaffold was 
performed using a similar protocol to the ones published by Werkhoven at el.[88] 
and Longin et al.,[85] however certain modifications were introduced. It was 
observed, that depending on the sequence in which the loops were introduced 
onto the TAC scaffold, the conditions varied, especially the ratio between DMF 
and water as a solvent system, and reaction times (which are described in detail 
in Chapter 6.6). Even though structurally the constructs 1-2-3 and 3-2-1 are the 
same, the synthesis conditions might vary. Therefore, each of the three 
synthesized constructs which were used in the biological and structural studies 
will be discussed separately (Figure 36). 
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Figure 36 Schematic representation of the three final gp120 mimics used in biological and structural 
studies. 
 
3.2.3.1 Synthesis of the construct 22 (3-1-2) 
A schematic representation of the synthesis of construct 22 is shown in Figure 37. 
 
Figure 37 Schematic representation of the synthesis of construct 22. 
 
Loop 1 (16) was coupled with the free alkyne of the TAC scaffold 15 by CuAAC, 
which was typically completed in 2 h. This was followed by treatment with AgNO3 
and under these conditions the TES group was easily removed in 45-60 min. The 
synthesized construct 19 was then purified by preparative HPLC and obtained in 
the overall yield of 67% (average yield per step: 82%). Loop 3 (18) was 
subsequently coupled to the construct 19 in 4 h and purified to afford the product 
20 in 68% yield and 89% purity (the yield takes into account 89% purity of the 
product). Since the impurity was identified to be 
tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine (TBTA) which did not interfere 
with the following TIPS-deprotection step, it was decided to proceed to the next 
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reaction without further purification. TIPS removal was accomplished with 
tetra-n-butylammonium fluoride (TBAF). A total of 87.5 equiv. of 1.0 M TBAF/THF 
had to be added to remove TIPS successfully and the reaction was completed after 
29.5 h. The TIPS-removal reaction was found to be cumbersome and will be 
discussed in more detail in section 3.2.3.5. Once the TIPS-deprotected construct 
21 was purified it was obtained in 60% yield. Lastly, loop 2 (17) was clicked to the 
scaffold bearing two cyclic peptides. This reaction was complete in 4 h and the 
construct 22 was obtained in a yield of 35%. Progress of the attachment of the 
subsequent loops to the TAC-scaffold can be followed in Figure 38 and the final 
structure of the construct 22 is presented in Figure 39. 
 
Figure 38 Progress of attachment of the peptide loops on the TAC scaffold to obtain construct 22 as 
monitored by analytical HPLC.  
The constructs are named to describe the order in which loops were attached. Top trace to bottom 
trace: subsequent attachment of peptide loops to the TAC-scaffold. 
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Figure 39 Structure of the final construct 22. 
 
3.2.3.2 Synthesis of the construct 30 (1-3-2): 
A schematic representation of the synthesis of construct 30 is shown in Figure 
40. 
 
Figure 40 Schematic representation of the synthesis of construct 30. 
 
Synthesis of the second protein mimic was started by positioning loop 3 (18) in 
the “middle” of the TAC scaffold. The synthesis of this construct could be 
shortened by one purification step, which was performed for the first time after 
introduction of the second loop on to the TAC scaffold. In this way the synthesis 
time was shortened, and the number of performed purifications decreased. 
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Loop 3 (18) was coupled to TAC scaffold 15, which was completed after 3.5 h. 
This was followed by TES-removal with AgNO3 in 1 h. The next step was to couple 
loop 1 (16) to the scaffold. When after 7 h the reaction was still incomplete, the 
reaction was left to continue overnight. After the total of 18 h, the reaction was 
found to be complete and could be purified to afford the product 28 in 36% yield 
after three steps (71% average yield per step). TIPS removal was then performed 
using 40 equiv. of TBAF∙3H2O in DMF and the reaction was complete in 2.5 h and 
after purification by preparative HPLC product 29 was obtained in 62% yield. 
Lastly, loop 2 (17) was introduced, which was accomplished after 19 h and 
resulted in a very low yield of 9% of the final product 30. Progress of the 
attachment of the subsequent loops to the TAC-scaffold can be followed in Figure 
41 and the final structure of the construct 22 is presented in Figure 42. 
 
Figure 41 Progress of attachment of the peptide loops on the TAC scaffold to obtain construct 30 as 
monitored by analytical HPLC.  
The constructs are named to describe the order in which loops were attached. Top trace to bottom 
trace: subsequent attachment of peptide loops to the TAC-scaffold. 
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Figure 42 Structure of the final construct 30. 
 
3.2.3.3 Synthesis of the construct 26 (1-2-3) 
A schematic representation of the synthesis of construct 26 is shown in Figure 43. 
 
Figure 43 Schematic representation of the synthesis of construct 26. 
 
The synthesis of the last construct in this small library was started by coupling 
loop 2 (17) to TAC scaffold 15, which was complete after 3 h and the subsequent 
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deprotection step was started and completed after 1 h. Then, loop 1 (16) was 
coupled to the construct bearing one cyclic peptide. This reaction was completed 
after 2 h and the product 24 was obtained in a yield of 22% over three steps (60% 
average yield per step). TIPS removal was performed with 40 equiv. of TBAF∙3H2O 
in DMF and after work-up and preparative HPLC the deprotected product 25 was 
obtained in 69% yield. Finally, loop 3 (18) was coupled to the last free alkyne and 
this reaction was completed after 2.5 h. After purification, product 26 was 
obtained in a good yield of 69%. Progress of the attachment of the subsequent 
loops to the TAC-scaffold can be followed in Figure 44 and the final structure of 
the construct 22 is presented in Figure 45. 
 
Figure 44 Progress of attachment of the peptide loops on the TAC scaffold to obtain construct 26 as 
monitored by analytical HPLC.  
The constructs are named to describe the order in which loops were attached. Top trace to bottom 
trace: subsequent attachment of peptide loops to the TAC-scaffold. 
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Figure 45 Structure of the final construct 26. 
 
Moreover, the synthesis of the construct 26 was also attempted by reversing the 
order in which loops 1 and 3 were introduced (Figure 46). Firstly, after 
introduction of loop 2 and TES removal as described above, loop 3 was coupled to 
the construct. This reaction was complete after 10 h and proved to be difficult to 
monitor, since the product peak overlaps with the TBTA peak on LCMS. Also, 
because the product and TBTA run closely together on the chromatography 
column, the product could not be purified and was obtained as a mixture with 
TBTA with the yield of 11% after three steps. TIPS-removal with 40 equiv. of 
TBAF∙3H2O was complete after 4.5 h with 54% yield. Finally, loop 1 was 
introduced, which was complete after 3 h and after the purification the final 
product 26 was obtained in 23% yield. However, only 0.6 mg of this product was 
obtained, which was mostly due to the loss of the product after introduction of 
the second loop. Due to the small amount of the obtained product, it was not used 
for structural or biological studies. The progress of this reaction was followed by 
analytical HPLC (see Appendix Figure 146 - Figure 157). 
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Figure 46 Schematic representation of the synthesis of construct 26 with different order of loops 
attachment. 
 
3.2.3.4 Overview of loops attachment to TAC-scaffold 
The attempt to synthesize compound 26 by introducing the loops in different order 
clearly demonstrated, that the order in which the loops were introduced onto the 
scaffold was of enormous importance. Another explanation for this difference was 
the slightly more hydrophobic character of loop 3. When comparing the retention 
times on analytical HPLC of loops 1 and 3, which were 14.593 min and 15.227 min 
(gradient of A into B of 0-100% over 30 min), respectively, it was observed that 
loop 3 was slightly more hydrophobic. Loop 2 was known to be less soluble and 
more hydrophobic when compared to loops 1 and 3, with the retention time on 
analytical HPLC of 17.023 min. Moreover, the loops are of different sizes, since 
loop 1 consists of of 9 amino acids, loop 2 of 12 amino acids and loop 3 of 11 amino 
acids. The hydrophobic character and size of the loops are schematically shown in 
Figure 47. 
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Figure 47 Comparison of size and hydrophobic character of independent loops with the retention 
times obtained from analytical HPLC. 
 
It is believed, that the final yield of the gp120 mimics is a result of 
hydrophilic/hydrophobic character of the loops, the amino acid composition in the 
primary structure and the order in which they are introduced (Table 8). 
Introduction of loop 1, which is the smallest of the loops (shortest peptide 
sequence) and the most hydrophilic, which is followed by loop 3 (medium sized, 
medium hydrophilicity) and then loop 2 (the biggest and most hydrophobic) 
resulted in a good yield of the final product 22. This might indicate, that loops 1 
and 3 interacted with each other and “left enough space” for an efficient, albeit 
time-consuming, introduction of loop 2 (Table 8, entry 1). If loop 2 was introduced 
as the first one, it had the most space to be coupled efficiently. When followed 
by loop 1, which is the smallest of the loops, again enough space is left for loop 
3. This combination resulted in the highest overall yield of the compound 26 
(Table 8, entry 2). However, when the synthesis is started from loop 3 and 
followed by loop 1 (reverse order when compared to entry 1), it seemed that the 
loops might be interacting with each other  differently, since the final overall 
yield is significantly lower and coupling times longer (Table 8, entry 3). When the 
synthesis was started from loop 2 and followed by loop 3, which are the two 
biggest loops, it seemed that the free alkyne in the “right” position was hindered 
significantly, and loop 1 could not be coupled efficiently, resulting in the lowest 
overall yield of 1.3% (Table 8, entry 4). However, the yields of each loop 
introduction could not be compared, because in two out of three constructs two 
loops were introduced in a one-pot reaction. It was also noted, that depending on 
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the position on the scaffold in which the loop is being attached, the coupling times 
vary. For example, introduction of loop 3 followed by loop 1 was accomplished in 
18 or 3 h (Table 8, entry 3 and 4, respectively), depending on the position of the 
loops on the scaffold. However, introduction of loop 1 followed by loop 3 was 
complete in 4 or 2.5 h (Table 8, entry 1 and 2, respectively). All these 
observations indicated, that several variables, including hydrophilic/hydrophobic 
character of the loops, the amino acid composition in the primary structure, the 
order in which they were introduced have influenced the final yield of the 
obtained product. 
The secondary structure of the peptides and their interactions with each other 
when assembled on the scaffold were studied in more detail by 1H-NMR and 
CD-spectroscopy and are described in section 3.3. 
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Table 8 Synthesized constructs with attached loops in different positions, yields and amounts in 
which they were obtained. The arrow in the schematic structure indicates the order in which the loops 
were introduced, with the arrow starting as the first one. 
Entry 
(compound) 
Amount 
obtained 
Overall 
yield 
Schematic structure 
1. (22) 
3.2 mg 
(0.6 μmol) 
9.4% 
 
2. (26) 
3.4 mg 
(0.7 μmol) 
10.6% 
 
3. (30) 
1.2 mg 
(0.2 μmol) 
2.3% 
 
4. 
0.6 mg 
(0.1 μmol) 
1.3% 
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3.2.3.5 TIPS-removal 
The TIPS-protecting group has proven to be very stable and even difficult to 
remove. Removal conditions were screened to find the best method and the 
reactions were monitored by LCMS or analytical HPLC. Selected examples will be 
shown below. A very fine balance between the number of TBAF equiv. and reaction 
times had to be found. Extended reaction times and too small amount of equiv. 
of TBAF led to the decomposition of both product and starting material. 
In one example, compound 28 served as a starting material. After 19 h from 
addition of 30 equiv. 1 M TBAF/THF, only starting material was observed by LCMS 
(Figure 48). After addition of another 18 equiv. and a further 4 h, there was still 
no conversion (Figure 49), therefore another 18 equiv. of TBAF were added. After 
a total of 26 h the formation of the product was observed, however, the majority 
still being starting material (Figure 50). 17.5 h later the ratio between the 
product and the starting material started shifting even further towards formation 
of the product. To speed up the reaction, another 18 equiv. of TBAF were added, 
however after next 6.5 h no further conversion was observed. Addition of another 
18 equiv. of TBAF and leaving the reaction mixture for 16.5 h more resulted in the 
complete decomposition of both starting material and the product (Figure 52). 
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Figure 48 Progress of TIPS removal after 19 h. 
 
 
Figure 49 Progress of TIPS removal after 23 h. 
 
starting material 
starting material TBAF 
86 
 
 
Figure 50 Progress of TIPS removal after 26 h. 
 
 
Figure 51 Progress of TIPS removal after 43.5 h. 
 
starting material 
TBAF 
product 
product 
starting material 
TBAF 
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Figure 52 Product decomposition after the total of 66.5 h. 
 
In contrast to the above example, it was found that the reaction led to the 
formation of the desired product in 2-4.5 h depending on the composition of loops 
on the scaffold, if between 40-50 equiv. of TBAF∙3H2O was added all at once 
instead of adding it in portions (Figure 53). TBAF∙3H2O was preferred to 1 M 
TBAF/THF, because it has less basic character and a smaller chance of causing 
decomposition and racemisation in peptides. 
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Figure 53 Zooming in on progress of the TIPS deprotection reaction with TBAF∙3H2O over time 
monitored by analytical HPLC.  
Black line: reaction after 2 h, pink line: reaction after 3 h, blue line: complete conversion after 4.5 h. 
 
3.2.3.6 One-pot assembly of the peptide loops on the TAC scaffold 
A successful attachment of two peptide loops and removal of TES-protecting group 
in one-pot allowed to shorten synthesis time and decrease the number of 
purification steps. This inspired us to investigate whether it was possible to 
assemble all loops in a one-pot reaction. A single attempt towards one-pot 
attachment of the loops and removal of the protecting-groups was performed. It 
was not possible to repeat this reaction due to the limited availability of the 
starting materials. 
Attachment of the first peptide loop (loop 2), TES-removal and attachment of the 
second peptide loop (loop 1) in one-pot was followed by analytical HPLC and was 
performed successfully (for the reaction scheme, see Figure 43. For analytical 
HPLC chromatograms monitoring the reaction see Appendix Figure 158 - Figure 
160). The bottleneck reaction proved to be TIPS-removal. The progress of this 
reaction can be followed in Figure 54. After 2 h from addition of 34.2 equiv. of 
TBAF∙3H2O the ratio between the product and the starting material was 20:80%. 
After addition of 18 equiv. of TBAF∙3H2O and further 1 h the ratio shifted to 
34%:66%. After addition of further 21 equiv. and another 1 h, formation of a side 
starting material 
product 
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product was observed as well as decomposition of the starting material. The ratio 
between the side product, product and (decomposed) starting material was: 
34%:25%:41%. After leaving the reaction overnight, neither product nor starting 
material could be detected. 
 
Figure 54 Progress of the TIPS-removal in one-pot assembly of the discontinuous mimics monitored 
by analytical HPLC.  
Black line: reaction after 2 h, pink line: -reaction after 3 h, blue line: reaction after 4 h, brown line: 
reaction after overnight. 
 
LCMS analysis (Figure 55) of the reaction mixture after 4 h had shown that the 
mass of the side product was lower than the mass of the desired product by 174 
mass units. The same difference was observed between the starting material and 
its decomposed variant. It shows that both constructs undergo a similar 
decomposition pathway caused by presence of TBAF which might be caused by β-
elimination. The base could abstract the αH of the Cys, which is coupled to the 
cyclisation linker. If the sulphur is oxidised, which might happen in presence of 
remains of cooper, as it is in the click reactions, β-elimination would be even 
easier. A possible remedy to this undesired reaction would be to exchange cysteine 
to homocysteine, which would be less susceptible to the β-elimination. 
This example showed, that if the reaction conditions were carefully optimised, it 
would be possible to remove TIPS-protecting group in presence of the click 
reagents. This would make the one-pot synthesis feasible. However, as it was 
starting material 
product 
side product 
decomposition 
decomposing 
starting 
material 
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shown in the previous sections, that the amount of TBAF is of critical importance, 
as well as the time for how long the reaction is performed.  
 
Figure 55 LCMS analysis of the TIPS removal reaction in one pot after 4 h. 
 
3.3 CD and NMR-spectroscopy towards structural 
characterisation of the synthesized gp120 mimics and 
independent peptide loops 
Linear peptides corresponding to the primary sequence of gp120 discontinuous 
epitopes, their cyclised versions as well as the total constructs with loops 
assembled on the TAC scaffold were analysed by NMR and CD-spectroscopy. These 
experiments allowed to gain insight into the secondary structure of the 
synthesized molecules, the amount of the structural organisation, and if and how 
the loops were interacting with each other once assembled on the TAC scaffold.  
product + side 
product 
starting material + 
decomposing starting 
material 
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3.3.1 1H-NMR-spectroscopy analysis of synthesized linear and 
cyclic peptides and assembled constructs 
The NMR experiments were performed and analysed with the assistance of Dr. 
Brian Smith (Institute of Molecular, Cell and Systems Biology University of 
Glasgow). 
The samples were prepared as 100 μM solutions of the compound in 20 mM 
phosphate buffer, pH 7.5, supplemented with D2O to a final concentration of 5%, 
total volume 600 μL. However, both accuracy of weighing out these molecules 
(less than 0.3 mg per sample, which was further diluted to obtain the desired 
concentration) as well as problems with their precipitation in the aqueous buffer 
(especially linear peptide 2) might have caused that the actual concentration was 
lower than expected. Moreover, linear peptides were prepared both with addition 
and without TCEP as reducing agent to compare, whether the linear peptides are 
present in reduced or oxidised form in a solution. It was found however, that 
addition of TCEP did not influence significantly the obtained spectra, which 
suggests that the linear peptides are in the reduced state. Selected spectra are 
shown and analysed below. Since spectra of the linear peptides with and without 
TCEP are almost identical, only the spectra without TCEP are shown below. 
Spectra of the TCEP treated linear peptides are shown in the Appendix (Figure 
161 - Figure 163). The water signal was supressed in all the spectra. 
The NMR spectra of peptides can be analysed similarly to proteins, as it was 
described in the section 2.1.4. 
The same samples were used for the CD-spectroscopy experiments. 
3.3.1.1 Linear peptides 
1H-NMR analysis of the linear peptide 1 suggested, that it was present in a random 
coil configuration (Figure 56). Very weak signals coming from the amide backbone 
NH protons mean that these amide protons are rapidly exchanging with the solvent 
and are not protected from the environment. This observation suggests that linear 
peptide 1 is mostly disordered. The spectrum of an unfolded peptide corresponds 
to the spectrum of a sum of random coil spectra of the amino acid residues of 
which the peptide is composed.[156] The sharp and not very well dispersed peaks 
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in the aliphatic region allow to find some of the characteristic shifts of the amino 
acids (all values given in ppm): Leu: δ CH3: 0.87, 0.94; Hβ: 1.62, 1.64; Thr γCH3: 
1.21; Arg δCH2: 3.20, 3.19; Lys ϵCH2: 3.00, 2.98. However, 1H-NMR experiment did 
not allow to assign all the protons found in the spectrum. 
 
Figure 56 1H NMR analysis of linear peptide 1. 
The red box indicates where the amide backbone proton signals should be present if the linear 
peptide 1 would have had ordered secondary structure. 
The linear peptide 2 heavily precipitated out in the buffer, therefore the 
signal:noise ratio in the NMR spectrum is low (Figure 57). The most characteristic 
is the peak present at 10.16 ppm, which belongs to the proton of the amine in the 
indol ring of the tryptophan residue. Moreover, the aromatic protons of the 
tryptophan residue are visible in the 7.00-8.00 ppm region. Overall, more 
dispersed peaks in the aliphatic region, when compared to the linear peptide 1, 
suggest that linear peptide 2 is more structured. The signals coming from the NH 
protons of the amide backbone indicated that these are more protected from the 
solvent environment, which could be caused by the fact that this peptide is more 
constrained already in its linear form. 
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Figure 57 1H NMR analysis of linear peptide 2.  
Green box indicates aromatic protons belonging to the indol ring of Trp. The blue box indicates the 
NH proton from the indol ring. 
In the 1H-NMR spectrum of the linear peptide 3 (Figure 58) the signals coming 
from NH protons of amide bonds are very strong (8.0-8.5 ppm), which indicats that 
these protons are protected from the surrounding solvent and the amide backbone 
is more constrained. Linear peptide 3 does not have any aromatic amino acids in 
its primary sequence nor primary NH2 groups as in Asp, Glu or Lys, therefore the 
signals present in the 7.0-7.5 ppm region originats from the NH2 group of the 
C-terminus. Linear peptide 3 seems to have the most constrained structure out of 
the three linear peptides. 
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Figure 58 1H NMR analysis of linear peptide 3.  
The red box indicates the proton signals coming from the amide backbone of the peptide suggesting 
that it obtains a certain secondary structure. The cyan box indicates protons signals coming from the 
C-terminal NHs. 
3.3.1.2 Cyclic peptides 
In the 1H-NMR spectrum of loop 1 small changes in the amide region were observed 
(Figure 59). The clustered amide NH protons signals in the 8.0-8.5 ppm region 
indicate a random coil structure in this peptide. Moreover, the proton signals of 
Arg and Lys NH protons can be observed. The aliphatic region representing the 
side chains of the peptide is almost identical to the linear peptide. 
If the two spectra are stacked over each other, it can be observed that there are 
differences in the amide backbone region (Figure 60). This suggests that even 
though both peptides are disordered, they adopt different conformations. 
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Figure 59 1H NMR analysis of Loop 1.  
The red box the proton signals coming from the amide backbone of the peptide. The purple box 
indicates the signals coming from the NH protons of Arg and Lys. 
 
Figure 60 1H-NMR spectra of linear peptide 1 and loop 1 stacked over each other.  
Brown – the spectrum of the linear peptide 1. Blue – the spectrum of the loop 1. 
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The proton signals of the NH protons within amide bonds of loop 2 are more visible 
than in loop 1, however they are still relatively broad and clustered (Figure 61). 
This observation indicates, that loop 2 was more structured than loop 1. Moreover, 
the proton signals of the Asp NH2 group and aromatic signals from Trp were 
observed in the spectrum. In the spectrum of loop 2 two populations of signals are 
present in the region of 3.2-3.4 ppm, which corresponds to the (βH) of Trp. This 
suggests that different conformers are present in the sample of this peptide. 
 
Figure 61 1H NMR spectra loop 2.  
The red box indicates the proton signals coming from the amide backbone of the peptide. The green 
box indicates aromatic protons belonging to the indol ring of Trp and NH2 protons of Asn. The blue 
box indicates the NH proton from the indol ring. 
Once the two spectra were stacked over each other (Figure 62), the changes in 
the aliphatic region corresponding to the amino acid side chains become more 
visible. Since the hinge used for the cyclisation is in a chair-like conformation,[155] 
a conclusion can be drawn that the side chains of Asn, Gln, Trp and Lys might be 
interacting with each other causing the peptide to obtain a more constrained 
secondary structure. Linear peptide 2, due to precipitation, was at too low 
concentrations to be able to draw conclusions whether the amide backbone region 
was different from the loop 2. 
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Figure 62 1H NMR spectra of linear peptide 2 and loop 2 stacked over each other.  
Red – the spectrum of the linear peptide 2. Green – the spectrum of the loop 2. 
The proton signals present in the amide backbone region in the 1H-NMR spectrum 
of loop 3 are broader than those present in the spectra of loop 1 or 2 (Figure 63). 
Moreover, these signals are strong, which indicates that the amide backbone of 
the peptide is protected from the solvent because it is well constrained. As in the 
linear peptide, in the region 7.0-7.5 ppm signals from the NH2 protons of the 
C-terminus are visible. 
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Figure 63 1H NMR spectra loop 3.  
The red box indicates the proton signals coming from the amide backbone of the peptide. The cyan 
box indicates the protons signals coming from the C-terminal NHs. 
After stacking of the 1H-NMR spectra of the linear peptide 3 and loop 3 over each 
other it became clearer, that better dispersed proton signals are present in the 
region of 7.0-7.5 ppm, corresponding to the NH2 protons of the C-terminus in the 
spectrum of loop 3 (Figure 64). Also changes in the chemical shifts of the protons 
in the amide backbone are present: in the spectrum of loop 3 these signals are 
broader and better resolved. These observations suggest, that the backbone of 
the loop 3 is constrained and ordered. More changes can be observed also in the 
region 0.8-1.0 ppm which corresponds to the proton signals of Val (γCH3) and Ile 
(δCH3 and γCH3). Also, very subtle changes can be observed at 1.15-1.25 ppm 
where γCH3 protons of Thr are present. These changes might stem from the 
intramolecular hydrophobic interactions between the methyl groups of the 
aforementioned amino acids, which is another evidence towards the 
well-organised structure of the loop 3. 
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Figure 64 1H NMR spectra of linear peptide 3 and loop 3 stacked over each other.  
Orange – the spectrum of the linear peptide 3. Blue – the spectrum of the loop 3. 
Overall, it can be concluded that out of three linear peptides, linear peptide 3 is 
the most constrained and linear peptide 1 is the most disordered. The same was 
observed among three loops. 
3.3.1.3 gp120 mimics – scaffolded cyclic peptides 
In order to find out whether the TAC scaffold induced further structural constraint 
and whether the peptide loops were interacting with each other once 
scaffolded,1H-NMR spectra of the assembled peptides on the scaffold were 
obtained. If the loops were disordered and did not interact with each other on the 
scaffold, a spectrum which would be a sum of independent spectra would be 
expected. If the scaffold induced certain structural constraints, the chemical shift 
of the construct would differ from the signals of the independent loops. To 
monitor these changes, the spectra of constructs 22, 26 and 30 were stacked over 
the spectra of loops 1-3. Moreover, the spectra of the three constructs were 
stacked over each other to compare whether there were any structural differences 
between them. 
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As an example, the spectrum of construct 22 stacked over loop 1, 2 and 3 is 
presented below in Figure 65. The different final concentrations of the samples 
did not allow to add up independent spectra. Therefore, it cannot be concluded, 
whether the spectrum of the construct 22 was or was not a simple sum of all the 
independent spectra. However, it can be observed that there are certain 
differences in the aliphatic region, especially at 0.7-1.1 ppm, which suggests that 
the loops might be interacting with each other once present on the scaffold. 
Similarly, the amide backbone and aromatic regions have a different overall 
shape. 
 
Figure 65 1H-NMR stacked spectra of construct 22, loops 1, 2 and 3. 
Red: construct 22, green: loop 1, cyan: loop 2, purple: loop 3. 
The spectra of constructs 22 and 30 were stacked over each other, which 
revealed, that they were almost identical (Figure 66). However, very subtle 
changes in the region of 0.7-1.0 ppm corresponding to the methyl groups suggest 
that the amino acids containing these groups (Thr, Ala, Val, Ile, Leu, Met) might 
be interacting with each other differently once scaffolded. 
101 
 
 
Figure 66 1H-NMR spectra of constructs 22 and 30 stacked over each other. Cyan: construct 22, 
Red: construct 30. 
 
However, more subtle differences were observed once the 1H-NMR spectra of 
constructs 22 and 26 were stacked over each other (Figure 67). The peaks in the 
aromatic region of construct 26 are sharper than in the construct 22. Also, the 
signal coming from the NH of the indol ring of Trp is sharper when compared to 
the corresponding signal in the construct 22. There are two possible explanations 
for this observation. The first one assumes that the entire construct 26 obtains a 
very defined conformation and the peaks are sharp because there is no exchange 
with the surrounding solvent. The second hypothesis is that the construct 26 is 
less constrained than construct 22 (and construct 30, since it is identical to 
construct 22) and is present in different conformations. If the conformations of 
this construct are exchanging between each other quickly or the molecule in the 
sample is tumbling slowly, then the average signal becomes sharp. Due to the 
known cyclophane ring flipping[144] the second hypothesis is more probable. 
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Figure 67 1H NMR spectra of constructs 22 and 26 stacked over each other. 
Cyan: construct 22, orange: construct 26. The blue box indicates the signal of the NH within the indol 
ring of Trp. 
Moreover, construct 22 was subjected to 1H-NMR analysis at a range of 
temperatures to see whether the temperature change affects the obtained 
spectrum. The temperature was decreased by with steps of 4° from 298-278K 
(Figure 68). The obtained spectra were stacked over each other to investigate if 
any changes were apparent. The obtained spectra appear almost identical, with 
only very subtle peak sharpening in both aliphatic and amide-backbone regions. 
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Figure 68 Variable temperature 1H-NMR of the construct 22.  
The temperature was decreased by 4° in 5 steps from 298-278K. 
3.3.2 CD - spectroscopy analysis of synthesized linear and cyclic 
peptides and assembled constructs 
To complement the results obtained by 1H-NMR of the peptides and constructs, 
the same samples were used to obtain CD-spectroscopy spectra. The 
CD-spectroscopy experiments were performed and analysed with the assistance of 
Dr. Sharon Kelly (University of Glasgow, Institute of Molecular, Cell and Systems 
Biology). Linear peptide samples were analysed both with and without TCEP and 
minor differences were observed in the spectra. 
The results of these experiments are summarised in Table 9. 
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Table 9 Summary of the secondary structure composition estimates – closest matching solution with 
all of the linear peptides, cyclic peptides and the constructs with assembled loops. The goodness of 
fits as judged by NRMSD. Values lower than 0.1 were favourable. Method used: Contin-LL 
(Provencher & Glockner method).[131] 
Compound Helix Strand Turns Unordered Total NRMSD 
Linear 1 0.096 0.297 0.250 0.367 1 0.090 
Linear 1 
+TCEP 
0.094 0.327 0.244 0.335 1 0.136 
Linear 2 0.060 0.404 0.121 0.416 1.001 0.249 
Linear 2 + 
TCEP 
0.061 0.396 0.123 0.421 1.001 0.190 
Linear 3 0.117 0.282 0.248 0.353 1 0.030 
Linear 3 + 
TCEP 
0.093 0.304 0.242 0.360 0.999 0.039 
Loop 1 0.086 0.334 0.236 0.344 1 0.143 
Loop 2 0.070 0.367 0.126 0.437 1 0.261 
Loop 3 0.084 0.330 0.233 0.353 1 0.080 
Construct 
22 
0.067 0.372 0.126 0.434 0.999 0.136 
Construct 
26 
0.073 0.359 0.127 0.440 0.999 0.131  
Construct 
30 
0.071 0.373 0.124 0.432 1 0.138 
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The samples in Table 9 are described by the secondary structure composition and 
total content and the normalised root mean square deviation (NRMSD) value. 
NRMSD value represents a goodness-of-fit. A low NRMSD value (<0.1) suggested 
that the analysis produced good results. Conversely, a high NRMSD value (>0.1) 
suggested that the similarity between the calculated secondary structure and the 
actual structure (experimental) was unlikely to be correct.[157] As can be observed 
among the linear peptide samples, the addition of TCEP caused minor differences 
in the CD-spectra (the difference of maximum 3% between the values with and 
without TCEP). This suggested, that the linear peptides are present in the reduced 
form regardless of addition of the reducing agent. Comparison of the linear 
peptides with their cyclic counterparts allowed to observe that cyclisation of the 
peptides seemed to induce minor changes in the secondary structure composition. 
Among the constructs with attached peptides loops, constructs 22 and 30 appear 
to be almost identical. Construct 26 appeared to be slightly more disordered. 
These observations were in agreement with conclusions drawn from 1H NMR 
experiments. 
The obtained results suggest that all the obtained compounds are in 33-44% 
disordered. However, the NRMSD value for several compounds was unfavourable 
therefore conclusions drawn for these compounds were uncertain. 
All synthesized compounds apart from linear peptide 2, had the elliplicity 
minimum around 200 nm as shown in Figure 69 (CD spectra for linear peptides are 
shown without TCEP. CD spectra of linear peptides supplemented with TCEP are 
in the Appendix, Figure 164 - Figure 166). Moreover, spectra of the peptides 
assembled on the TAC scaffold were superimposed on each other. As can be 
observed in Figure 70, compounds 22 and 30 are almost identical. This 
observation was in line with results obtained from 1H NMR experiments. 
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Figure 69 CD-spectra of the synthesized compounds. 
In linear peptides (without TCEP) from left spectra of: linear peptide 1, 2 and 3. In cyclic peptides from left spectra of: loop 1, loop 2, and loop 3. In constructs from left 
spectra of: 22, 26, 30.
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Figure 70 Superimposition of the CD-spectra of compounds 22 (blue), 26 (green) and 30 (red). 
 
3.4 Conclusions 
Three linear peptides corresponding to the discontinuous epitope sequences in 
gp120 were synthesized and cyclised with a novel cyclisation hinge to increase the 
solubility of the obtained cyclic peptides. These loops were then successfully 
sequentially attached to the TAC scaffold to obtain three different constructs (22, 
26, 30) which would mimic the CD4-binding site of gp120. Moreover, the synthesis 
of the constructs was timewise shortened by attachment of two loops and 
TES-deprotection in one-pot reaction. An attempt to synthesize the full construct 
in one-pot was performed, however during the TIPS-deprotection the compound 
decomposed. All the obtained compounds were then analysed by 1H-NMR and 
CD-spectroscopy to gain further insight in to the secondary structure. From the 
obtained results it can be concluded that the linear peptide 3 is the most ordered, 
while the linear peptide 1 is the most disordered out of the three peptides. The 
same observation applies to the cyclic peptides, respectively. The analysis of the 
three constructs revealed, that two out of them are almost identical (22 and 30) 
and the third one (26) is possibly less constrained than the other two. 
The biological evaluation of the obtained compounds by SPR will be described in 
the Chapter 4. 
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4 Evaluation of the binding of gp120 protein 
mimics to the CD4D12 by SPR 
4.1 Introduction 
The main objective of this project was to evaluate binding of the synthesized 
gp120 discontinuous epitope mimics to the CD4 receptor protein, which is the 
main port of entry of HIV-1. Previous attempts in the Liskamp group to evaluate 
binding of gp120 mimics to the CD4-receptor relied on an ELISA assay, which has 
proven to be unreliable since it often afforded variable results even with values 
below 0% or above 100% of control binding.[114] A robust, reproducible, and a 
reliable method to study binding properties of the synthesized gp120 mimics was 
needed. Initially it was decided, that binding between the mimics and the protein 
could be evaluated by ITC. However, ITC required large quantities of concentrated 
protein samples, therefore in order to meet these requirements, attempts towards 
CD4 and gp120 expression and purification were made. The obtained proteins were 
subjected to an ITC experiment; however, it was found that the concentrations of 
both proteins were too low to obtain any responses. The entire gp120 sample was 
consumed by this experiment and much more would be needed to obtain good 
quality results and to optimise the method. Moreover, large scale expression and 
purification of gp120 was cumbersome and not feasible, and in the end efforts in 
this direction were discontinued. Therefore, SPR was used since this technique 
requires smaller quantities and lower concentrations of the proteins. Moreover, in 
contrast to ELISA it should allow investigation of the kinetics and affinity of an 
interaction. In an SPR experiment, one of the molecules (ligand) is attached 
(covalently or non-covalently) to the sensor chip and a sample with the interacting 
partner (analyte) is passed over the surface (Figure 71). 
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Figure 71 Illustration of the interacting partners in the SPR experiment.  
a) A covalently immobilised ligand binds an analyte in the solution; b) A ligand is non-covalently 
bound to a capturing molecule (e.g. antibody, streptavidin) and interacts with an analyte in the 
solution. 
Binding of the two molecules will generate a response, which is proportional to 
the bound mass on the surface and can be detected (Figure 72). In the literature, 
SPR has been successfully used for investigation of the binding between CD4 (both 
4-domain and 2-domain) and gp120.[124][128][130][158][159] The principle of SPR is 
described in more detail in section 1.3.3. 
 
Figure 72 Response of the SPR experiment in the form of sensogram. Adapted from [160]. 
 
CD4D12 and gp120 were obtained commercially. The two domain CD4D12 was 
obtained to set up an experiment and compare the activity and binding profile of 
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the expressed CD4D12 with the commercial product. Binding of gp120 to CD4D12 
served as a positive control that could be compared with the literature data. 
4.2 Results and discussion 
An SPR experiment could be set up in two ways: as a direct binding assay, where 
binding of gp120 mimics to immobilised CD4D12 is measured or as a competition 
assay, where inhibition of the binding of CD4D12 to immobilised gp120 in presence 
of gp120 mimics is measured. Both approaches were investigated in order to find 
optimal conditions for evaluation of binding properties of synthesized gp120 
mimics, as described in sections 4.2.1 and 4.2.2. However, the first objective was 
to optimise experimental conditions of gp120-CD4D12 binding as a positive 
control, as the obtained results could be compared with the literature data. Only 
then, binding of gp120 mimics to CD4D12 could be measured. 
The process of setting up an SPR experiment can be divided into four phases: 
1) determination of the optimal pH for immobilisation (pH scouting) and 
pre-concentration, 2) immobilisation of the ligand, 3) determination of 
regeneration conditions (regeneration scouting), and 4) the binding experiment. 
The CM5 sensor chip (Biacore) was chosen for the SPR experiments as it was 
described in the literature.[124][128][130][158][159] 
4.2.1 Towards a competition assay of the binding of CD4D12 to the 
immobilised gp120 
In an SPR experiment, the sample that is the analyte and passed over the sensor 
surface is needed in larger quantities than the sample of an immobilised ligand. 
Gp120 had to be commercially obtained, while CD4D12 could be expressed and 
purified in larger quantities, therefore once the experimental conditions were 
determined using commercial proteins, in house expressed CD4D12 could be easily 
used. To minimise utilisation of gp120 protein we decided to perform a 
competition assay. To achieve this, gp120 had to be immobilised on the sensor 
surface while CD4D12 was passed over it and the binding was measured to obtain 
a positive control. In the competition experiment, gp120 mimics would be 
pre-incubated with the CD4D12 protein and passed over immobilised gp120. The 
decrease in binding of CD4D12 to gp120 in relation to gp120-CD4D12 binding in the 
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absence of gp120 mimics would allow an estimation of the binding capacity of the 
mimics. 
4.2.1.1 pH scouting and pre-concentration 
In order to achieve the desired immobilisation level of the highly diluted (typically 
10-50 μg∙mL-1) protein on the sensor surface, it had to be electrostatically 
pre-concentrated in the negatively charged dextran matrix of the sensor. The 
carboxymethylated dextran on the sensor surface is negatively charged at a pH 
above 3.5, therefore to efficiently concentrate ligand on the surface it has to 
obtain a positive charge. To optimally pre-concentrate the ligand on the sensor 
surface, the ligand should be present in a solution at a pH between 3.5 and its 
isoelectric point (pI). Thus, the ligand and the sensor surface carry opposite net 
charges. 
To find optimal coupling conditions for gp120 immobilisation, gp120 under 
different buffer conditions was passed over an unactivated sensor chip (pH 
scouting) and the extent of its preconcentration was observed as an increase in 
response. 
Gp120 was prepared in 10 mM acetate buffers at different pH values: 5.5, 5.0 and 
4.5 and exposed to the unactivated surface of a CM5 chip. After each protein 
injection, 1 M ethanolamine solution at pH 8.5 was injected to remove all 
electrostatically bound ligand. As is shown in Figure 73 pre-concentration levels 
of gp120 on the chip surface vary at different pH values. At pH 5.5 the lowest 
pre-concentration level was obtained (6127.6 response units, (RU)). At pH 5.0 the 
pre-concentration level was the highest (7215.6 RU). At pH 4.5 the 
pre-concentration level was also reasonably high (6913.6 RU), however it could be 
observed that the bound protein dissociated to a lesser extent after injection. 
Therefore, lower pH values were not tested, as they could lead to protein 
aggregation or denaturation. The optimal pH for immobilisation was determined 
to be 5.0. 
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Figure 73 pH scouting and pre-concentration studies of gp120. 
gp120 (10 μg∙mL-1) in 10 mM acetate buffers at pHs: 5.5, 5.0, 4.5 injections over unactivated CM5 
chip over 300 s.  
4.2.1.2 Immobilisation of gp120 
The approach used for gp120 immobilisation was the covalent attachment of the 
protein to the surface of the sensor chip. 
To immobilise gp120 on CM5 chip, firstly, the sensor surface in the flow cell 2 was 
activated by preparation of the hydroxy succinic ester derivatives of the 
carboxylic acid moieties on the dextrane layer by injection of 0.4 M 1-ethyl-3-(3-
dimethylaminopropyl)-carbodiimide (EDC)/0.1 M N-hydroxysuccinimide (NHS) 
solution. Activation was followed by injection of a gp120 solution. In the first 
immobilisation test, gp120 was present at a concentration of 10 μg∙mL-1 and was 
injected over 105 s. The last step was removal of the non-covalently bound ligand 
and deactivation of the chip surface by conversion of the remaining active ester 
groups to amides by injection of 1 M ethanolamine pH 8.5. The amount of 
immobilised gp120 was 1900 RU (Figure 74). 
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Later on, gp120 was used at 20 μg∙mL-1 was injected in short pulses until the 
desired amount of the protein on the surface of the chip was achieved (3600 RU 
or 1000 RU). 
The test chip with 1900 RU of immobilised gp120 was used to find optimal 
regeneration conditions. The chip with 3600 RU of immobilised gp120 was used to 
investigate binding of CD4D12 to gp120. 
Flow cell 1 served as a reference surface, therefore it was activated and 
deactivated similarly to the active surface in flow cell 2, albeit not exposed to 
gp120. 
 
Figure 74 The process of gp120 covalent immobilisation on the surface of CM5 chip. 
 
4.2.1.3 Regeneration scouting 
Regeneration of the chip consisted of removal of the bound analyte to prepare the 
chip surface for the next analysis cycle, ideally without destroying the activity of 
the immobilised protein. Efficient regeneration allowed the reuse of the chip in 
the next assays, therefore finding the optimal conditions was of the utmost 
importance. Determination of the regeneration conditions was achieved by 
evaluation of the different regeneration conditions by repeated injections of the 
analyte at the highest concentration planned for experiments and subsequent 
injection of a tested regeneration buffer. After each regeneration cycle response 
levels were examined to find the optimal regeneration procedure. 
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Since several SPR experimental procedures were described for the gp120-CD4 
interaction, the procedure described by Cerutti et al.[130] was chosen where 10 mM 
glycine at pH 2.5 was used as a starting point in determining the regeneration 
procedure. 
Three regeneration buffers were tested, these contained: 10 mM glycine at 
different pH values: 2.5, 2.0 and 1.5 (Figure 75). The regeneration was started 
by testing the mildest regeneration conditions (pH 2.5). At pH 2.5 an increase in 
baseline was observed, which suggested that the analyte was not removed 
completely and accumulated on the sensor surface. At pH 2.0 the baseline was 
still higher than the sample response, while at pH 1.5 both baseline and sample 
response started decreasing, which suggested deterioration of the analyte binding 
capacity. Therefore, intermediate conditions of 10 mM glycine at pH 1.75 were 
chosen as the regeneration buffer conditions. 
 
Figure 75 Regeneration scouting.  
The ligand CD4D12 was immobilised and gp120 was injected over it at the concentration of 100 nM. 
The conditions tested from the left: 10 mM glycine pH 2.5, 10 mM glycine pH 2.0, 10 mM glycine pH 
1.5. 
4.2.1.4 Binding of CD4D12 to immobilised gp120 
Serial dilutions (0-250 nM) of CD4D12 were prepared in 1×PBS-P buffer and 
injected over 3600 RU immobilised gp120 on the CM5 chip. The association time 
was 120 s, followed by 600 s of dissociation and finally removal by injection of 
10 mM glycine at pH 1.75 for 60 s. Each concentration of CD4D12 was injected 
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once, starting from the lowest to the highest concentration. A 15.6 nM CD4D12 
solution was injected for a second time after all the samples were tested, to 
monitor if the response is at the same level after the entire assay. This experiment 
was repeated twice. Binding of the CD4D12 to gp120 was fitted a 1:1 Langmuir 
binding model describing the interaction of the two molecules in a 1:1 complex. 
It was observed however, that the binding model did not fit the curve 
corresponding to the injection of the highest concentration (250 nM) of CD4D12. 
Therefore, this concentration was excluded from the kinetic analysis. The 
sensograms corresponding to the 3 replicates of the experiment are shown in 
Figure 76, Figure 77 and Figure 78. 
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Figure 76 Replicate 1 of the interaction of analyte CD4D12 with immobilised ligand gp120 at 25C. 
The coloured lines depict the double-referenced sensograms obtained from injections of 0, 125, 62.5, 
31.3, 15.6, 7.8, 3.9, 1.9, 0.9 nM analyte CD4D12 across 3600 RU immobilised ligand gp120. Injection 
of 15.6 nM CD4D12 was repeated at the end of the experiment. The ligand surface was regenerated 
with a 60 s injection of 10 mM glycine pH 1.75 between each binding cycle. The black lines depict 
the global fit of the data to a 1:1 Langmuir interaction model, yielding ka = 1.97∙105 M-1 s-1, kd = 
1.45∙10-4 s-1, Kd = 7.36∙10-10 M. 
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Figure 77 Replicate 2 of the interaction of analyte CD4D12 with immobilised ligand gp120 at 25C. 
The coloured lines depict the double-referenced sensograms obtained from injections of 0, 125, 62.5, 
31.3, 15.6, 7.8, 3.9, 1.9, 0.9 nM analyte CD4D12 across 3600 RU immobilised ligand gp120. Injection 
of 15.6 nM CD4D12 was repeated at the end of the experiment. The ligand surface was regenerated 
with a 60 s injection of 10 mM glycine pH 1.75 between each binding cycle. The black lines depict 
the global fit of the data to a 1:1 Langmuir interaction model, yielding ka = 2.52∙105 M-1 s-1, kd = 
2.34∙10-4 s-1, Kd = 9.30∙10-10 M. 
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Figure 78 Replicate 3 of the interaction of analyte CD4D12 with immobilised ligand gp120 at 25C. 
The coloured lines depict the double-referenced sensograms obtained from injections of 0, 125, 62.5, 
31.3, 15.6, 7.8, 3.9, 1.9, 0.9 nM analyte CD4D12 across 3600 RU immobilised ligand gp120. Injection 
of 15.6 nM CD4D12 was repeated at the end of the experiment. The ligand surface was regenerated 
with a 60 s injection of 10 mM glycine pH 1.75 between each binding cycle. The black lines depict 
the global fit of the data to a 1:1 Langmuir interaction model, yielding ka = 2.52∙105 M-1 s-1, kd = 
2.34∙10-4 s-1, Kd = 9.30∙10-10 M. 
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The obtained kinetic data are summarised in Table 10. 
Table 10 Kinetic data obtained from the three experiments of binding CD4D12 to immobilised gp120. 
ka – association rate, kd – dissociation rate, Kd – equilibrium dissociation, constant, Rmax – analyte 
binding capacity. 
Replicate ka (M-1 s-1) kd (s-1) Kd (M) Rmax (RU) 
1 1.97∙105 1.45∙10-4 7.36∙10-10 68.39 
2 2.52∙105 2.34∙10-4- 9.27∙10-10 40.78 
3 1.99∙105 1.95∙10-4- 9.81∙10-10 19.2 
Mean 2.16∙105 1.91∙10-4 8.81∙10-10 - 
Standard 
deviation 
15% 23% 15% - 
 
After analysis of the obtained kinetic data (Table 10), it was observed that the 
activity of gp120 immobilised was decreasing, which was obvious from the 
decreasing Rmax value. As can be observed in Figure 76, the fitted model 
overlayed with the obtained data set, however in the next two experiments 
(Figure 77 and Figure 78) the models did not fit the highest concentrations any 
longer. The selected obtained responses from the three experiments at different 
concentrations were compared (Table 11). One cycle can be defined as an 
injection of the analyte at a certain concentration, followed by regeneration of 
the chip surface. As can be observed, within replicate 1 the binding level response 
between cycles 17 and 24 decreased by 1.2 RU, in replicate 2 by 1.4 RU and in 
replicate 3 by 0.1 RU. Between the cycle 17 of replicate 1 and 2 there are 24 
cycles and the binding level between these decreased by 6.3 RU. From these 
observations it was calculated, that the response decreased by 0.013-0.016 RU 
per cycle. In the third replicate the responses were 4× lower when compared to 
the first replicate. This decrease in binding level was caused by degradation of 
gp120 by regeneration and over time. The decrease in gp120 activity was 
connected to the decrease in the concentration of active gp120, therefore 
decrease in the Kd value was observed (Table 10). 
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Table 11 Comparison of the obtained binding level responses (RU) at different concentrations of 
CD4D12 in the consequent experiments. 
Cycle 
Concentration 
(nM) 
Binding level (RU) 
Replicate 1 Replicate 2 Replicate 3 
17 15.6 20.1 13.8 5.2 
19 62.5 46.8 29.1 10.8 
20 125 62.2 33.9 12.7 
24 
15.6 (second 
injection) 
18.9 12.4 5.1 
 
The previously published kinetic constants for interaction between CD4D12-gp120 
were as follows: Kd = 6-52 nM, ka = 5.3∙103-4.3∙104 M-1∙s-1, and kd = 
2.6∙10-4∙s-1.[128][124][130] Here a Kd of 0.7 nM, ka = 2.28∙105 M-1∙s-1 and kd = 
1.68∙10-4∙s-1 (mean values) were obtained. 
The equilibrium dissociation constant Kd is described by the equation: 𝐾𝑑 =
[𝐴][𝐵]
[𝐴𝐵]
, 
where [A] and [B] are concentrations of interacting partners and [AB] is the 
concentration of the AB complex. The lower the Kd, the higher the stability of the 
formed complex. However, if the concentration of one of the interacting partners 
decreases, the Kd also decreases. Therefore, the obtained Kd of 0.7 nM might be 
caused by the decreased concentration of the immobilised active gp120. 
Once the positive control was obtained by testing both commercial proteins, the 
experiment with the expressed and purified CD4D12 was performed. As it was 
shown in the experiments with commercial CD4D12, at the concentration of 
250 nM the models did not fit the data set, it was decided to decrease the 
concentration of tested CD4D12 down to 100 nM. 
Serial dilutions of the expressed CD4D12ex were prepared (0-100 nM) in 1×PBS-P 
buffer and injected over 1000 RU of immobilised gp120 on the CM5 chip. The 
association time was 120 s, followed by 600 s of dissociation and finally removal 
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by injection of 10 mM glycine at pH 1.75 for 60 s. Each concentration of CD4D12 
was performed in duplicate, starting injections from the lowest to the highest. 
The experiment was carried out twice. Binding of the CD4D12 to gp120 was fitted 
a 1:1 Langmuir binding model describing the interaction of two molecules in a 1:1 
complex. 
The sensogram of one of the two experiments is shown on Figure 79 (for the 
second replicate see Appendix Figure 167). 
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Figure 79 Replicate 1 of interaction of analyte CD4D12ex with immobilised ligand gp120 at 25C.  
The coloured lines depict the double-referenced sensograms obtained from duplicate injections of 
100, 50, 25, 12.5, 6.3 nM analyte CD4D12ex across 1000 RU immobilised ligand gp120. The ligand 
surface was regenerated with a 60 s injection of 10 mM glycine pH 1.75 between each binding cycle. 
The black lines depict the global fit of the data to a 1:1 Langmuir interaction model, yielding ka 
=3.426 M-1∙s-1, kd = 2.425∙10-4∙s-1, Kd = 7.08∙10-5 M. 
As can be observed in Figure 79 the model did not fit the obtained data set in any 
of the tested concentrations. Moreover, the obtained kinetic constants: ka =3.426 
M-1∙s-1, kd = 2.425∙10-4∙s-1, Kd = 7.08∙10-5 M were not in the range of the published 
data (Kd = 6-52 nM, ka = 5.3∙103-4.3∙104 M-1∙s-1, and kd = 2.6∙10-4 ∙s-1).[128][124][130] 
To understand the obtained values better, our attention was turned towards the 
raw data obtained from the SPR experiment. The baseline increased significantly 
during the experiment and was not regenerated properly (Figure 80, top). 
Moreover, the binding level at higher concentrations (50 and 100 nM, Figure 80, 
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bottom) was not reproducible and decreased significantly, which might have been 
caused by the analyte built-up on the immobilised gp120. The underlying cause of 
the obtained results might be the ununiform content of the CD4D12ex sample. As 
it was shown in section 2.1, the expressed CD4D12ex was present in two 
populations: the properly folded and misfolded variant. The misfolded fraction of 
the protein could be interacting with gp120 differently from the properly folded 
CD4D12, which in consequence obscured the obtained results. 
 
 
Figure 80 Baseline and binding level in binding CD4D12ex to immobilised gp120.12ex to 
immobilised gp120. 
Top: Scatter plot of baseline report point values (RU) against consequent cycles. Bottom: Scatter 
plot of binding level report point values (RU) against consequent cycles. The blue box encircles 
injection of 100 nM CD4D12ex. The orange box encircles injection of 50 nM CD4D12ex. The red box 
encircles injection of 25 nM CD4D12ex. The green box encircles injection of 12.5 nM CD4D12ex. 
The purple box encircles injection of 6.25 nM CD4D12ex. The cyan box encircles injection of 0 nM 
CD4D12ex. 
4.2.1.5 Conclusions 
Binding of commercial CD4D12 and expressed CD4D12ex with immobilised gp120 
was evaluated. In case of commercial CD4D12 the obtained kinetic data were 
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similar to the published data[128][124][130], however immobilised gp120 was highly 
unstable and degraded rapidly on the surface of the CM5 chip. gp120 degraded 
over time and this degradation was accelerated by repeated regeneration cycles. 
The binding of expressed CD4D12ex was obscured by the heterogenous content of 
the sample, since it probably consisted of both folded and misfolded protein, as 
was discussed in section 2.1. The obtained kinetic data did not reproduce the 
published data.[128][124][130] Therefore it was decided not to carry out competition 
assays. 
To investigate whether a change in experimental setup would be a remedy to the 
problems of gp120 instability and loss of its activity, it was decided to immobilise 
commercial CD4D12, which is described in section 4.2.2. Moreover, immobilisation 
of CD4D12 instead of gp120 would make gp120 mimics binding experiments to 
CD4D12 experiments easier to analyse, since this would involve measuring direct 
binding of the protein mimics to CD4D12. 
4.2.2 Towards measuring direct binding to immobilised CD4D12 
In the process of setting up the binding assay of CD4D12 to immobilised gp120 it 
was found, that the volumes and concentrations of both interacting partners were 
lower than expected. Therefore, utilisation of gp120 could be used as an analyte. 
Moreover, if CD4D12 was immobilised on the chip, it would allow preparation of a 
sample of gp120 immediately before the experiment, which would minimise the 
chance of gp120 losing activity over time. Immobilisation of CD4D12 also simplified 
the analysis of the binding capacity of gp120 mimics to CD4D12 easier, since there 
are less variables that should be taken into account. 
In order to test the binding of gp120 mimics to CD4D12, a surface with immobilised 
CD4D12 had to be prepared. Therefore, the optimal conditions for this 
immobilisation had to be determined. 
4.2.2.1 pH scouting and pre-concentration 
To find optimal coupling conditions for CD4D12 immobilisation, CD4D12 was 
passed over an unactivated sensor chip under different buffer conditions and the 
extent of its preconcentration was observed as an increase in response. 
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Solutions of CD4D12 (concentration of 10 μg∙mL-1) were prepared in 10 mM 
acetate buffers of different pH values: 5.5, 5.0, 4.5 and 4.0, and exposed to the 
unactivated surface of the CM5 chip. After completion of each protein injection, 
1 M ethanolamine solution was injected at pH 8.5 to remove the last traces of 
electrostatically bound ligand. As can be observed in Figure 81, the 
pre-concentration levels of CD4D12 on the chip surface varied at different pH 
values. At pH 5.5 the obtained pre-concentration level was the lowest (4513.0 RU) 
and it was observed that the surface was well regenerated. At pH 5.0 the 
pre-concentration level is high (7146.5 RU) and the baseline is reasonably well 
regenerated. At pH 4.5 the pre-concentration level is the highest (7573.1 RU), 
however the surface of the chip does not regenerate well. At pH 4.0 the 
pre-concentration level is very low (4777/3 RU) and the surface of the chip is also 
not regenerated. Therefore, the pH values of 4.0-4.5 might have led to protein 
aggregation or denaturation. The optimal pH for immobilisation was decided to 
be 5.0. 
 
Figure 81 pH scouting and pre-concentration studies of CD4D12. 
a) pH scouting and pre-concentration studies of CD4D12. CD4D12 (10 μg∙mL-1) in 10 mM acetate 
buffers at pHs: 5.5, 5.0, 4.5 and 4.0 injections over unactivated CM5 chip over 120 s; b) the table 
with responses (RU) obtained after each injection of CD4D12. 
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4.2.2.2 Immobilisation of CD4D12 
The approach used for CD4D12 immobilisation was the covalent attachment of the 
protein to the surface of the sensor chip. 
To immobilise CD4D12 on the CM5 chip, firstly, the sensor surface was activated 
by preparation of the hydroxy succinic ester derivatives of the carboxylic acid 
moieties on the dextran layer by injection of 0.4 M EDC/0.1 M NHS solution. 
Activation was followed by injection of a CD4D12 solution at the concentration of 
10 μg∙mL-1. The protein was injected in short pulses until the desired amount of 
the protein on the surface of the chip was achieved. The last step was the removal 
of the non-covalently bound ligand and deactivation of the sensor surface by 
conversion of the remaining active ester groups to amides by injection of 1 M 
ethanolamine pH 8.5. 
A test chip with 1700 RU of CD4D12 immobilised on it was used to find optimal 
regeneration conditions as well as to investigate binding of gp120 to CD4D12. The 
chip with 1200 RU of CD4D12 immobilised (Figure 82) was used to find optimal 
experimental conditions for binding of the gp120 mimics, and also in the binding 
assays of the gp120 mimics. 
Flow cell 1 served as a reference surface, therefore it was activated and 
deactivated similarly to the active surface in flow cell 2, albeit not exposed to 
CD4D12. 
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Figure 82 The process of CD4D12 covalent immobilisation on the surface of CM5 chip. 
 
4.2.2.3 Regeneration scouting 
Four regeneration buffers were tested, these contained: 10 mM glycine buffers 
with different pH values: 2.0, 1.75, 1.5 and 10 mM glycine pH 1.75 supplemented 
with 150 mM NaCl. The regeneration buffer was injected for 30 s. The 
regeneration was started from testing the mildest regeneration conditions (10 mM 
glycine pH 2.0). At pH 2.0 an increase in baseline and decrease in the sample 
response was observed, which suggested that gp120 was not removed completely, 
and it had accumulated on the sensor surface. At pH 1.75 the baseline was still 
decreasing while the sample response was steady. The decrease in a baseline 
might have been caused by removal of the accumulated gp120 from the previous 
cycle. At pH 1.5 the baseline was still decreasing while the sample response was 
steady. When two different conditions give similar responses (pH 1.75 and pH 1.5), 
milder conditions (pH 1.75) should be chosen. At pH 1.75 with added 150 mM NaCl 
the baseline started increasing again, while the sample response decreased. These 
results confirmed that 10 mM Glycine at pH 1.75 was an optimal regeneration 
buffer. 
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Figure 83 Regeneration scouting of the chip surface with immobilised CD4D12.  
The ligand CD4D12 was immobilised and gp120 was injected over it at the concentration of 100 nM. 
The conditions tested from the left: 10 mM glycine pH 2.0, 10 mM glycine pH 1.75, 10 mM, 10 mM 
glycine pH 1.5, 10 mM glycine pH 1.75 + 150 mM NaCl. 
4.2.2.4 Binding of gp120 to the immobilised CD4D12 
Binding of gp120 to the immobilised CD4D12 was evaluated to investigate whether 
CD4D12 is more stable on the sensor surface than gp120, which would then allow 
to test gp120 mimics. Since in the previous section it was shown, that at 
concentrations of 250 nM the models did not fit the obtained data sets, the 
maximum concentration was decreased to 200 nM in the first replicate. Since at 
this concentration the models did not fit the data either, the highest 
concentration was decreased further to 100 nM in replicates 2 and 3. The 200 nM 
concentration from the first replicate was excluded from calculations of the 
kinetic data. 
Serial dilutions (0-100 nM) of gp120 were prepared in 1×HBS-P buffer and injected 
over 1700 RU immobilised CD4D12 on the CM5 chip. The association time was 
120 s, followed by 600 s of dissociation and finally removal by two injections of 
10 mM glycine at pH 1.75 for 30 s each. Each concentration of gp120 was injected 
once, starting with the highest concentration of gp120. A solution of 50 nM gp120 
was injected for the second time after all the samples had been evaluated, to 
determine if the response was at the same level after the entire assay. This 
experiment was repeated twice. Binding of gp120 to the immobilised CD4D12 was 
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fitted a 1:1 Langmuir binding model describing the interaction of two molecules 
in a 1:1 complex. 
The sensograms corresponding to the 3 replicates of the experiment are shown in 
Figure 84, Figure 85 and Figure 86 and the obtained kinetic data are summarised 
in Table 12. 
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Figure 84 Replicate 1 of the interaction of analyte gp120 with immobilised ligand CD4D12 at 25C. 
The coloured lines depict the double-referenced sensograms obtained from injections of100, 50, 25, 
12.5, 6.25 nM analyte gp120 across 1700 RU immobilised ligand CD4D12. Injection of 50 nM gp120 
was repeated at the end of the experiment. The ligand surface was regenerated with two 30 s 
injections of 10 mM glycine pH 1.75 between each binding cycle. The black lines depict the global fit 
of the data to a 1:1 Langmuir interaction model, yielding ka = 7.274∙104 M-1∙s-1, kd = 3.748∙10-4∙s-1, 
Kd = 5.152∙10-9 M. 
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Figure 85 Replicate 2 of the interaction of analyte gp120 with immobilised ligand CD4D12 at 25C.  
The coloured lines depict the double-referenced sensograms obtained from injections of100, 50, 25, 
12.5, 6.25 nM analyte gp120 across 1700 RU immobilised ligand CD4D12. Injection of 50 nM gp120 
was repeated at the end of the experiment. The ligand surface was regenerated with two 30 s 
injections of 10 mM glycine pH 1.75 between each binding cycle. The black lines depict the global fit 
of the data to a 1:1 Langmuir interaction model, yielding ka = 7.332∙104 M-1∙s-1, kd = 3.220∙10-4∙s-1, 
Kd = 4.392∙10-9 M. 
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Figure 86 Replicate 3 of the interaction of analyte gp120 with immobilised ligand CD4D12 at 25C. 
The coloured lines depict the double-referenced sensograms obtained from injections of 100, 50, 25, 
12.5, 6.25 nM analyte gp120 across 1700 RU immobilised ligand CD4D12. Injection of 50 nM gp120 
was repeated at the end of the experiment. The ligand surface was regenerated with two 30 s 
injections of 10 mM glycine pH 1.75 between each binding cycle. The black lines depict the global fit 
of the data to a 1:1 Langmuir interaction model, yielding ka = 7.775∙104 M-1∙s-1, kd = 3.141∙10-4∙s-1, 
Kd = 4.039∙10-9 M. 
Table 12 Kinetic data obtained from the three experiments of binding gp120 to immobilised CD4D12. 
ka – association rate, kd – dissociation rate, Kd – equilibrium dissociation, constant, Rmax – analyte 
binding capacity. 
Replicate ka (M-1∙s-1) kd (s-1) Kd (M) Rmax (RU) 
1 7.274∙104 3.748∙10-4 5.152∙10-9 546.9 
2 7.332∙104 3.220∙10-4 4.392∙10-9 606.3 
3 7.775∙104 3.141∙10-4 4.039∙10-9 591.4 
Mean 7.46∙104 3.37∙10-4 4.53∙10-9 - 
Standard 
deviation 
3.7% 9.8% 12.6% - 
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As can be observed from Table 12 the obtained kinetic values were consistent 
with the previously published kinetic data for gp120-CD4D12 interaction (Kd = 6-
52 nM, ka = 5.3∙103-4.3∙104 M-1∙s-1, and kd = 2.6∙10-4∙s-1).[128][124][130] Kd’s of 4.5 nM, 
ka = 7.775∙104 M-1∙s-1 and kd = 3.37∙10-4∙s-1 (mean values) were obtained. This was 
also a significant improvement over the previous experimental setup with gp120 
immobilised on the sensor chip. These results also indicated, that in contrast to 
immobilised gp120, immobilised CD4D12 was more stable on the chip and could 
be reused in several assays successfully. 
With the successfully obtained positive control of gp120-CD4D12 interaction and 
the found good experimental setup, which yielded reproducible kinetic data it was 
now possible to perform experiments with gp120 mimics. 
4.2.2.5 Binding of gp120 mimics to the immobilised CD4D12 
The binding of the synthesized constructs 22, 26 and 30 (Figure 87) to the 
immobilised CD4D12 was tested. 
 
Figure 87 Upper: Schematic representation of loops 1, 2 and 3 structures; lower: schematic 
representation of the synthesized gp120 discontinuous mimics 22, 26 and 30 structures. 
Firstly, the experimental conditions for evaluating the gp120 constructs were the 
same as for binding of gp120 to the immobilised CD4D12, and construct 30 was 
used first since it was obtained in the highest amount. However, it was found that 
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by using the same conditions, negative unprocessed sensograms were obtained 
both in the reference flow cell and in the flow cell with immobilised ligand, which 
did not allow to calculate the kinetic data (Figure 88, left and right). 
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Figure 88 Unprocessed sensograms of construct 30 binding to: left: the blank sensor surface; right: 
the immobilised ligand CD4D12. 
 
One of the possible explanations would be binding of the mimic 30 to the blank 
sensor surface instead of to the ligand, which would result in the negative 
sensogram. However, no binding to the reference surface was observed (Figure 
89, top). Moreover, the binding level throughout the experiment was not 
consistent (Figure 89, bottom). 
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Figure 89 Top: Binding to the reference channel (RU) in each cycle, bottom: binding level responses 
(RU) in each cycle. 
 
Since the most obvious cause (binding to the reference surface) was eliminated, 
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Assay Handbook[161] suggested that HBS-P buffer is preferred in protein assays, 
while PBS-P is preferred in small molecule assays, as HEPES could bind the ligand 
and interfere with detection of low molecular weight compounds. Change of the 
buffer was a major improvement, and all the constructs could be tested. 
gp120 protein mimics are significantly smaller when compared to gp120 (5 kDa 
and 120 kDa, respectively). SPR monitors the change in mass on the surface of the 
chip, therefore the larger the molecular weight of the analyte, the easier it is to 
obtain a response. Therefore, it was decided to increase the highest concentration 
of tested constructs from 100 nM to 100 μM. Moreover, recently published IC50 
values for similar constructs were in the range of 41.3-57.3 μM.[88] The highest 
concentration that could be obtained to repeat each experiment and test each 
concentration in duplicate was 100 μM, which was due to the limited amount of 
the synthesized constructs. 
Serial dilutions of gp120 mimics 22, 26 and 30 were prepared (0-100 μM) in 
1×PBS-P buffer and injected over 1200 RU immobilised CD4D12 on the CM5 chip. 
The association time was 120 s, followed by 600 s of dissociation and finally 
removed by two injections of 10 mM glycine at pH 1.75 for 30 s each. Each 
experiment was performed in a duplicate. Since CD4D12 proved to be stable on 
the sensor surface, each concentration of gp120 mimic was injected twice, 
starting from the lowest concentration to the highest. Binding of the gp120 mimics 
to the immobilised CD4D12 was fitted a 1:1 Langmuir binding model describing 
the interaction of two molecules in a 1:1 complex. 
Firstly, construct 22 was tested for binding to CD4D12. Binding of construct 22 
was very weak even at the highest (100 μM) concentration. The selected obtained 
sensogram is shown in Figure 90 (the sensogram of the duplicated experiment is 
attached in the Appendix Figure 168). The obtained kinetic constants were as 
follow: ka = 39.40 M-1∙s-1, kd = 4.203-4∙s-1, Kd = 1.067∙10-5 M. However, the 
reported kinetic constant ka was outside the limits that could by measured by the 
instrument (detection limit of Biacore™ X100 for ka: 103-107 M-1 s-1 and for kd: 10-
5-0.1 s-1 as reported in the Biacore™ X100 handbook[162]), therefore this value 
unfortunately could not be considered a valid result. 
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Figure 90 Replicate 1 of performed experiment to measure binding of mimic 22 to the immobilised 
CD4D12 at 25C. 
The coloured lines depict the double-referenced sensograms obtained from duplicate injections of 
100, 50, 25, 12.5, 6.25 μM analyte 22 across 1200 RU immobilised ligand CD4D12. The ligand 
surface was regenerated with two 30 s injections of 10 mM glycine pH 1.75 between each binding 
cycle. The black lines depict the global fit of the data to a 1:1 Langmuir interaction model, yielding ka 
= 30.40 M-1∙s-1, kd = 4.203∙10-4∙s-1, Kd = 1.067∙10-5 M. 
Binding of the second tested construct 26 was very weakly detectable even at the 
highest 100 μM concentration. The selected obtained sensogram is shown in Figure 
91 (the sensogram of the duplicated experiment is attached in the Appendix 
Figure 169). The kinetic constants could not be uniquely determined for this 
construct. 
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Figure 91 Replicate 1 of performed experiment to measure binding of mimic 26 to the immobilised 
CD4D12 at 25C.  
The coloured lines depict the double-referenced sensograms obtained from duplicate injections of 
100, 50, 25, 12.5, 6.25 μM analyte 26 across 1200 RU immobilised ligand CD4D12. The ligand 
surface was regenerated with two 30 s injections of 10 mM glycine pH 1.75 between each binding 
cycle. The black lines depict the global fit of the data to a 1:1 Langmuir interaction model. 
Binding of the last tested construct 30 was very weak even at the highest 100 μM 
concentration. This construct showed intermediate potency between constructs 
22 and 26. The selected obtained sensogram is shown in Figure 92 (the sensogram 
of the duplicated experiment is attached in the Appendix Figure 170). The 
obtained kinetic constants were as follow: ka =4.603∙105 M-1∙s-1, kd = 
5.197∙10-4∙s-1, Kd = 1.129∙10-9 M. However, care has to be taken when reviewing 
the obtained kinetic constant values. 
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Figure 92 Replicate 1 of performed experiment to measure binding of mimic 30 to the immobilised 
CD4D12 at 25C. 
The coloured lines depict the double-referenced sensograms obtained from duplicate injections of 
100, 50, 25, 12.5, 6.25 μM analyte 30 across 1200 RU immobilised ligand CD4D12. The ligand 
surface was regenerated with two 30 s injections of 10 mM glycine pH 1.75 between each binding 
cycle. The black lines depict the global fit of the data to a 1:1 Langmuir interaction model, yielding ka 
= 4.603∙105 M-1∙s-1, kd = 5.197∙10-4∙s-1, Kd = 1.129∙10-9 M. 
4.2.2.6 Binding of independent loops to CD4D12 
The binding of synthesized loops 1, 2 and 3 (Figure 87) to the immobilised CD4D12 
was also evaluated. 
Loops mimicking the discontinuous epitope of gp120 are similarly to constructs 
22, 26 and 30 significantly smaller in terms of molecular weight when compared 
to the protein gp120 (1 kDa and 120 kDa, respectively). Therefore, the tested 
range of concentrations was the same as for the constructs, 0-100 μM. 
Loops 1, 2 and 3 were prepared in serial dilutions (0-100 μM) in 1×PBS-P buffer 
and injected independently over 1200 RU immobilised CD4D12 on the CM5 chip. 
The association time was 120 s, followed by 600 s of dissociation and finally 
removed by two injections of 10 mM glycine at pH 1.75 for 30 s each. Each 
experiment was performed in duplicate and each concentration of the loop was 
injected twice, starting from the lowest to the highest. Binding of the loops to the 
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immobilised CD4D12 was fitted a 1:1 Langmuir binding model describing the 
interaction of two molecules in a 1:1 complex. 
Firstly, loop 1 was tested for binding to CD4D12 Binding of loop 1 was not 
detectable even at the highest 100 μM concentration. The selected obtained 
sensogram is shown on Figure 93 (the sensogram of the duplicated experiment is 
attached in the Appendix Figure 171). The kinetic constants could not be uniquely 
determined for this loop. 
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Figure 93 Replicate 1 of performed experiment to measure binding of loop 1 to the immobilised 
CD4D12 at 25C.  
The coloured lines depict the double-referenced sensograms obtained from duplicate injections of 
100, 50, 25, 12.5, 6.25 μM analyte loop 1 across 1200 RU immobilised ligand CD4D12. The ligand 
surface was regenerated with two 30 s injections of 10 mM glycine pH 1.75 between each binding 
cycle. The black lines depict the global fit of the data to a 1:1 Langmuir interaction model. 
Next, loop 2 was tested for binding to the immobilised CD4D12. Interestingly, this 
loop showed the highest potency out of all the tested constructs or independent 
loops. The selected obtained sensogram is shown on Figure 94 (the sensogram of 
the duplicated experiment is attached in the Appendix Figure 172). The obtained 
kinetic constants were as follow: ka = 226.9 M-1∙s-1, kd = 1.229-3∙s-1, Kd = 5.418∙10-
6 M. However, the reported kinetic constant ka was outside the limits that could 
by measured by the instrument, therefore this value unfortunately could not be 
considered a valid result. 
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Figure 94 Replicate 1 of performed experiment to measure binding of loop 2 to the immobilised 
CD4D12 at 25C.  
The coloured lines depict the double-referenced sensograms obtained from duplicate injections of 
100, 50, 25, 12.5, 6.25 μM analyte loop 2 across 1200 RU immobilised ligand CD4D12. The ligand 
surface was regenerated with two 30 s injections of 10 mM glycine pH 1.75 between each binding 
cycle. The black lines depict the global fit of the data to a 1:1 Langmuir interaction model, yielding ka 
= 226.9 M-1∙s-1, kd = 1.229-3∙s-1, Kd = 5.418∙10-6 M. 
Lastly, loop 3 was tested for binding to CD4D12 Binding of loop 3 was not 
detectable even at the highest 100 μM concentration. The selected obtained 
sensogram is shown on Figure 95 (the sensogram of the duplicated experiment is 
attached in the Appendix Figure 173). The kinetic constants could also not be 
uniquely determined for this loop. 
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Figure 95 Replicate 1 of performed experiment to measure binding of loop 3 to the immobilised 
CD4D12 at 25C.  
The coloured lines depict the double-referenced sensograms obtained from duplicate injections of 
100, 50, 25, 12.5, 6.25 μM analyte loop 3 across 1200 RU immobilised ligand CD4D12. The ligand 
surface was regenerated with two 30 s injections of 10 mM glycine pH 1.75 between each binding 
cycle. The black lines depict the global fit of the data to a 1:1 Langmuir interaction model. 
4.3 Conclusions 
Binding of gp120 to immobilised CD4D12 as a positive control was successfully 
optimised by immobilisation of the latter. The obtained kinetic constants of 
binding of the two proteins were consistent with the published kinetic data of 
gp120-CD4D12 interaction.[128][124][130] Therefore, a reliable method for 
investigation of gp120 mimics to CD4D12 was developed. Unfortunately, all tested 
compounds proved to be inactive (construct 26) or very weakly active (constructs 
22 and 30). This was followed by testing of the binding of the independent loops 
to CD4D12. Loops 1 and 3 were inactive, while loop 2, interestingly, showed the 
highest potency out of the all tested loops and constructs. However, the obtained 
results have to be reviewed with some care, as the obtained kinetic constant ka 
was outside of the limit of the instrument and the obtained responses were very 
low. 
The difference between the constructs synthesized within this project and 
recently published constructs[88] lies in the used cyclisation hinge. As initial 
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binding studies showed activity of compounds based on N3-DBMB hinge (Figure 96) 
it was decided to prepare compounds with small structural alterations (change of 
a cyclisation hinge) that would improve their chemical properties. In order to 
improve the solubility of the cyclic peptides the N3-TADB cyclisation hinge was 
used instead of N3-DBMB.  
 
Figure 96 Structures of the cyclisation linkers. Left: N3-DBMB; right: (polar hinge) N3-TADB. 
 
The polar hinge N3-TADB increased significantly the polarity of the synthesized 
peptide loops, however similarly to the recently published results by van de 
Langemheen et al.[155] it decreased the potency of the obtained products. This 
trend can be explained by an increased flexibility of the N3-TADB hinge when 
compared to N3-DBMB. The N3-DBMB hinge obtains planar conformation and it has 
one methylene unit between the benzene ring and the attached peptide. The 
N3-TADB hinge on the other hand, is present in a chair-like conformation and has 
one methylene unit more, which introduces more flexibility into the system. 
Taken together with the flipping cyclophane ring of the TAC scaffold, it might be 
concluded that the entire molecule is not constrained enough and too flexible to 
fit into the gp120 binding site of CD4D12. These results show, that computer 
modelling supplemented with molecular docking to predict preferred orientation 
of gp120 mimics towards CD4D12 should be approached. Such studies would be 
helpful, as they would allow to study in greater depth how the individual peptide 
loops or constructs fit into the binding pocket of CD4D12. In this way it would be 
possible to assess the correct distance between the TAC scaffold and the loops, 
the size of the loops (whether they should be bigger or smaller), as well as their 
rigidity and geometry. Moreover, as could be observed in the experiments of 
binding of independent loops, apart from loop 2, none of the loops bound CD4D12. 
Since loop 2 was the most hydrophobic out of the three loops, therefore it was 
the most capable of creating hydrophobic interactions with CD4D12. Furthermore, 
since Trp427 of gp120 is one of the residues contributing in majority to the binding, 
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it can be assumed that this residue adopts correct geometry and is responsible for 
binding of loop 2 to CD4D12. The other two residues of gp120 contributing to the 
binding of CD4D12 are Asp368 and Glu370, which are present in the sequence of loop 
3. However, this loop showed no binding towards CD4D12, which allows to draw 
conclusion, that its design is not optimal. These results do not give insight whether 
the recognition is sequence specific, therefore it would be beneficial in the future 
to scramble the peptide sequence and test its binding properties.  
Previous studies done in the Liskamp group based on the same concept, however 
with slightly altered scaffold or cyclisation linker, showed that binding of the loops 
or constructs to CD4D12 is highly dependent on the used methodology. In the 
course of this thesis, loop 2 showed the highest binding potential which is in 
contrast to the previously described results.[142][144] The results published by 
Werkhoven at al.[88] with the gp120 mimics that resemble the most closely 
constructs synthesised and tested in the course of this thesis had the IC50 values 
of 41.3 – 57.3 μM, with the compound having loop 2 in the “middle” position 
showing the highest inhibitory potential. Its structural counterpart however, 
compound 26, showed no binding potential. Compound 22, which out of the three 
constructs showed the best binding properties, had loop 1 in the “middle” 
position, and loop 2 in the “right” position. Compound 30, which showed very 
weak binding, had loop 3 in the “middle” position and, similarly to construct 22, 
loop 2 was in the “right” position of the TAC scaffold. Since left and right positions 
are interchangeable as it was discussed chapter 3.2.3, it can be concluded that 
loop 2 positioned in either of these positions is responsible for binding to CD4D12. 
However, if the loop and scaffold size were optimised, it could be possible that 
binding to CD4D12 of the new constructs would have increased. Results published 
by Werkhoven et al.[88] suggest that cyclic compounds offer small benefits over 
the use of linear peptides when it comes to their activity, however cyclic 
compounds have better proteolytic stability in serum, which makes them more 
attractive than their linear counterparts. 
A synergistic effect of assembled loops on the TAC scaffold was expected, however 
the obtained results indicated, that the attachment of the peptides corresponding 
to the discontinuous epitopes of gp120 is not enough to obtain an active gp120 
mimic. A possible remedy to the flexibility of the TAC scaffold would be utilisation 
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of a highly pre-organised CTV scaffold.[108] Moreover, it would be interesting to 
design and test other cyclisation hinges, which would allow to solubilise the cyclic 
peptides without decreasing their potency. 
One of the possible explanations of the lack of binding of loops and constructs to 
CD4D12, was the fact that the protein was immobilised on the chip by covalent 
binding of the amines at its N-terminus. According to the literature, 
[124][128][130][158][159] this is the most often utilised method, however, gp120 binding-
site is located in the proximity of the N-terminus. What is also possible, is that 
CD4D12 was immobilised heterologously, binding to the chip with other amine 
residues than the ones present in the N-terminus. To ensure that gp120, gp120 
mimics or the loops bind without obstacles to CD4D12, future wise it could be 
beneficial to immobilise CD4D12 with its C-terminus. Still more, it would be 
advantageous to attach a linker via the carboxylic moiety of the TAC scaffold that 
would allow its immobilisation on the chip. In this way, the SPR experiments would 
benefit, as a “heavy” CD4D12 protein (21 kDa) would be binding to the ligand, 
which should give better signal response than binding of a “light” analyte – gp120 
mimics (4.7 kDa) to CD4D12. Another possibility would be to use MST rather than 
SPR, as it is highly sensitive technique which requires only very small amounts of 
the samples. 
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5 Conclusions and future work 
Protein-protein interactions play a crucial role in many biological processes. The 
interactions sites are often large and complex, therefore their mimicry by small 
molecules is a challenging task. An alternative approach includes application of 
peptides, which benefit from close structural resemblance to proteins and have 
enormous potential in the protein mimicry. Since discontinuous epitopes 
interactions with proteins play a major role in many diseases, inhibition or 
controlled modulation of PPIs participating in their development has become an 
important target in drug design. Despite efforts dedicated to the development of 
an HIV-1 vaccine, a successful candidate has not yet emerged. Among many 
evasive mechanisms of HIV, its error-prone replication and capability of mutation 
accumulation and emergence of mutants made the design of a successful vaccine 
an extremely difficult task. However, in order to maintain binding towards CD4 
receptor, certain crucial residues within HIV must be conserved, which makes it 
an interesting approach towards development of the vaccine. 
The main objective of this thesis was the synthesis of HIV gp120 protein mimics 
and evaluation of their binding to CD4 receptor. 
In order to evaluate binding of the protein mimics, CD4 and gp120 proteins were 
needed. In chapter 2, efforts towards expression, purification and 
characterisation of CD4 and gp120 proteins are described. Both proteins were 
expressed successfully. However, the refolding of CD4D12 proved to be 
challenging and obtained protein was a mixture of properly folded and misfolded 
variants. gp120 was also expressed and purified, however low-yield did not allow 
to use this protein for evaluation assays and its further expression was 
discontinued. Future work should include further optimisation of refolding 
conditions of CD4D12 and scale-up of gp120 expression. 
Synthesis of peptide-based mimics of gp120 conserved CD4-binding site was 
described in chapter 3. Three peptides corresponding to the gp120 discontinuous 
epitope were synthesized and cyclised in order to improve the mimicry of loop-
like epitope structure and stability. The cyclisation was performed using a novel 
polar hinge, which improved their solubility. These peptides were mounted then 
on the TAC scaffold, which was used as a skeleton to display the peptide loops in 
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the correct 3D-conformation. Moreover, first approaches towards characterisation 
of the secondary structure of the synthesized linear and cyclic peptides as well as 
the final gp120 mimics by means of 1H NMR and CD-spectrometry are described. 
These techniques allowed to gain insight into the secondary structure features of 
the synthesized compounds and might aid future design of the constructs in order 
to make constructs biologically active. 
Chapter 4 describes the development of a reliable and reproducible SPR method 
to evaluate binding of gp120 mimics to CD4 receptor. Careful optimisation of the 
experimental conditions yielded a highly reproducible method for the evaluation 
of gp120 discontinuous mimics. All tested constructs as well as loops 1 and 3 
proved to be inactive or very weakly active, while loop 2 showed significant 
binding. The observed weak binding was probably due to an increased flexibility 
of the linker used for cyclisation of the peptides or peptide sequence specificity. 
It underlined the necessity to design a cyclisation linker, which would not only 
increase the solubility of the peptides but also increase their rigidity. Moreover, 
exploration scrambled peptide sequences and use of other molecular scaffolds 
which are more pre-organised could be possibly a remedy and give insight into to 
the low activity of the synthesized gp120 mimics. 
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6 Materials and methods 
6.1 Molecular biology 
DNA plasmids V1Jnstpagp120 and pET28CD4 were kindly donated by 
Prof. Raghavan Varadarajan. 
6.1.1 Plasmid purification 
DNA plasmids were purified from E.coli cultures (DH5α cells) using Wizard Plus SV 
Miniprep Kit (Promega, #A1330). Purifications were carried out in accordance to 
the supplied centrifugation protocol. DNA was eluted in Nuclease-free water. 
6.1.2 DNA quantification 
DNA solutions were quantified by measuring the absorbance at 260 nm (A260) using 
the NanoDrop 2000C spectrophotometer (Thermo Scientific). 
6.1.3 DNA restriction digest 
Restriction digests were set-up following supplied protocols. A typical restriction 
digest was set-up as follows: 1× CutSmart buffer (5 μL), DNA (1 μg), enzyme Blp I 
(1 μL), enzyme Sma I or SSpI-HF (1 μL) were mixed together and topped up to 50 
μL with sterile, deionised water. Enzyme Blp I (New England BioLabs, #R0585S) 
was used for both expressed proteins, enzymes Sma I (New England BioLabs, 
#R0141S) and SSpI-HF (New England BioLabs, #R3132S) were used for CD4D12 and 
gp120 respectively. Digests were then left at 37°C for 1 h. Restriction digests were 
then analysed by DNA electrophoresis. 
6.1.4 DNA electrophoresis 
Certified™ Molecular Biology Agarose (Bio-Rad, #161-3101) at 1% (w/v) was 
dissolved in TBE buffer (90 mM Tris, 90 mM boric acid, 2.5 mM EDTA). The slurry 
was heated in a microwave until the agarose melted, then it was left until it was 
cool enough to handle. 10,000 × SYBR safe stain (Invitrogen™, #S33102) 
concentrate was diluted 1:10,000 in agarose gel buffer. The molten agarose was 
poured into the cast and allowed to set at room temperature. Once the gel had 
set, the comb was removed and mounted in an electrophoresis tank filled with 1× 
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TBE buffer. The DNA samples were mixed with the gel loading dye Purple (6×, New 
England Biolabs, #B7024S) and loaded slowly into the wells alongside DNA 
molecular weight marker (1 Kb Plus DNA ladder, Invitrogen™, #10787018). 
Electrophoresis was carried out at 80 V for 55 min. The gels were visualised and 
imaged using myECL™ imager (Thermo Scientific). 
6.1.5 Transformations 
Transformations were carried out in accordance with the protocol supplied with 
the MAX Efficiency® DH5α™ competent cells (Invitrogen, #18258-012). Briefly, a 
typical transformation was carried out as follows: 50 μL of competent cells were 
taken from -85°C storage and defrosted on ice. 1 ng of plasmid was added to the 
competent cells and mixed by gentle swirling. The cells were incubated for 30 min 
on ice, before heating for 45 s at 42°C in a water bath. The cells were placed back 
on ice for 2 min and 950 μL of S.O.C. medium (Invitrogen™, 15544-034) was added. 
The transformation mixture was incubated at 37°C with shaking (225 rpm) for 1 h. 
Then, 100 μL of transformations was spread onto kanamycin resistant agar plate. 
The plates were incubated overnight at 37°C. 
6.1.6 Recipes 
6.1.6.1 LB agar plates 
For 500 mL mixture tryptone (5 g), yeast extract (2.5 g), NaCl (5 g) and bacto-
agar (7.5 g) were weighed out. Tryptone, yeast extract and NaCl were dissolved 
in 400 mL ddH2O and pH adjusted to 7.5. Bacto-agar was added, the mixture was 
made up to 500 mL with ddH2O and autoclaved. 
6.2 Protein expression in Bacteria and Purification 
6.2.1 Protein Over-Expression 
Expression media (10 mL) was treated with selective antibiotics (at 1:1000 dilution 
from 50 mg∙mL-1 stock concentrations), warmed to 37°C and inoculated with a 
single colony from the streaked LB agar plate. The culture was incubated at 37°C 
overnight in a shaking incubator (200 rpm). After incubation, the bacterial growth 
was visually assessed by a cloudy haze in the media. The primary inoculum was 
146 
 
transferred into 500 mL of media containing selective antibiotics and incubated 
at 37°C, with 200 rpm shaking until reaching an OD600 ≈ 0.8. At this point 
expression was induced with Isopropyl β-D-1-thiogalactopyranoside (IPTG) (Fisher 
Scientific, #BP1755-10) at a final concentration of 1 mM. The cultures were left 
to express overnight at 37°C with shaking (200 rpm). 
6.2.2 Recipes 
6.2.2.1 LB medium 
For 1 L mixture tryptone (10 g), yeast extract (5 g) and NaCl (10 g) were weighed 
out and dissolve in 800 mL ddH2O. pH was adjusted to 7.5, the mixture was made 
up to 1 L with ddH2O and autoclaved. 
6.2.2.2 LB overnight express medium. 
For 250 mL mixture Overnight Express Instant LB Medium (11.25 g) was weighed 
out and dissolved in 250 mL ddH2O. 2.5 mL glycerol was added, and the mixture 
was gently swirled until the medium was dissolved. The medium was heated in a 
microwave oven on a high-power setting until appearance of bubbles. Then, the 
mixture was cooled to room temperature. 
6.2.2.3 2×YT medium 
For 600 mL mixture tryptone (9.6 g), yeast extract (6 g) and NaCl (3 g) were 
weighed out and dissolved in 500 mL ddH2O. pH was adjusted to 7.0, the mixture 
was made up to 600 mL with ddH2O and autoclaved. 
6.2.3 Cell Lysis - sonication 
Cells were harvested by centrifugation (9 000 × g, 30 min, 4°C), supernatant was 
decanted, and cells were resuspended in the lysis buffer (30 mL per 1 L of culture, 
1×PBS + protease inhibitor (Thermo Scientific, #88666, 1 tablet per 10 mL of 
extract). Sonication was carried out on a Sanyo Soniprep 150 at 8 amplitude 
microns for 30 min of 15 s on, 15 s off, while keeping cells on ice. The lysate was 
centrifuged at 40 000 × g for 30 min at 4°C. Supernatant was decanted. A pale, 
white pellet of inclusion bodies was resuspended and washed with a solution of 
methionine (a few grams per litre of water)/1 mM EDTA. Then the inclusion bodies 
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were centrifuged (40 000 × g, 30 min, 4°C) and the pellet was washed with ddH2O 
and centrifuged to remove EDTA (18 000 × g, 10 min, 4°C, ×3). 
6.2.4 Ni-affinity Chromatography 
The inclusion body pellet was resuspended in 50 mL of the solubilization buffer 
(6 M Gdn×HCl, 5 mM imidazole, 2 mM β-mercaptoethanol, PBS, pH 8.0) while 
mixing with a rotating wheel overnight. The lysate was filtered through a syringe 
filter 0.2 μm (sartorius stedim biotech, Minisart®, #16534-K) to remove any 
insoluble debris. The column (HiFliQ5 Ni-NTA column, Generon) was washed with 
5 column volumes (CV) of ddH2O at 1 mL∙min-1 to remove EtOH, then it was 
equilibrated with the solubilization buffer. The lysate was then loaded onto the 
resin, which was followed by the washing step with 10 CVs of the wash buffer (6 M 
Gdn×HCl, 20 mM imidazole, 2 mM β-mercaptoethanol, PBS, pH = 8.0). Finally, the 
bound protein was eluted with an increasing gradient from 20 mM imidazole to 
300 mM imidazole over 6 CVs with the elution buffer (6 M Gdn×HCl, 300 mM 
imidazole, 2 mM β-mercaptoethanol, PBS, pH 8.0). 
6.2.5 Dialysis and refolding 
The purified protein was immediately after purification dialyzed overnight at 4°C 
against 1 L of refolding buffer 1 (3 M Gdn×HCl, 10% sucrose, 1 mM EDTA, 1 mM L-
Glutathione reduced (GSH, Sigma, #G4251), 0.1 mM L-glutathione oxidised (GSSG, 
Sigma, #G4376), pH 9.6) and then changed into 1 L of refolding buffer 2 (50 mM 
Na2CO3, 10% sucrose, 1 mM EDTA, 0.1 mM GSH, 0.01 mM GSSG, pH 9.6) for a 
second overnight dialysis at 4°C. Afterwards, the protein was exhaustively 
dialyzed against PBS, (pH 7.4) at 4°C, the buffer was exchanged for a fresh one 
every 4 h for the first two dialyses, and then overnight for the final dialysis. 
6.2.6 Protein sample concentration 
The recovered fractions of the protein were filtered through 0.2 μm filter 
(sartorius stedim biotech, Minisart®, #16534-K) to remove any precipitated 
protein and concentrated using ultrafiltration tubes (VivaSpin 20 MWCO 10 kDa, 
GE Healthcare #28-0323-60). Columns were first pre-rinsed with ddH2O to remove 
any trace contaminants. Proteins samples were centrifuged at 8000 × g until the 
desired concentration was achieved. The concentrated pure protein sample was 
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aliquoted, a sample of each fraction was kept for Bradford assay and SDS-PAGE, 
then the rest was snap-frozen in liquid nitrogen and stored at -80°C. Using this 
method, 2-3 mg of purified recombinant protein was obtained (per 1 L of bacterial 
cell culture) and 6.8 mg of protein that would require further purification. 
6.2.7 Recipes 
6.2.7.1 Preparation of dialysis tubing 
For 2 L of 0.2 M NaHCO3/5 mM EDTA solution NaHCO3 (33.6 g) and EDTANa2 
(3.72 g) were weighed out. NaHCO3 and EDTANa2 were dissolved in 2 L of ddH2O. 
The required length of dialysis membrane (Visking Dialysis Tubing, Medicell, MWCO 
– 10-14000 Da, #DTV.12000.01) was cut. 1 L of 0.2 M NaHCO3/5 mM EDTA solution 
was poured into a glass beaker, the membrane was inserted, and the solution was 
stirred and brought to boil. Afterwards, the solution was discarded, the membrane 
washed with ddH2O (2-3×), and the excess water poured off. The final 1 L of 0.2 M 
NaHCO3/5 mM EDTA solution was added to cover the membrane and brought to 
boil. Then, the solution was discarded, the membrane was washed with ddH2O (2-
3×), inserted in ddH2O and autoclaved. Prepared dialysis tubing was stored in 
ddH2O at 4°C. 
6.3 Protein expression in mammalian cells and 
purification 
6.3.1 Transfection and expression 
Transfections were carried out in accordance to the protocol supplied with 
jetPRIME® reagent (Polyplus transfection, #114-01). Briefly, a typical transfection 
was carried out as follows: 2 × 106 – 5 × 106 HEK 293 cells were seeded in a 150 cm2 
flask 24 h prior to transfection. 10 μg DNA was diluted in 1000 μL pf jetPRIME™ 
buffer and mixed by vortexing. 20 μL of jetPRIME™ reagent was added, the mixture 
was vortexed for 10 s, spinned down briefly and incubated for 10 min at room 
temperature. 1 mL pf transfection mix was added dropwise onto cells in regular 
cell growth medium and distributed evenly by gentle rocking plates back and forth 
and from side to side. The cultures were incubated at 37°C for 72 h. 
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As a transfection control, EGFP plasmid was also transfected into HEK293 cells 
using the same transfection conditions. The plasmid coding for EGFP was donated 
by Prof. Graeme Milligan (Institute of Molecular, Cell and Systems Biology, 
University of Glasgow). The fluorescence was measured using the excitation at 
488 nm (± 14 nm) and detection at 535 (± 30 nm). The fluorescence was measured 
after 24 h, and at least a 2-fold increase in fluorescence was observed, which 
confirmed a successful transfection. 
6.3.2 Purification 
Purification was performed according to a slightly modified literature method.[139] 
The tissue culture supernatant was collected and centrifuged (3000 × g, 20 min, 
4°C). Empigen® BB detergent (Sigma, #30326) was added to a final concentration 
of 0.25% and the sample was directly used for purification. 
The sample was loaded at 1 mL∙min-1 onto a 5 mL HiTrap™ Capto™ Lentil Lectin 
column (GE Healthcare, #17-5489-11) pre-equilibrated with binding buffer 
(150 mM NaCl, 20 mM Tris-HCl, 0.25% Empigen® BB, pH 7.5) which was followed 
by washing step with 10 CVs of high salt buffer (500 mM NaCl, 20 mM Tris-HCl, 
0.25% Empigen® BB, pH 7.5). Then the column was washed with 10 CVs of binding 
buffer, and the protein was eluted with elution buffer (150 mM NaCl, 20 mM Tris-
HCl, 0.25% Empigen® BB, 1 M MMP, pH 7.5) containing methyl-α-mannopyranoside 
(MMP, Sigma, #M6882). 
6.3.3 Protein sample concentration 
Protein containing fractions were pooled together and concentrated using 
Amicon® Ultra Centrifugal Filters (0.5 mL, 50K MWCO, Merck Millipore, 
#UFC505024). Columns were first pre-rinsed with ddH2O to remove any trace 
contaminants. Proteins samples were centrifuged at 14000 × g at 4°C until the 
desired concentration was achieved. The concentrated pure protein sample was 
aliquoted, a sample of each fraction was kept for Bradford assay and SDS-PAGE, 
then the rest was snap-frozen in liquid nitrogen and stored at -80°C. 
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6.3.4 Recipes 
6.3.4.1 DMEM medium supplementation 
50 mL of DMEM medium (Sigma, #D5671) was removed from the original 500 mL 
bottle. 50 mL of filter-sterilised Fetal Bovine Serum (Sigma, #F9665) was added 
directly to the bottle with DMEM. This was followed by addition of 5 mL of sterile 
Penicillin-Streptomycin mix (Sigma, #P0781) and 5 mL of GlutaMAX™ (Gibco®, 
#35050-038). Ready-to-use medium was stored at 2-8°C 
6.4 Protein Characterisation 
6.4.1 Bradford assay 
Coomassie Protein Assay Reagent (Thermo Scientific, #1856209) was removed 
from the 4°C fridge and left to warm up to ambient temperature. A series of BSA 
(HyClone™ BSA, #SH40015.01) standards diluted with ddH2O to final 
concentrations of 0 (blank = no protein), 200, 400, 600, 800 and 1000 μg∙min-1 
were prepared. A serial dilutions of the protein samples were prepared. Out of 
each sample 5 μL was loaded into a well of 96-well plate (each sample in 
triplicate). 200 μL of the dye reagent was added into each sample and the samples 
were incubated for 10 min with mixing using a Bibby Stuart GYRO-ROCKER® STR9. 
Absorbance was measured at 595 nm using microplate reader (CLARIOstar 
microplate reader with Corning® 96 well UV-transparent plates). 
6.4.2 SDS-PAGE 
Protein electrophoresis was carried out using Invitrogen’s Mini Gel Tank system 
Invitrogen, #A25977). The samples conditions were prepared by mixing 2.5 μg of 
the protein with 1.5 μL of 10× Bolt™ Sample Reducing Agent 10× (Invitrogen, 
#B0009), 4× loading buffer (Invitrogen, #B0007) and adding ddH2O to top up to 
15 μL. The samples for non-reducing conditions were prepared in a similar way 
apart from excluding the reducing agent. Once prepared, the samples were heated 
at 70°C for 10 min to aid unfolding. Then the samples alongside Spectra™ 
Multicolor Broad Range Protein Ladder (Thermo Fisher, #26634) were loaded onto 
Bolt™ 4-12% Bis Tris Plus gels (Invitrogen, #NW04125BOX) in 1× MES running buffer 
(20× Bolt™ MES SDS Running Buffer, Invitrogen, #B0002) and the gel was ran at 
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200V for 35 min. Gels were then washed with ddH2O for 5 min and fixed for 1 h at 
room temperature in a gel-fixing solution (50% (v/v) methanol in water with 10% 
(v/v) acetic acid). Then, the gels were washed with ddH2O (5 min, 5×) and stained 
with GelCode™ Blue Stain Reagent (Thermo Fisher, #24590) for 1 h at room 
temperature. Afterwards, the gels were destained in ddH2O overnight at room 
temperature. 
6.4.3 Western Blot 
Preceding western blotting, protein samples and pre-stained marker were 
separated by mass by SDS-PAGE. The protein bands from the unstained gels were 
transferred to PVDF Blotting Membrane (GE Healthcare, 0,2 μm, #10600021) using 
Mini Bolt™ module (Invitrogen, #B1000) following the supplied protocol. Western 
transfer was carried out in the transfer buffer (Bolt™ Transfer buffer, 20×, 
Invitrogen, #BT0006) at a constant voltage of 20 V for 1 h. Then the membrane 
was washed with 1× TBST (3× ,5 min) and blocked with a solution of 5% dried 
skimmed milk (Marvel) in 1× TBST buffer for 1 h at room temperature using Bibby 
Stuart GYRO-ROCKER® STR9. The membrane was then incubated with the primary 
antibody with gentle agitation overnight at 4°C. The membrane was washed with 
1× TBST (3× ,5 min), which was followed by an incubation with a secondary 
antibody for 1 h at room temperature. The membrane was washed with 1× TBST 
(3× ,5 min) and drained. Detection reagents (Pierce™ ECL Western Blotting 
Substrate, Thermo Scientific, #32106) were mixed at a 1:1 ratio, added to the blot 
and incubated for 1 min. The excess of the reagent was drained, the blot was 
covered with a clear plastic sheet protector and visualised using myECL™ imager 
(Thermo Scientific). 
Antibodies used: 
Rabbit Monoclonal Primary Anti-CD4 antibody [EPR7276], Abcam, #ab133622 
Secondary antibody Goat anti-Rabbit IgG, Invitrogen, #31462 
Primary Goat pAb to hiv1 gp120 abcam #ab85054 100ug 1mg/ml 
Secondary antibody Donkey anti-Goat IgG (H+L), Invitrogen, #A16005 
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6.4.4 Dot Blot 
As a quick way to check in which fractions after purification the protein was 
present a dot blot procedure was carried out. On a Nitrocellulose Blotting 
membrane (GE HEALTHCARE, #10600002) a table of 2×2 cm was drawn. 5 μL 
sample of each fraction were pipetted in the centre of each square. The 
membrane was left until the samples were dry and then it was washed with 1× 
TBST (1× ,5 min) and blocked with a solution of 5% dried skimmed milk (Marvel) in 
1× TBST buffer for 1 h at room temperature using Bibby Stuart GYRO-ROCKER® 
STR9. The membrane was then incubated with the primary antibody with gentle 
agitation for 1 h at room temperature. The membrane was washed with 1× TBST 
(3× , 5 min), which was followed by an incubation with a secondary antibody for 
1 h at room temperature. The membrane was washed with 1× TBST (3× ,5 min) 
and drained. Detection reagents (Pierce™ ECL Western Blotting Substrate, Thermo 
Scientific, #32106) were mixed at a 1:1 ratio, added to the blot and incubated for 
1 min. The excess of the reagent was drained, the blot was covered with a clear 
plastic sheet protector and visualised using myECL™ imager (Thermo Scientific). 
6.4.5 In-gel trypsin digest for MS analysis 
25 μL of the purified protein was mixed with 5 μL of 5× loading buffer. The sample 
was heated at 90°C for 10 min. Then the samples were removed from the heat 
source and 1.5 μL of 1 M DTT, 6 μL of 500 mM iodoacetamide (in 100 mM 
ammonium bicarbonate solution) were added for reduction and alkylation and the 
sample was incubated in the dark for 5 min. The sample was loaded onto 10% Mini 
Protean® TGX™ gel (Bio-Rad, #456-1033) and separated with 1× SDS/glycine 
running buffer at 150 V for 60 min. The gel was stained for 10 min with Coomassie 
Blue stain and destained for 20 min in a destaining solution, which was followed 
by washing the gel with ddH2O (5 min, 3×). A piece of the gel where the protein 
of interest was resolved was separated and transferred into an Eppendorf and cut 
into several pieces. The gel sample was washed with acetonitrile-ddH2O (1:1) 
mixture. The solution was discarded, and the gel sample was washed with 100 mM 
ammonium bicarbonate (30 min). Then the gel pieces were washed with shaking 
in 50% acetonitrile/100 mM ammonium bicarbonate solution (1 h). The solvents 
were discarded and 50 μL of acetonitrile to shrink gel pieces. After 10 min the 
solvent was removed, and gel pieces were dried in a dry bath (30-38°C). 50 μL of 
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0.2 μg∙μL-1 sequencing grade modified Porcine Trypsin (Promega, #V111) in 25 mM 
ammonium bicarbonate was added to the gel pieces to rehydrate them. The 
protein was left to digest overnight at 37°C.50 μL of 50% acetronitrile was added 
to the digest and incubated for 20 min. The sample was then briefly centrifuged 
to pellet gel pieces. The supernatant was transferred to clean tubes. 15 μL of 80% 
acetonitrile/0.1% formic acid in ddH2O was added to the gel pieces and incubated 
for 20 min. The sample was then briefly centrifuged, and the supernatant was 
transferred to the same tube as used for the first extract. The wash step with 
formic acid solution was repeated once again. The solvents were then removed 
from the combined extract using Speed-Vac. 100 μL of 0.1% formic acid was added 
to the sample, which was followed by centrifugation to remove any solid particles 
that could interfere with analysis. The lysate was carefully transferred to a clean 
vial and analysed by the Ultimate 300 (Dionex) HPLC system with the MS analysis 
of peptide sequences. 
6.4.6 Recipes 
6.4.6.1 10× TBST buffer 
For 1 L of buffer NaCl (116 g) and Tris (2.42 g) were weighed out and dissolved in 
800 mL ddH2O. pH was adjusted to 7.5, Tween® 20 (10 mL) was added and the 
buffer was made up to 1 L with ddH2O. 
6.4.6.2 Destaining solution 
Mix ddH2O, methanol and acetic acid in a ratio of 50/40/10 (v/v/v). 
6.5 Binding assays – Surface Plasmon Resonance (SPR) 
Experiments were performed with BIAcore X-100 instrument using Sensor Chip CM5 
(BIAcore, Uppsala, Sweden, #BR-1000-12) at 25°C. 
6.5.1 pH scouting and pre-concentration studies – determination 
of coupling conditions 
Ligand solutions (10 μg∙mL-1, 75 μL), were prepared in 10 mM acetate buffers at 
different pH values: 5.5, 5.0, 4.5, 4.0. The ligand solution was injected using a 
contact time of 120 s in 1× HBS-P (prepared from the 10× concentrated stock 
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solution, pH 7.4, GE Healthcare, #BR100827) as a running buffer, starting at the 
highest pH to reduce the risk of aggregation or precipitation of the ligand. The 
chip surface was regenerated with 50 mM NaOH after each injection of the ligand. 
6.5.2 Immobilization 
Ligand solution was prepared at 10 μg∙mL-1 or 20 μg∙mL-1 in 10 mM acetate buffer 
pH 5.0 (175 μL) for CD4D12 and gp120, respectively. The surface in the flow cell 
2 was activated by injection of the mixture of following solutions (provided in the 
Amine Coupling Kit, GE Healthcare, #BR100050): EDC (0.4 M in water), NHS (0.1 M 
in water) for 7 min. This was followed by injection of the ligand until the desired 
response was reached. Then 1 M ethanolamine pH 8.5 (Amine Coupling Kit) was 
injected for 7 min to deactivate remaining active groups on the surface and 
remove non-covalently bound ligand. The flow rate of 10 μL∙min-1 was used. 
A naked sensor surface in flow cell 1, which was activated and deactivated in the 
same was as in flow cell 2, served as a negative control for each binding 
interaction. 
6.5.3 Regeneration scouting 
To find optimal regeneration conditions the regeneration scouting procedure was 
carried out. A previously unused sensor surface, with a representative for 
experiments amount of immobilized ligand, was used. An analyte was prepared at 
the highest concentration that was planned to be used in the binding experiments. 
Scouting was performed by testing a few (3-5) repeated cycles of analyte binding 
and regeneration with each of the conditions. Scouting was started with the 
mildest conditions and progressed towards harsher conditions. The entire 
procedure was as follows: the analyte was injected for 60 s, which was followed 
by injection of regeneration solution for 30 s. The regeneration solutions that 
were tested included 10 mM glycine at a range of pHs: 3.0, 2.5, 2.0, 1.75, 1.5. 
6.5.4 Binding assays 
Sensor chip was primed with degassed and filtered running buffer. 5 start-up 
cycles, consisting of injections of the running buffer followed by regeneration 
solution, were performed to obtain a stable baseline. The analyte was prepared 
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in serial dilutions (0-100 nM gp120, 0-100 μM gp120 mimics, 0-250 nM CD4D12) and 
applied to the sensor chip at a flow rate of 30 μL∙min-1 allowing 120 s for 
association and 600 s for dissociation. Between sample applications the chip was 
regenerated with two injections of the regeneration buffer for 30 s each. During 
the experiment, the response obtained using reference surface and the response 
obtained from the 2-3 blank injections (zero analyte concentrations) was 
subtracted (double referencing). Each sample concentration was performed in a 
duplicate and each experiment was repeated in total two times. The results were 
plotted as RU versus time and analysed with the BIAcore X100-evaluation software 
2.0.1 (BIAcore, Uppsala, Sweden). Binding of all the molecules was fitted a 1:1 
Langmuir binding model describing the interaction of two molecules in a 1:1 
complex. 
Used solutions: 
for protein-protein interactions HBS-P: 0.01 M HEPES pH 7.4, 0.15 M 
NaCl, 0.005% v/v surfactant P20, GE 
Healthcare, #BR100368 
for protein-gp120 mimics or 
independent loops interactions 
PBS-P+: 0.2 M phosphate buffer with 
0.27 mM KCl, 1.37 M NaCl and 0.5% 
surfactant P20, pH 7.4, GE Healthcare, 
#28995084 
Regeneration solution 10 mM Glycine pH 1.75 
6.6 Synthesis 
6.6.1 General experimental 
All reagents were obtained from commercial sources and used without further 
purification unless specified otherwise. Fmoc-amino acids were obtained from 
Activotec (Cambridge, United Kingdom) and N,N,N’,N’-Tetramethyl-O-(6-chloro-
1H-benzotriazol-1-yl)uranium hexafluorophosphate (HCTU) was obtained from 
Matrix Innovation, Quebec, Canada). Tentagel S RAM resin (particle size 90 μm, 
capacity 0.25 mmol∙g-1) was obtained from IRIS Biotech (Markredwitz, Germany). 
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Methyl tert-butyl ether (MTBE), n-hexane (HPLC grade) and TFA were obtained 
from Aldrich (Milwaukee, USA). DMF (peptide grade) was obtained from VWR 
(Lutterworth, United Kingdom). Piperidine and DiPEA were obtained from AGC 
Bioproducts (Hessle, United Kingdom), and 1,2-ethanedithiol (EDT) was obtained 
from Merck (Darmstadt, Germany). HPLC grade DCM and acetonitrile were 
obtained from Fischer Scientific (Loughborough, United Kingdom). Solid phase 
peptide synthesis (SPPS) was performed on a PTI Tribute-UV peptide synthesizer. 
Lyophilisations were performed on a Christ Alpha 2-4 LDplus freeze dryer. 
Reactions were carried out at ambient temperature unless stated otherwise. Air 
and/or moisture sensitive reactions were performed in the glass apparatus dried 
with a heat-gun under vacuum and flushed with nitrogen. Solvents were 
evaporated under reduced pressure at 40°C. Dry solvents of tetrahydrofuran, 
dichloromethane and diethyl ether were purified using a Pure-SolvTM 500 Solvent 
Purification System. All other solvents of analytical or HPLC grade were used 
without any further purification. Ultra-pure water was obtained with the use of 
Sartorious Arium® Comfort I water purification system. 
Thin Layer Chromatography (TLC) was performed using Merck silica gel glass 60 
F254. TLC plates were visualised by fluorescent quenching at λ = 254 nm with 
incident UV light produced from a UV Minerallight® lamp. TLC plates were also 
visualised by staining using the most appropriated solution: potassium 
permanganate (5 g potassium carbonate and 10 g potassium permanganate in 
500 mL water), p-anisaldehyde (10 mL of concentrated sulphuric acid, 10 mL 
glacial acetic acid, 20 mL of p-anisaldehyde to 360 mL of absolute ethanol). Flash 
column chromatography was performed using Merck silica gel 60 (40-63 µm) from 
Silicycle (Canada). 
1H-NMR and 13C-NMR spectra were recorded on a Bruker® Avance™ III 400 MHz and 
500 MHz spectrometers at ambient temperature. Chemical shifts are quoted in 
parts per million (ppm) downfield of TMS δTMS = 0 ppm). Data are reported as 
follows: chemical shift in ppm relative to CDCl3 (7.26) or trimetylsilane (TMS, 0.00 
ppm), multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, 
b = broad), coupling constant(s) J (Hz), integration and assignment. 
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Analytical HPLC was carried out with a Shimadzu Prominence system consisting of 
a communication module (CBM-20A), autosampler (SIL-20HT), pump modules (LC-
20AT), UV/VIS detector (SPD-20A) and system controller (Labsolutions V5.54 SP), 
with a Dr. Maisch GMBH ReproSil-Pur Gold 200 C18 column (200 Å, 5 μm, 250 × 
4.6 mm). UV absorbtion was recorded at 214 and 254 nm, by use of a standard 
protocol: 100% buffer A [acetronitrile/H2O 5:95 with TFA (0.1%)] for 2 min 
followed by a linear gradient of buffer B [acetonitrile /H2O 95:5 with TFA (0.1%)] 
to buffer A (0-100%) over 30 min at a flow rate of 1.0 mL min-1. 
Purification of peptidic compounds was performed on an Agilent Technologies 
1260 infinity preparative system coupled to a UV detector at 214 nm with a Dr. 
Maisch GMBH Reprosil Gold 200 C18 column (200 Å, 10 μm, 250 × 20 mm). Auto-
collection of fractions was based on the UV measurements at 214 nm, using either 
100% buffer A or 95% buffer A with 5% buffer B for 5 min followed by a linear 
gradient of buffer B into buffer A (specified for each compound) over 65 min at a 
flow rate of 12.5 mL∙min-1 using the same buffers as described for analytical HPLC. 
Liquid chromatography mass spectrometry (LC-MS) was carried out on a Thermo 
Scientific LCQ Fleet Quadrupole mass spectrometer and a Dionex Ultimate 3000 
LC with use of a Dr. Maisch Reprosil Gold 120 C18 column (110 Å, 3 µm, 150 × 
4.0 mm), and a 0-100% linear gradient of buffer B into buffer A with a flow of 
1 mL∙min-1.  
High-resolution electrospray ionization (ESI) mass spectra were measured with a 
Bruker micrOTOF-Q II instrument in a positive mode. 
6.6.2 Scaffold synthesis 
Apart from compound 2, the synthesis of TAC scaffold was performed according 
to the literature procedure.[88] 
N-(3-bromopropyl)-2-nitrobenzene-sulfonamide (7) 
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Bromopropylamine hydrobromide (43.6 g, 200 mmol) and 2-nitrobenzenesulfonyl 
chloride (53.2 g, 240 mmol) were dissolved in DCM (320 mL) and cooled in an ice 
bath. After dropwise addition of triethylamine (64.1 mL, 460 mmol) the reaction 
mixture was stirred overnight at room temperature affording a yellow suspension. 
The solvent was removed under vacuum and EtOAc (500 mL) was added and the 
mixture was washed with KHSO4 solution (1 M, 250 mL, 2×), NaHCO3 solution (1 M, 
250 mL, 2×) and brine (250 mL, 2×). The organic phase was dried over MgSO4, 
filtered and the solvent was removed by evaporation and co-evaporation with 
CHCl3 under vacuum, yielding the product as an off-white solid (61.68 g, 95%). 
1H NMR (400 MHz, CDCl3): δ = 2.11 (m, 2H), 3.28 (q, 2H), 3.47 (t, 2H, J = 6.2 
Hz), 5.41 (t, 1H, J = 6.3 Hz), 7.77 (m, 2H), 7.89 (m, 1H), 8.16 (m, 1H). 
13C NMR (100 MHz, CDCl3): δ = 29.90, 32.39, 41.97, 125.48, 131.11, 132.93, 
133.41, 133.77, 148.04. 
Spectroscopic data were in accordance with literature.[88] 
N-(3-(2-nitrophenylsulfonamido)propyl)-N-(3-(2,2,2-
trifluoroacetamido)propyl)pent-4-unamide (10) 
 
 
 
To a cooled solution (ice bath) of 1,3-diaminopropane (159 mL, 190.87 mmol) in 
DMA (650 mL) a solution of sulfonamide bromide 7 in DMA (650 mL) was added 
dropwise. The solution turned dark orange/red with a white precipitate. The 
resulting mixture was allowed to warm up to room temperature and was stirred 
overnight. An aqueous solution of 4 M NaOH (47.7 mL, 1 equiv.) was added after 
which the precipitate was fully dissolved. The mixture was concentrated in vacuo 
until a third of the volume. DMA (600 mL) was added and again the mixture was 
concentrated until a third of the volume remained. This co-evaporation was 
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repeated until the collected DMA was not basic (litmus paper). After a final 
evaporation of all remaining DMA, compound 8 was obtained as a yellow oil. 
Acetonitrile (630 mL), H2O (3.4 mL, 190.9 mmol) and ethyl trifluoroacetate 
(90.85 mL, 763.5 mmol) were added to the crude intermediate 8. The reaction 
was stirred overnight under reflux (90°C) followed by concentration in vacuo to 
afford triamine 9 as a yellow oil. 
Crude triamine compound 9 was dissolved in DCM (1200 mL). BOP (88.6 g, 
200.4 mmol), 4-pentynoic acid (18.7 g, 190.9 mmol) and NMM (95.1 mL, 
874.5 mmol) were added and the mixture was stirred overnight. The solvent was 
evaporated, and the residue was dissolved in EtOAc (600 mL) and divided into two 
portions. Each of the portions was washed with 1 M NaHCO3 (400 mL, 2×), 1 M 
KHSO4 (400 mL, 2×) and brine (400 mL). The organic layers were dried over MgSO4, 
filtered and the solvent was removed in vacuo. The crude product (99.43 g) was 
purified by column chromatography in a batch wise process with 10 to 15 g crude 
product until all purification was complete. For each batch, column 
chromatography was conducted with ca. 750 g silica and the gradient as follows: 
(EtOAc/hexane 4:6 until first a yellow band was eluted, then 1:1 until the product 
started to elute, then gradually increasing the amount of EtOAc up to 8:2 until the 
product had eluted) to obtain compound 10 as a yellow oil, which slowly solidified 
(65.12 g, 132 mmol, 69% over 3 steps). Rf = 0.61 (EtOAc/hexane 8:2). 
1H NMR (400 MHz, CDCl3): δ = 1.69-1.73, 1.85-1.90 (m, 4H, N-CH2-CH2), 1.96 (s, 
1H, CCH), 2.56 (m, 4H, C(O)-CH2-CH2), 3.06-3.18, 3.25-3.30 (2m, 4H, 2 × NH-CH2-
CH2), 3.41-3.44 (m, 4H, CH2-N-CH2), 5.58, 6.27, 6.90 (3m, 2H, NH), 7.71-7.90, 
8.08-8.17 (2m, 4H, Ar-H). 
13C NMR (100 MHz, CDCl3): δ = 14.76, 14.90, 26.76, 28.07, 28.45, 29.01, 31.72, 
31.85, 35.87, 37.40, 40.75, 41.05, 41.96, 42.21, 42.71, 45.01, 45.36, 69.01, 69.20, 
82.98, 83.12, 114.58, 117.44, 125.16, 125.53, 130.69, 131.05, 132.72, 132.99, 
133.17, 133.51, 133.98. 
LCMS-ESI: tR = 16.59, exact mass calculated [M+H]+: 493.1290; found: 493.08. 
Spectroscopic data in accordance with literature.[88] 
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Triamine cyclization (12) 
 
 
 
Dibromide 11 was provided by Dr Helmus van de Langemheen. 
The reaction described below was performed ten times to react all of the starting 
material at the desired, high (12 mM) dilution. 
Compound 10 (6.5 g, 13.2 mmol, 1 equiv.), dibromide 11 (4.25 g, 13.2 mmol, 
1 equiv.) and Cs2CO3 (17.2 g, 52.8 mmol, 4 equiv.) were dissolved in DMF 
(1100 mL) and the resulting mixture was stirred overnight. The DMF was then 
evaporated in vacuo and EtOAc (650 mL) was added. The organic layer was washed 
with water (1 x 400 mL), 1 M KHSO4 (1 x 450 mL) and with brine (1 x 450 mL), 
dried over MgSO4 and filtered. Evaporation of the solvent afforded 85.08 g of the 
crude product (which was divided in several fractions for purification, each of 
them 15 – 18 g) as an orange oil which was purified using flash column 
chromatography (EtOAc/hexane 7:3). Compound 12 was obtained as a yellow foam 
(37.84 g, mmol, 44%). Rf = 0.33 (EtOAc/hexane 7:3). 
1H NMR (400 MHz, CDCl3): δ = 1.26-1.42, 1.60-1.70 (2m, 4H, 2 × N-CH2-CH2), 1.92 
(m, 1H, CCH), 2.38-2.45 (m, 4H, C(O)-CH2-CH2),3.93, 3.96 (2s, 3H, OCH3), 4.41-
4.52, 4.66-4.79 (2m, 4H, 2 × Ar-CH2-N), 7.67-8.10 (m, 7H, Ar-H). 
LCMS-ESI: tR = 19.87, exact mass calculated [M+H]+: 653.1815; found: 653.08. 
Spectroscopic data in accordance with literature.[88] 
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Pentynoic acid amidated Fmoc protected TAC-scaffold (13) 
 
 
 
Compound 12 (13.0 g, 20 mmol) was dissolved in dioxane/MeOH/aq. NaOH (4 M) 
(15:4:1, 700 mL, 140 mmol) and the resulting mixture was stirred overnight at 
room temperature. 1 M HCl was added until the pH of the mixture was neutral, 
after which acetonitrile (500 mL) and H2O (500 mL) were added. The pH was 
adjusted to approximately 8 using DiPEA and a solution of Fmoc-OSu (7.4 g, 
22 mmol, 1.1 equiv.) in Acetonitrile (75 mL) was added. This was followed by 
dropwise addition of DiPEA to maintain pH 8 and the reaction was considered to 
be complete when the pH remained above 7.5 for 10 min. For the purpose of ease 
of handling, the reaction mixture was divided into 3 equal fractions, each fraction 
was treated as follows: An aqueous solution of HCl (1 M, 75 mL), and H2O (500 mL) 
was added followed by extraction with EtOAc (2 × 500 mL). The combined organic 
layers were washed with brine (1 × 500 mL) and dried over MgSO4, filtered and 
evaporated in vacuo Combination of all fractions afforded the crude product 
(17.9 g) as a yellow solid. Further purification by flash gel chromatography 
(MeOH/DCM 2:98 with 0.1% AcOH) gave the Fmoc-protected TAC scaffold 13 
(14.6 g, 19 mmol,95%). Rf = 0.52 (6% MeOH/DCM with 0.1% AcOH). 
LCMS-ESI: tR = 21.33, exact mass calculated [M+H]+: 765.2516; found: 765.00. 
Tert-butyl pent-4-ynoate (2) 
  
 
4-pentynoic acid (5 g, 51 mmol) was dissolved in anhydrous DCM (75 mL) and an 
excess of tert-butyl-2,2,2-trichloroacetimidate (33.4 g, 153 mmol, 3 equiv.) was 
added. The reaction mixture was stirred overnight at room temperature, then it 
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was filtered through celite to remove trichloroacetamide (white crystals). After 
filtration, the solvent was carefully removed by evaporation under reduced 
pressure with water bath kept at room temperature. Tert-butyl pent-4-ynoate was 
obtained as a yellow oil (7.1 g, 46 mmol, 90%). Rf = 0.43 (Et2O/hexane 0.5/9.5) 
1H NMR (500 MHz, CDCl3): δ = 1.45 (s, 9H, C(CH3)3), 1.96 (m, 1H, CH), 2.45 (m, 
4H, CH2-CH2). 
13C NMR (100 MHz, CDCl3): δ = 14.45, 28.03, 34.46, 68.72, 80.72, 82.67, 170.96. 
Spectroscopic data were in agreement with literature.[151] 
Tert-butyl 5-(triisopropylsilyl)-pent-4-ynoate (4) 
 
 
 
Compound 4 was prepared according to a modified literature procedure.[88] 
Compound 2 (0.8 g, 5 mmol) was dissolved in anhydrous THF (15 mL) and cooled 
to -78°C (dry ice/acetone bath). n-BuLi (2.0 mL, 2.5 M in hexanes, 5 mmol) was 
added dropwise and the reaction was stirred for 30 min. the solution was warmed 
to 0oC by replacing the dry ice/ acetone bath with an ice bath and TIPS-Cl (1.3 mL, 
6 mmol, 1.2 equiv.) was added dropwise. The reaction was stirred for 3 h at room 
temperature after which it was quenched with 30 mL saturated aqueous NH4Cl. 
Et2O was carefully removed by evaporation under reduced pressure with water 
bath kept at room temperature. The aqueous slurry was diluted with H2O (40 mL) 
and the mixture was extracted with Et2O (3 × 50 mL) and the combined organic 
layers were dried over MgSO4. After filtration the solvent was evaporated under 
reduced pressure with room temperature water bath. The crude product was 
purified by flash column chromatography (1% Et2O/pentane) to give the desired 
product 4 as a yellow oil (0.89 g, 2.3 mmol, 46%) Rf = 0.51 (2% Et2O/Petroleum 
ether with 0.1% of AcOH). 
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1H NMR (400 MHz, CDCl3): δ = 1.04 (m, 21H, Si(CH(CH3)2)3), 1.44 (s, 9H, C(CH3)3), 
2.42-2.52 (m, 4H, CH2-CH2). 
13C NMR (100 MHz, CDCl3) ): δ = 11.22 (SiCH(CH3)2)3), 15.92 ((C(O)CH2CH2), 18.58 
(Si(CH(CH3)2)3), 28.06 (C(CH3)3), 35.14 ((C(O)CH2), 80.54, 80.77 (CCH3, CCSi), 
107.12 (CCSi), 171.07 (C=O). 
HRMS-ESI: exact mass calculated [M+Na]+: 333.2226; found: 333.2205. 
Spectroscopic data was in agreement with literature [88] 
Tert-butyl 5-(triethylsilyl)-pent-4-ynoate (3) 
 
 
 
Compound 3 was prepared according to a modified literature procedure.[88] 
Compound 2 (2.7 g, 17 mmol) was dissolved in anhydrous THF (40 mL) and cooled 
to -78°C (dry ice/acetone bath). n-BuLi (6.8 mL, 2.5 M in hexanes, 17 mmol) was 
added dropwise and the reaction mixture was stirred for 10 min. Dry ice/acetone 
bath was replaced by an ice bath and TES-Cl (3.4 mL, 20.4 mmol, 1.2 equiv.) was 
added dropwise. The reaction mixture was stirred for 3 h at room temperature, 
after which it was quenched with 50 mL of saturated aqueous NH4Cl. Et2O was 
carefully removed by evaporation under reduced pressure with a water bath at 
room temperature. The crude product was purified by flash column 
chromatography (1% Et2O/pentane) to give the desired product as a yellow oil 
(1.96 g, 7.3 mmol, 43%) Rf = 0.53 (4% Et2O/Petroleum ether with 0.1% AcOH). 
1H NMR (400 MHz, CDCl3): δ = 0.55 (q, J = 7.8 Hz, 6H, Si(CH2-CH3)3), 0.96 (t, J = 
7.9 Hz, 9H, Si(CH2-CH3)3), 1.44 (s, 9H, CCH3), 2.41-2.53 (m, 4H, CH2-CH2). 
13C NMR (100 MHz, CDCl3): δ = 4.45(Si(CH2-CH3)3), 7.40 (Si(CH2-CH3)3), 15.96 
(C(O)CH2-CH2), 28.05 (CCH3), 35.00 (C(O)CH2), 80.59, 82.16 (CCH3, CCSi), 106.49 
(CCSi), 171.09 (C=O). 
164 
 
HRMS-ESI: exact mass calculated [M+Na]+: 291.1756; found: 291.1754. 
Spectroscopic data were in agreement with literature.[88] 
5-(triisopropylsilyl)-4-pentynoic acid (6) 
 
 
 
Compound 6 was prepared according to a modified literature procedure.[88] 
Compound 4 (1.3 g, 4.2 mmol) was dissolved in 10% TFA/DCM (50 mL) and the 
resulting mixture was stirred for 2 h. Then the reaction was quenched with 1 M 
ammonium acetate (100 mL) and extracted with DCM (2 × 75 mL). The combined 
organic layers were dried over MgSO4, filtered and evaporated under reduced 
pressure. The crude product was purified using flash column chromatography (5-
7% Et2O/pentane with 0.1% AcOH). Eluted fractions were merged and solvents 
were evaporated under reduced pressure. Excess acetic acid was then removed 
by an additional washing step rather than by evaporation due to compound 
volatility as follows: The concentrated fractions were dissolved in Et2O (15 mL) 
and washed with H2O to remove AcOH (3 × 10 mL). Then, the combined organic 
layers were dried over MgSO4, filtered and concentrated. The product 6 was 
obtained as a yellow oil (0.61 g, 2.4 mmol, 57%). Rf = 0.46 (20% EtOAc/hexanes 
with 0.1% AcOH). 
1H NMR (400 MHz, CDCl3): δ = 1.05 (m, 21H, Si(CH(CH3)2)3), 2.54-2.65 (m, 4H, 
CH2-CH2). 
13C NMR (100 MHz, CDCl3): δ = 11.18 (Si(CH2-CH3)3), 15.65 (C(O)CH2-CH2), 18.53 
(Si(CH2-CH3)3), 33.80 (C(O)CH2), 81.62 (CCSi), 106.21 (CCSi), 178.05 (C=O). 
HRMS-ESI: exact mass calculated [M+Na]+: 277.1600; found: 277.1589. 
Spectroscopic data were in agreement with literature.[88] 
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5-(triethylsilyl)-4-pentynoic acid (5) 
 
 
 
Compound 3 (0.81 g, 7.3 mmol) was dissolved in 15% TFA/DCM (50 mL) and the 
resulting mixture was stirred for 2 h. The reaction was then quenched with 1 M 
ammonium acetate (100 mL) and extracted with DCM (2 × 75 mL). The combined 
organic layers were dried over MgSO4, filtered and evaporated under reduced 
pressure. The crude product was purified by flash column chromatography (5-7% 
Et2O/pentane with 0.1% AcOH). Eluted fractions were merged and solvents were 
evaporated under reduced pressure. Afterwards, the crude product was dissolved 
in Et2O (15 mL) and washed with H2O to remove AcOH (3 × 10 mL). Then, the 
combined organic layers were dried over MgSO4, filtered and concentrated. The 
product 5 was obtained as a yellow oil (0.42 g, 1.97 mmol, 66%). Rf = 0.43 (20% 
EtOAc/hexanes with 0.1% AcOH). 
1H NMR (400 MHz, CDCl3): δ = 0.56 (q, J = 7.9 Hz, 6H, Si(CH2-CH3)3), 0.96 (t, J = 
7.9 Hz, 9H, Si(CH2-CH3)3), 2.53-2.64 (m, 4H, CH2-CH2). 
13C NMR (100 MHz, CDCl3): δ = 4.40 (Si(CH2-CH3)3), 7.34 (Si(CH2-CH3)3), 15.61 
(C(O)CH2-CH2), 33.58 (C(O)CH2), 82.69 (CCSi), 105.86 (CCSi), 176.86 (C=O). 
HRMS-ESI: exact mass calculated [M+Na]+: 235.1130; found: 235.1120 
Spectroscopic data were in agreement with literature.[88] 
Orthogonally protected trialkyne TAC-scaffold (15) 
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TAC-scaffold 13 (0.45 g, 0.59 mmol) was loaded onto 2-chlorotrityl resin by 
dissolving in DCM (10 mL). DiPEA (102 μL, 0.59 mmol) was added, followed by 
addition of 2-chlorotrityl chloride resin (1.0 g, 0.8 mmol). After 5 min, another 
portion of DiPEA (154 μL, 0.88 mmol, 1.5 equiv.) was added and the mixture was 
stirred overnight at room temperature. DiPEA (1 mL) and MeOH (4 mL) were then 
added and the mixture was stirred for 30 min. The resin was transferred to a solid 
phase reaction vessel and washed with DCM (3 × 20 mL), MeOH (3 × 20 mL) and 
Et2O (3 × 20 mL). 
Resin load determination. After drying for 1 h, 8.9 mg of the loaded resin was 
transferred to a 25 mL volumetric flask and 20% piperidine/DMF (2 mL) was added. 
The flask was shaken for 30 min, after which MeOH was added until a volume of 
25 mL. UV absorption was measured at 300 nm (ε = 7800 M-1cm-1) resulting in a 
loading of 0.25 mmol∙g-1 resin (loading yield of 43%). 
Fmoc deprotection. The rest of the resin was washed with DCM (3 × 20 mL), DMF 
(3 × 20 mL) and 20% piperidine/DMF (1 x 20 mL) was added and the mixture was 
shaken for 1 min, then the solvents were discarded. Another 20 mL of 20% 
piperidine/DMF was added and the mixture was shaken for 30 min, after which 
the solvents were discarded. The resin was washed with DMF (3 × 20 mL), DCM 
(3 × 20 mL). A positive Bromophenol Blue-test indicated Fmoc removal. 
Coupling of TIPS-protected pentynoic acid 6. BOP (0.22 g, 0.5 mmol, 2 equiv.), 
DMF (10 mL), TIPS protected pentynoic acid 6 (0.13 g, 0.5 mmol, 2 equiv.) DiPEA 
(0.17 mL, 1.0 mmol, 4 equiv.) were added. The mixture was shaken for 2 h. Then, 
the resin was washed with DMF (3 × 20 mL), DCM (3 × 20 mL). A negative 
Bromophenol Blue-test indicated coupling of the pentynoic acid derivative. 
oNBS deprotection. The resin was washed with DMF (3 × 20 mL). DMF (15 mL), β-
mercaptoethanol (0.18 mL,2.5 mmol, 10 equiv.) and DBU (0.19 mL, 1.3 mmol, 
5 equiv.) were added and the mixture was shaken for 15 min. The deprotection 
step was repeated once and the resin was washed with DMF (3 × 20 mL), DCM 
(3 × 20 mL). A positive Bromophenol Blue-test indicated oNBS protecting group 
removal. 
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Coupling of TES-protected pentynoic acid 5. BOP (0.22 g, 0.5 mmol, 2 equiv.), 
DMF (10 mL), TES-protected pentynoic acid 5 (0.11 g, 0.5 mmol, 2 equiv.) and 
DiPEA (0.18 mL, 1.0 mmol, 4 equiv.) were added and the mixture was shaken for 
2 h. The resin was washed with DMF (3 × 20 mL), DCM (3 × 20 mL) and a negative 
Bromophenol Blue-test indicated successful coupling. 
Resin cleavage. The resin was transferred to a round bottom flask and a solution 
of 30% HFIP/DCM (20 mL) was added. The mixture was stirred for 45 min. After 
filtration and washing of the residue with DCM, EtOAc (30 mL) was added to the 
filtrate. The solvents were removed by evaporation under reduced pressure. Flash 
column chromatography (5% MeOH/DCM) afforded the scaffold as a yellow oil. The 
oil was dissolved in t-BuOH/H2O 1:1 and lyophilised to obtain a white solid 15 
(0.17 g, 0.22 mmol, 88%). Rf = 0.73 (10% MeOH/DCM). tR = 31.862, 
LCMS-ESI: average mass calculated [M+H]+: 788.4854; found: 788.42, HRMS exact 
mass calculated [M+Na]+: 810.4673, found: 810.4628, MALDI-TOF found: 788.45. 
1H NMR (400 MHz, CDCl3): δ = 0.57 (q, J = 7.9 Hz, 6H, Si(CH2CH3)3), 0.97 (t, J = 
7.9 Hz, 9H, Si(CH2CH3)3), 1.05 (m, 21H, Si(CH(CH3)2)3), 1.25-1.56 (m, 4H, N-CH2-
CH2-CH2-N), 1.94 (m, 1H, CCH), 2.45 (m, 4H, CH2CH2CCH), 2.60-2.79 (m, 8H, 2 × 
CH2CH2CCSi), 2.85-3.05, 3.40-3.50 (2m, 8H, N-CH2-CH2-CH2-N), 4.63-4.69 (m, 4H, 
2 × N-CH2-Ar), 7.40-7.47, 7.89-7.95 (dd, J = 194.3, 27.6 Hz, 2H, Ar-H), 8.02-8.06 
(d, 16 Hz, 1H, Ar-H). 
13C NMR (100 MHz, CDCl3): δ = 4.46, 7.49, 11.26, 14.55, 14.60, 16.39, 16.41, 
18.65, 28.00, 28.09, 28.36, 31.91, 31.93, 32.84, 33.11, 33.15, 43.55, 45.56, 45.61, 
45.72, 46.04, 48.24, 28.30, 52.10, 52.18, 53.85, 53.92, 81.28, 81.34, 82.70, 82.75, 
83.11, 83.22, 106.45, 106.48, 107.07, 107.15, 128.82, 130.03, 130.07, 130.09, 
130.34, 131.37, 131.38, 131.41, 131.43, 138.19, 140.51, 168.85, 170.80, 172.12, 
172.55. 
Spectroscopic data were in agreement with literature.[88] 
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6.6.3 Peptide synthesis 
6.6.3.1 Solid phase synthesis of linear peptides 
General method for automated peptide synthesis: Linear peptides were 
synthesized on a PTI Tribute-UV peptide synthesizer. Tentagel S RAM resin (1.0 g, 
0.25 mmol 1 equiv.) was allowed to swell (3 × 10 min). Removal of Fmoc-group 
was performed using 20% piperidine in DMF using Tribute-UV peptide synthesizer 
RV_top_UV_Xtend protocol which was followed by a DMF washing step (5 × 30 s). 
Fmoc-protected amino acids (0.25 mmol, 4 equiv.) were coupled using HCTU 
(1 mmol, 4 equiv.) and DiPEA (2 mmol, 8 equiv.) in DMF as a solvent. The coupling 
time was 20 min. After each coupling the resin was washed with DMF (6 × 30 s). 
Capping was performed using a mixture of acetic anhydride (23.6 mL), DiPEA 
(10.9 mL) in DMF (500 mL). After the last amino acid coupling, the Fmoc group 
was cleaved under normal deprotection conditions (described above) and the 
resulting free N-terminus was acetylated by treatment of the resin bound peptide 
with acetic anhydride (250 μL) and DiPEA (2 mmol, 8 equiv.) in DMF using coupling 
times described above. After the last coupling step, the resin was washed with 
DMF (5 × 30 s), DCM (5 × 30 s), dried over a nitrogen flow for 10 min, followed by 
the cleavage of the resin bound peptide. 
Note: in the synthesis of linear loop 2 after the last Fmoc-removal the N-terminus 
was left as a free amine.  
General procedure for the cleavage and deprotection of the peptide from the 
solid support 
Deprotection of side chain protected amino acids and cleavage from the resin was 
achieved by treatment of the resin with a mixture of TFA:H2O:EDT:TIS (10 mL, 
90/5/2.5/2.5, v/v/v/v) for 3 h. Afterwards, the peptide was precipitated with 
MTBE/hexane (90 mL, 1:1 v/v). After centrifugation (3500 rpm, 5 min) the 
supernatant was discarded and the pellet was suspended in MTBE:hexane (90 mL, 
1:1, v/v) and centrifuged again. This procedure was repeated in total 3 times. 
Finally, the pellet was dissolved in t-BuOH/H2O (1:1, v/v) and lyophilized to yield 
the crude linear peptide. 
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A fraction of each of the crude linear peptides was purified for MALDI-TOF, 1H-
NMR and CD-spectrometry purposes. Otherwise, all of the crude peptides were 
used for cyclization. 
Linear peptides synthesized: 
Linear peptide 1 × 2TFA, Ac-CLTRDGGKC-NH2, tR = 13.461, LCMS-ESI: average 
mass calculated [M]+: 993.17; found: 993.58. MALDI-TOF: 993.32. 
Linear peptide 2 × 2TFA, H-CINMWQEVGKAC-NH2, tR = 17.394, LCMS-ESI: average 
mass calculated [M]+: 1380.67, found: 1380.92. MALDI-TOF: 1380.04. 
Linear peptide 3, Ac-CSGGDPEIVTC-NH2, tR = 14.358, LCMS-ESI: average mass 
calculated [M]+: 1121.25; found: 1121.08. MALDI TOF: as Na+ adduct: 1143.23, 
1165.07. 
6.6.3.2 Cyclic peptide synthesis 
Cyclization hinge N3-TADB was provided by Dr Helmus van de Langemheen. 
All cyclisations were performed at the concentration of 1 mM of the linear 
peptide. The crude linear peptide and 1,3,5-triazinane hinge N3-TADB were placed 
in a round bottomed flask and dissolved in acetonitrile. After 5 min, an aqueous 
solution of ammonium bicarbonate buffer (20 mM, pH = 7.8) was added to form a 
1:3 v/v mixture of acetonitrile/buffer. The progress of the cyclization was 
checked by LCMS after 30 min, which confirmed reaction completion. Next, the 
solvents were removed in vacuo until approximately 1/3 of the volume, and the 
remaining slurry was lyophilised. The crude cyclic peptides were purified using 
preparative HPLC. The product containing fractions were pooled together and 
lyophilised to yield the desired cyclic peptides as a white fluffy powder. 
Cyclic peptides synthesized:  
Loop 1 × 2∙TFA (16), , purified using gradient 0-40% of buffer 
B into buffer A over 40 min at a flow rate of 12.5 mL∙min-1. The title compound 
was obtained as a white fluffy powder after lyophilisation (49.3 mg, 33.5 μmol, 
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13%). (21 steps, average 91% per step). aHPLC tR = 14.593, LCMS-ESI: tR = 8.67, 
average mass calculated [M]+: 1243.38; found: 1243.25. MALDI-TOF found: 
1243.23. 
Loop 2 × 2∙TFA (17), , purified using gradient 5-40% of 
buffer B into buffer A over 35 min at a flow rate of 12.5 ml∙min-1. The title 
compound was obtained as a white fluffy powder after lyophilisation: 47.6 mg 
(25.6 μmol), 10%, (26 steps, average 92% per step). aHPLC tR = 17.023, LCMS-ESI: 
tR = 11.88, average mass calculated [M+2H]2+: 816.44; found: 816.08. Average 
mass calculated [M]+: 1630.87, MALDI-TOF found: 1630.56. 
Loop 3 × 2∙TFA (18), , purified using gradient 14-34% of 
buffer B into buffer A over 40 min at a flow rate of 10 mL∙min-1. The title 
compound was obtained as a white fluffy powder after lyophilisation: 99.8 mg 
(72.8 μmol), 29%, (25 steps, average 95% per step). aHPLC tR = 15.227, LCMS-ESI: 
tR = 10.24, average mass calculated [M]+: 1371.46.; found: 1371.50. Average mass 
calculated [M]+: 1371.46, MALDI-TOF found: 1371.40. 
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6.6.3.3 Preparation of gp120 mimics 
Synthesis gp120 mimic 22: 
 
First CuAAC (copper-catalysed azide-alkyne cycloaddition) and TES-removal: TAC-
scaffold 15 (5.12 mg, 6.5 μmol, 1 equiv.), peptide loop 1 16 (11.48 mg, 7.8 μmol, 
1.2 equiv.) and TBTA (1.72 mg, 3.25 μmol, 0.5 equiv.) were placed in a flask and 
degassed DMF (300 μL) was added. The reaction was stirred under nitrogen 
atmosphere until all components were dissolved. Then, aqueous 1 M CuSO4 
(3.5 μL, 3.25 μmol, 0.5 equiv.) and aqueous 0.25 M sodium ascorbate (38.6 μL, 
9.75 mmol, 1.5 equiv.) were added. The reaction mixture was stirred under 
nitrogen and monitored by analytical HPLC and LCMS. When reaction was 
complete (typically after 2 h), AgNO3 (15.6 mg, 91.83 μmol, 14 equiv.) was added 
and the mixture was stirred under nitrogen atmosphere, and monitored by 
analytical HPLC and LCMS, which showed complete conversion after 1 h. Then, 
NaCl (5.5 mg, 91.83 μmol, 14 equiv.) was added in order to precipitate out Ag+ as 
AgCl. Then, the solvents were removed with a nitrogen stream and the red residue 
was diluted with buffer A (1500 μL). The solution was centrifuged (4500 rpm, 
5 min) and the supernatant was purified using a gradient of 30-70% of buffer B into 
buffer A over 40 min at a flow rate of 12.5 ml∙min-1. TES-deprotected product 
fractions were pooled and lyophilized to obtain a white fluffy solid of 19 (9.3 mg, 
4.34 μmol, overall yield: 67%, yield per step: 82%). aHPLC tR = 24.246, LCMS-ESI: 
tR = 18.78, average mass calculated [M+2H]2+: 959.17; found: 959.42. 
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Second CuAAC: TES-deprotected TAC scaffold (9.3 mg, 4.34 μmol, 1 equiv.) 
peptide loop 3 18 (7.14 mg, 5.21 μmol, 1.2 equiv.), TBTA (0.7 mg, 1.3 μmol, 
0.3 equiv.), aqueous 1 M CuSO4 (6.1 μL, 1.3 μmol, 0.3 equiv.) and aqueous 0.25 M 
sodium ascorbate (20.6 μL, 5.21 μmol, 1.2 equiv.) were added and the resulting 
mixture was stirred under nitrogen atmosphere until all the reactants were 
dissolved. Then degassed deionized H2O (155 μL) was added. The progress of the 
reaction was monitored by analytical HPLC and LCMS. After 4 h the reaction was 
complete, and solvents were removed by a nitrogen stream. The remaining residue 
was diluted with buffer A (900 μL) and the resulting solution was centrifuged 
(4500 rpm, 5 min) and purified using a gradient of 35-65% of buffer B into buffer 
A over 60 min at a flow rate of 12.5 ml∙min-1. The product containing fractions 
were pooled and lyophilized to obtain the scaffold derivative 20 with two peptides 
attached as a white fluffy solid (11.5 mg in 89% purity, 2.90 μmol, yield 68%). 
aHPLC tR = 21.787, LCMS-ESI: tR = 16.78, average mass calculated [M+3H]3+: 
1097.27; found: 1097.08. 
TIPS removal: TIPS-protected scaffold 20 × 2∙TFA (10.2 mg, 2.90 μmol) was 
dissolved in degassed DMF (300 μL) and 1M TBAF in THF (42 μL, 145 μmol, 
50 equiv.) was added. The reaction mixture was stirred under nitrogen 
atmosphere and monitored by analytical HPLC and LCMS. After 21 h the reaction 
was incomplete, hence another portion of 1 M TBAF in THF was added (21 μL, 
72.5 μmol, 25 equiv.). After a further 5 h the reaction was still incomplete, hence 
another portion of 1 M TBAF in THF was added (10 μL, 36.25 μmol, 12.5 equiv.). 
Reaction completion was confirmed after a further 3.5 h and DMF was removed 
with nitrogen stream. The remaining solid was diluted with buffer A (350 μL) and 
centrifuged (4500 rpm, 5 min). The resulting solution was purified using a gradient 
of 0-55% of buffer B into buffer A over 55 min at 12.5 ml min-1. The TIPS-
deprotected product was obtained as a white fluffy solid of 21 (5.8 mg, 1.73 μmol, 
60%) after lyophilization. aHPLC tR = 16.294, LCMS-ESI: tR = 11.16, average mass 
calculated [M+3H]3+: 1044.82; found: 1044.83. 
Third CuCAAC: TIPS-deprotected scaffold 21 (5.8 mg, 1.73 μmol, 1 equiv.), 
peptide loop 2 17 (3.21 mg, 1.73 μmol, 1 equiv.), TBTA (0.46 mg, 0.86 μmol, 
0.5 equiv.) were placed in a vial and dissolved in degassed DMF (300 μL) and 
stirred under nitrogen atmosphere until dissolved. Then, aqueous 1 M CuSO4 
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(0.9 μL, 0.9 μmol, 1.1 equiv.) and aqueous 0.25 M sodium ascorbate (10.2 μL, 
2.6 μmol, 1.5 equiv.) were added. Degassed deionized H2O was added up to 500 μL 
total volume. The reaction was run under nitrogen atmosphere and monitored by 
analytical HPLC and LCMS. After 4 h the reaction was considered complete and 
solvents were removed by a nitrogen stream. The remaining solid was diluted with 
500 μL of buffer A and the solution was centrifuged (4500 rpm, 5 min) and purified 
using a gradient of 0-40% of buffer B into buffer A over 40 min at a flow rate of 
12.5 mL∙min-1. The final compound 22 was obtained as a white fluffy solid after 
lyophilization (3.2 mg, 0.61 μmol, 35%, overall yield: 9%). aHPLC tR = 16.434, 
LCMS-ESI: tR = 11.64, average mass calculated [M+4H]4+: 1191.84; found: 1191.67. 
Average mass calculated [M+H]+: 4764.33, MALDI-TOF found: 4764.28. 
Synthesis gp 120 mimic 30: 
 
First CuAAC, TES-removal and second CuAAC were conducted in one pot as 
follows: 
Step 1, first CuAAC: TAC-scaffold 15 (7.88 mg, 10 μmol, 1 equiv.), peptide loop 3 
18 (14.7 mg, 10.7 μmol, 1.07 equiv.) and TBTA (2.7 mg, 5.0 μmol, 0.5 equiv.) 
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were placed in a flask and degassed DMF (300 μL) was added. The reaction was 
stirred under nitrogen atmosphere until all components were dissolved. Then, 
aqueous 1 M CuSO4 (5 μL, 5.0 μmol, 0.5 equiv.) and aqueous 0.25 M sodium 
ascorbate (60 μL, 15 mmol, 1.5 equiv.) were added. Degassed deionized H2O was 
added up to 500 μL of volume to the reaction mixture. The reaction mixture was 
stirred under nitrogen and monitored by analytical HPLC and LCMS. When reaction 
was complete (typically after 3.5 h) the subsequent deprotection step was 
started. 
Step 2, TES removal: AgNO3 (20.4 mg, 120 μmol, 12 equiv.) was added to the 
above mixture and stirred under a nitrogen atmosphere. Reaction progress was 
followed by analytical HPLC and LCMS, which showed complete conversion after 
1 h. Then, NaCl (7 mg, 120 μmol, 12 equiv.) was added in order to precipitate out 
Ag+ as AgCl. This suspension was used for the subsequent (second) CuAAC step. 
Step 3, second CuAAC: To the above suspension, peptide loop 1 16 (16.2 mg, 
10.7 μmol, 1.07 equiv.), TBTA (2.7 mg, 5.0 μmol, 0.5 equiv.), aqueous 1 M CuSO4 
(5 μL, 5.0 μmol, 0.5 equiv.) and aqueous 0.25 M sodium ascorbate (60 μL, 
15 mmol, 1.5 equiv.) were added. The resulting mixture was stirred under 
nitrogen atmosphere and monitored by analytical HPLC and LCMS. The reaction 
was stirred overnight, and solvents removed by a nitrogen stream. A red liquid 
residue was diluted with buffer A and the resulting solution was centrifuged 
(4500 rpm, 5 min) and purified using a gradient of 20-70% of buffer B into buffer 
A over 50 min at 12.5 ml∙min-1. The product containing fractions were pooled and 
lyophilized to obtain the scaffold derivative 28 with two peptides attached as a 
white fluffy solid (12.4 mg, 3.53 μmol, 71% per step, 36% over 3 steps). aHPLC tR 
= 21.484, LCMS-ESI: tR = 16.66, average mass calculated [M+3H]3+: 1097.27; found: 
1097.00. 
TIPS-removal: TIPS-protected scaffold 28 × 2∙TFA (12.4 mg, 3.53 μmol) and 
TBAF∙3H2O (44.55 mg, 141.2 μmol, 40 equiv.) were weighed out into a vial and 
dissolved in degassed DMF (1491 μL). The reaction mixture was stirred under 
nitrogen atmosphere and monitored by analytical HPLC and LCMS. After 2.5 h, 
when the reaction was complete, DMF was removed with nitrogen stream. The 
remaining solid was diluted with buffer A (520 μL) and centrifuged (4500 rpm, 
5 min). The resulting solution was purified using a gradient of 0-40% of buffer B 
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into buffer A over 40 min at 12.5 ml∙min-1. TIPS-deprotected product was obtained 
as a white fluffy solid of product 29 (7.4 mg, 2.20 μmol, 62%) after lyophilization. 
aHPLC tR = 15.616, LCMS-ESI: tR = 11.12 average mass calculated [M+3H]3+: 
1044.82; found: 1044.92. 
Third CuAAC: TIPS-deprotected scaffold 29 (8.4 mg, 2.50 μmol, 1 equiv.), peptide 
loop 2 17 (4.88 mg, 2.63 μmol, 1.05 equiv.), TBTA (1.32 mg, 2.5 μmol, 1 equiv.) 
were placed in a vial and dissolved in degassed DMF (300 μL) and stirred under 
nitrogen atmosphere until dissolved. Then, aqueous 1 M CuSO4 (2.5 μL, 2.5 μmol, 
1 equiv.) and aqueous 0.25 M sodium ascorbate (28.5 μL, 3.75 μmol, 1.5 equiv.) 
were added. Degassed deionized H2O was added up to 500 μL of volume of the 
reaction mixture. The reaction was run under nitrogen atmosphere and monitored 
by analytical HPLC and LCMS. The reaction was stirred for 19 h and solvents were 
removed by a nitrogen stream. The remaining solid was diluted with 300 μL of 
buffer A and the solution was centrifuged (4500 rpm, 5 min) and purified using a 
gradient of 18-38% of buffer B into buffer A over 40 min at a flow rate of 
10.0 mL∙min-1. The final gp120 mimic TAC-scaffold containing 3 loops 30 was 
obtained as a white fluffy solid after lyophilization (1.2 mg, 0.23 μmol, 9%). aHPLC 
tR = 16.436, LCMS-ESI: tR = 11.65, average mass calculated [M+4H]4+: 1191.84; 
found: 1191.67. Average mass calculated [M+H]+: 4764.3292, MALDI-TOF found: 
4764.82. 
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Synthesis gp120 mimic 26: 
 
First cycloaddition, TES-removal and second cycloaddition in one pot:  
Step 1, First CuAAC: TAC-scaffold 15 (4.83 mg, 6.13 μmol, 1 equiv.), peptide loop 
2 17 (11.4 mg, 6. 13 μmol, 1 equiv.) and TBTA (1.64 mg, 3.0 μmol, 0.5 equiv.) 
were placed in a flask and degassed DMF (300 μL) was added. The reaction was 
stirred under nitrogen atmosphere until all components were dissolved. Then, 
aqueous 1 M CuSO4 (3.1 μL, 3.0 μmol, 0.5 equiv.) and aqueous 0.25 M sodium 
ascorbate (36.4 μL, 9.2 mmol, 1.5 equiv.). The reaction mixture was stirred under 
nitrogen and monitored by analytical HPLC and LCMS. When reaction was 
complete (typically after 3 h) the subsequent deprotection step was started. 
Step 2, TES removal: AgNO3 (12.5 mg, 73.6 μmol, 12 equiv.) was added and the 
mixture was stirred under nitrogen atmosphere, and monitored by analytical HPLC 
and LCMS, which showed complete conversion after 1 h. Then, NaCl (4 mg, 
73.6 μmol, 12 equiv.) was added in order to precipitate out Ag+ as AgCl. This 
suspension was used for the subsequent second CuAAC step. 
Step 3, Second CuAAC: Peptide loop 1 16 (9.0 mg, 6.13 μmol, 1 equiv.), TBTA 
(3.28 mg, 6.13 μmol, 1 equiv.), aqueous 1 M CuSO4 (6.1 μL, 6.13 μmol, 1 equiv.) 
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and aqueous 0.25 M sodium ascorbate (72.8 μL, 18.4 μmol, 3 equiv.) were added 
and the resulting mixture was stirred under nitrogen atmosphere and monitored 
by analytical HPLC and LCMS. After 2 h the reaction was complete, and solvents 
removed by a nitrogen stream. A red liquid residue was diluted with buffer A and 
the resulting solution was centrifuged (4500 rpm, 5 min) and purified using a 
gradient of 30-60% of buffer B into buffer A over 40 min at 12.5 ml∙min-1. The 
product containing fractions were pooled and lyophilized to obtain the scaffold 
derivative 24 with two peptides attached as a white fluffy solid (5.4 mg, 
1.35 μmol, 60% per step, 22% over 3 steps). aHPLC tR = 21.165 (in crude reaction 
mixture), LCMS-ESI: tR = 16.26, average mass calculated [M+3H]3+: 1183.75; found: 
1183.58. 
Step 3, TIPS removal: TIPS-protected scaffold 24 × 4∙TFA (5.4 mg, 1.34 μmol) and 
TBAF∙3H2O (17 mg, 54 μmol, 40 equiv.) were weighed out into a vial and dissolved 
in degassed DMF (570 μL). The reaction mixture was stirred under nitrogen 
atmosphere and monitored by analytical HPLC and LCMS. After 4 h, when reaction 
was complete, DMF was removed with nitrogen stream. The remaining solid was 
diluted with buffer A (300 μL) and centrifuged (4500 rpm, 5 min). The resulting 
solution was purified using a gradient of 0-50% of buffer B into buffer A over 50 min 
at 12.5 ml∙min-1. TIPS-deprotected product 25 was obtained as a white fluffy solid 
(3.6 mg, 0.94 μmol, 69%) after lyophilization. aHPLC tR = 16.666, LCMS-ESI: tR = 
11.59, average mass calculated [M+3H]3+: 1131.23; found: 1131.50. 
Step 4, Third CuAAC: TIPS-deprotected scaffold 25 (3.6 mg, 0.94 μmol, 1 equiv.), 
peptide loop 3 18 (1.3 mg, 0.94 μmol, 1 equiv.), TBTA (0.5 mg, 0.94 μmol, 
1 equiv.) were placed in a vial and dissolved in degassed DMF (300 μL) and stirred 
under nitrogen atmosphere until dissolved. Then, aqueous 1 M CuSO4 (1 μL, 
1.1 μmol, 1.1 equiv.) and aqueous 0.25 M sodium ascorbate (16.6 μL, 4.2 μmol, 
4.5 equiv.) were added. Degassed deionized H2O was added up to 500 μL of volume 
of the reaction mixture. The reaction was run under nitrogen atmosphere and 
monitored by analytical HPLC and LCMS. After 2.5 h the reaction was considered 
complete and solvents were removed by a nitrogen stream. The remaining solid 
was diluted with 300 μL of buffer A and the solution was centrifuged (4500 rpm, 
5 min) and purified using a gradient of 0-40% of buffer B into buffer A over 40 min 
at a flow rate of 12.5 mL∙min-1. The final gp120 mimic TAC-scaffold containing 3 
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loops 26 was obtained as a white fluffy solid after lyophilization (3.4 mg, 
0.65 μmol, 69%). aHPLC tR = 16.423, LCMS-ESI: tR = 11.62, average mass calculated 
[M+4H]4+: 1191.84; found: 1191.67. Average mass calculated [M+H]+: 4764.33, 
MALDI-TOF found: 4764.82. 
Synthesis gp120 mimic 26 by reversed order of attachment of loop 1 and 3: 
First cycloaddition, TES-removal and second cycloaddition in one pot: TAC-
scaffold 15 (6.61 mg, 8.4 μmol, 1 equiv.equiv..), peptide loop 2 17 (15.6 mg, 8.4 
μmol, 1 equiv. and TBTA (1.0 mg, 4.2 μmol, 0.5 equiv.) were placed in a flask and 
degassed DMF (300 μL) was added. The reaction was stirred under nitrogen 
atmosphere until all components were dissolved. Then, aqueous 1 M CuSO4 (4.2 
μL, 4.2 μmol, 0.5 equiv.) and aqueous 0.25 M sodium ascorbate (50 μL, 12.6 mmol, 
1.5 equiv.). The reaction mixture was stirred under nitrogen and monitored by 
analytical HPLC and LCMS. When reaction was complete (typically after 2.5 h), 
AgNO3 (17.1 mg, 100.8 μmol, 12 equiv.) was added and the mixture was stirred 
under nitrogen atmosphere, and monitored by analytical HPLC and LCMS, which 
showed complete conversion after 1h. Then, NaCl (5.9 mg, 100.8 μmol, 12 equiv.) 
was added in order to precipitate out Ag+ as AgCl. Afterwards, peptide loop 3 18 
(11.5 mg, 8.4 μmol, 1 equiv.), TBTA (2.2 mg, 4.2 μmol, 1 equiv.), aqueous 1 M 
CuSO4 (4.2 μL, 4.2 μmol, 1 equiv.) and aqueous 0.25 M sodium ascorbate (50 μL, 
12.6 μmol, 1.5 equiv.) were added and the resulting mixture was stirred under 
nitrogen atmosphere and monitored by analytical HPLC and LCMS. After 4h 0.25 M 
sodium ascorbate was added (50 μL, 12.6 μmol, 1.5 equiv.). When reaction was 
not finished after next 5 h, another portion of 1 MCuSO4 (4.2 μL, 4.2 μmol, 0.5 
equiv.), TBTA (2.2 mg, 4.2 μmol, 0.5 equiv.) and 0.25 sodium ascorbate (125 μL, 
31.5 μmol, 3.8 equiv.) were added. The reaction was stirred further under 
nitrogen atmosphere, and after 2 h another portion of 0.25 M sodium ascorbate 
(50 μL, 12.6 μmol, 1.5 equiv.) was added. Then, after 1 h the reaction was 
complete and solvents removed by a nitrogen stream. A red liquid residue was 
diluted with buffer A (700 μL) and the resulting solution was centrifuged (4500 
rpm, 5 min) and purified using a gradient of 10-60% of buffer B into buffer A over 
50 min at a flow rate of 12.5 ml min-1. The product containing fractions were 
pooled and lyophilized to obtain the scaffold derivative 31 with two peptides 
attached as a white fluffy solid (3.65 mg, 0.94 μmol, 48% per step, 11.2% over 3 
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steps). tR = 22.036, LCMS-ESI: average mass calculated [M+3H]3+: 1225.5406; 
found: 1226.17. 
Removal of the TIPS-protecting group: TIPS-protected scaffold 31 × 4TFA (3.65 
mg, 0.94 μmol) and TBAF∙3H2O (11.9 mg, 37.6 μmol, 40 equiv.) were weighed out 
into a vial and dissolved in degassed DMF (125 μL, to obtain concentration of 95 
mM of TBAF∙3H2O in DMF). The reaction mixture was stirred under nitrogen 
atmosphere and monitored by analytical HPLC and LCMS. After 4 h, when reaction 
was complete, DMF was removed with nitrogen stream. The remaining solid was 
diluted with buffer A (160 μL) and centrifuged (4500 rpm, 5 min). The resulting 
solution was purified using a gradient of 0-40% over 40 min at a flow rate of 12.5 
ml min-1. TIPS-deprotected 32 product was obtained as a white fluffy solid (1.9 
mg, 0.51 μmol, 54%) after lyophilization. tR = 17.319, LCMS-ESI: average mass 
calculated [M+3H]3+: 1173.9883; found: 1174.00. 
Cycloaddition of the third peptide onto the scaffold: TIPS-deprotected scaffold 
32 (1.9 mg, 0.51 μmol, 1 equiv.), peptide loop 1 16 (0.8 mg, 0.51 μmol, 1 equiv.), 
TBTA (0.9 mg, 1.5 μmol, 3 equiv.) were placed in a vial and dissolved in degassed 
DMF (300 μL) and stirred under nitrogen atmosphere until dissolved. Then, 
aqueous 1 M CuSO4 (1.5 μL, 1.5 μmol, 3.0 equiv.) and aqueous 0.25 M sodium 
ascorbate (18.0 μL, 4.6 μmol, 9.0 equiv.) were added. Degassed deionized H2O 
was added up to 500 μL of volume of the reaction mixture. The reaction was run 
under nitrogen atmosphere and monitored by analytical HPLC and LCMS. After 4 h 
the reaction was considered complete and solvents were removed by a nitrogen 
stream. The remaining solid was diluted with 400 μL of buffer A and the solution 
was centrifuged (4500 rpm, 5 min) and purified using a gradient of 0-40% of buffer 
B into buffer A over 40 min at a flow rate of 12.5 mL min-1. The final gp120 mimic 
TAC-scaffold containing 3 loops 26 was obtained as a white fluffy solid after 
lyophilization (0.6 mg, 0.12 μmol, 22.5%). tR = 16.381, LCMS-ESI: average mass 
calculated [M+4H]4+: 1191.8395; found: 1191.75.
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Figure 97 Results of protein mass spectrometry of CD4D12. 
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Figure 98 HRMS of Tert-butyl 5-(triethylsilyl)-pent-4-ynoate. 
 
 
Figure 99 HRMS of Tert-butyl 5-(triisopropylsilyl)-pent-4-ynoate. 
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Figure 100 HRMS of 5-(triisopropylsilyl)-4-pentynoic acid. 
 
 
Figure 101 HRMS of 5-(triethylsilyl)-4-pentynoic acid. 
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Figure 102 MALDI-TOF of orthogonally protected trialkyne TAC-scaffold 15. 
 
Figure 103 HRMS of orthogonally protected TAC scaffold 15. 
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Figure 104 LCMS of orthogonally protected TAC scaffold 15. 
 
 
Figure 105 analytical HPLC of orthogonally protected TAC scaffold 15. 
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Figure 106 MALDI-TOF of loop 1. 
 
 
Figure 107 LCMS of loop 1. 
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Figure 108 analytical HPLC of loop 1. 
 
 
Figure 109 MALDI-TOF of loop 2. 
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Figure 110 LCMS of loop 2. 
 
 
Figure 111 analytical HPLC of loop 2. 
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Figure 112 MALDI-TOF of loop 3. 
 
 
Figure 113 LCMS of loop 3. 
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Figure 114 analytical HPLC of loop 3. 
 
 
Figure 115 LCMS of cycloaddition of the first loop in the synthesis of construct 22. 
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Figure 116 LCMS of TES removal to obtain product 19. 
 
 
Figure 117 analytical HPLC of purified compound 19. 
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Figure 118 LCMS Cycloaddition of the second loop to obtain product 20. 
 
 
Figure 119 analytical HPLC of purified compound 20. 
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Figure 120 LCMS of product 21 after TIPS removal. 
 
 
Figure 121 analytical HPLC of purified compound 21. 
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Figure 122 MALDI-TOF of compound 22. 
 
 
Figure 123 LCMS of compound 22. 
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Figure 124 analytical HPLC of purified compound 22. 
 
 
Figure 125 LCMS of cycloaddition of the first loop in synthesis of compound 30. 
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Figure 126 analytical HPLC of crude reaction mixture after cycloaddition of the first loop in the 
synthesis of compound 30. 
 
 
Figure 127 LCMS of TES removal to obtain compound 27. 
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Figure 128 LCMS of product 28 after cycloaddition of the second loop. 
 
 
Figure 129 analytical HPLC of purified product 28. 
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Figure 130 LCMS of product 29 after TIPS removal. 
 
 
Figure 131 analytical HPLC product 29 after TIPS removal. 
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Figure 132 MALDI-TOF of product 30. 
 
 
Figure 133 LCMS of product 30. 
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Figure 134 analytical HPLC of purified compound 30. 
 
 
Figure 135 LCMS after cycloaddition of first loop in the synthesis of compound 26. 
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Figure 136 analytical HPLC after cycloaddition of the first loop in the synthesis of compound 26. 
 
 
Figure 137 LCMS after TES removal to obtain compound 23. 
 
201 
 
 
Figure 138 analytical HPLC after TES removal to obtain compound 23. 
 
 
Figure 139 LCMS after cycloaddition of the second loop to obtain product 24. 
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Figure 140 analytical HPLC of crude reaction mixture to obtain product 24. 
 
 
Figure 141 LCMS of product 25 after TIPS removal. 
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Figure 142 analytical HPLC of purified compound 25 after TIPS removal. 
 
 
Figure 143 MALDI-TOF of product 26. 
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Figure 144 LCMS of product 26. 
 
 
Figure 145 analytical HPLC of purified compound 26. 
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Figure 146 analytical HPLC: attachment of loop 2 to the TAC scaffold in the synthesis of compound 
26 with reverse order of loops attachment. 
 
 
Figure 147 LCMS analysis of attachment of loop 2 to the TAC scaffold n the synthesis of compound 
26 with reversed order of loops attachment. 
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Figure 148 TES deprotection to obtain product 22 in the synthesis of compound 26 with reverse order 
of loops attachment. 
 
 
Figure 149 LCMS analysis of TES deprotection to obtain product 22 in the synthesis of compound 
26 with reverse order of loops attachment. 
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Figure 150 Progress of attachment of loop 3 (18) to compound 22 to obtain compound 31 in the 
synthesis of compound 26 with reverse order of loops attachment as analysed by analytical HPLC. 
 
 
Figure 151 analytical HPLC of purified compound 31 (in the synthesis of compound 26 with reverse 
order of loops attachment as analysed by analytical HPLC), which could not be separated from TBTA. 
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Figure 152 LCMS analysis of purified compound 31(in the synthesis of compound 26 with reverse 
order of loops attachment), which could not be separated from TBTA. 
 
 
Figure 153 Progress of TIPS removal from compound 31 to obtain compound 32 in the synthesis of 
26 with reverse order of loops attachment as analysed by analytical HPLC. 
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Figure 154 analytical HPLC of purified compound 32 (in the synthesis of compound 26 with reverse 
order of loops attachment as analysed by analytical HPLC). 
 
 
Figure 155 LCMS analysis of TIPS removal from compound 31 to obtain compound 32 in the 
synthesis of compound 26 with reverse order of loops attachment. Crude reaction mixture after 2h. 
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Figure 156 analytical HPLC of purified compound 26 in the synthesis with reversed order of loops 
attachment. 
 
 
Figure 157 LCMS analysis of purified compound 26 in the synthesis with reversed order of loops 
attachment. 
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Figure 158 analytical HPLC: attachment of loop 2 to TAC scaffold in an attempt of one-pot synthesis 
of gp120 mimic. 
 
 
Figure 159 analytical HPLC of TES deprotection to obtain compound 23 in an attempt of one-pot 
synthesis of gp120 mimic. 
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Figure 160 analytical HPLC of loop 1 attachment in the synthesis of compound 24 in an attempt of 
one-pot synthesis of gp120 mimic. 
 
 
Figure 161 1H-NMR analysis of linear peptide 1 with added TCEP. Water signal was suppressed. 
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Figure 162 1H-NMR analysis of linear peptide 2 with added TCEP. Water signal was suppressed. 
 
 
Figure 163 1H-NMR analysis of linear peptide 3 with added TCEP. Water signal was suppressed. 
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Figure 164 CD spectrum of linear peptide 1 with TCEP. 
 
 
Figure 165 CD spectrum of linear peptide 2 with TCEP. 
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Figure 166 CD spectrum of linear peptide 3 with TCEP. 
 
 
Figure 167 Replicate 2 of interaction of analyte CD4D12ex with immobilised ligand gp120 at 25C.  
The coloured lines depict the double-referenced sensograms obtained from duplicate injections of 
100, 50, 25, 12.5, 6.3 nM analyte CD4D12ex across 1000 RU immobilised ligand gp120. The ligand 
surface was regenerated with a 60 s injection of 10 mM glycine pH 1.75 between each binding cycle. 
The black lines depict the global fit of the data to a 1:1 Langmuir interaction model, yielding ka =2.69 
M-1∙s-1, kd = 1.22∙10-6∙s-1, Kd = 4.53∙10-7 M. 
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Figure 168 Replicate 2 of performed experiment to measure binding of mimic 22 to the immobilised 
CD4D12 at 25C.  
The coloured lines depict the double-referenced sensograms obtained from duplicate injections of 
100, 50, 25, 12.5, 6.25 μM analyte 22 across 1200 RU immobilised ligand CD4D12. The ligand 
surface was regenerated with two 30 s injections of 10 mM glycine pH 1.75 between each binding 
cycle. The black lines depict the global fit of the data to a 1:1 Langmuir interaction model, yielding ka 
= 2.04∙109 M-1∙s-1, kd = 3.45∙10-4∙s-1, Kd = 1.69∙10-13 M. 
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Figure 169 Replicate 2 of performed experiment to measure binding of mimic 26 to the immobilised 
CD4D12 at 25C.  
The coloured lines depict the double-referenced sensograms obtained from duplicate injections of 
100, 50, 25, 12.5, 6.25 μM analyte 26across 1200 RU immobilised ligand CD4D12. The ligand 
surface was regenerated with two 30 s injections of 10 mM glycine pH 1.75 between each binding 
cycle. The black lines depict the global fit of the data to a 1:1 Langmuir interaction model. 
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Figure 170 Replicate 2 of performed experiment to measure binding of mimic 30 to the immobilised 
CD4D12 at 25C.  
The coloured lines depict the double-referenced sensograms obtained from duplicate injections of 
100, 50, 25, 12.5, 6.25 μM analyte 30 across 1200 RU immobilised ligand CD4D12. The ligand 
surface was regenerated with two 30 s injections of 10 mM glycine pH 1.75 between each binding 
cycle. The black lines depict the global fit of the data to a 1:1 Langmuir interaction model. 
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Figure 171 Replicate 2 of performed experiment to measure binding of loop 1 to the immobilised 
CD4D12 at 25C.  
The coloured lines depict the double-referenced sensograms obtained from duplicate injections of 
100, 50, 25, 12.5, 6.25 μM analyte loop 1 across 1200 RU immobilised ligand CD4D12. The ligand 
surface was regenerated with two 30 s injections of 10 mM glycine pH 1.75 between each binding 
cycle. The black lines depict the global fit of the data to a 1:1 Langmuir interaction model. 
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Figure 172 Replicate 2 of performed experiment to measure binding of loop 2 to the immobilised 
CD4D12 at 25C.  
The coloured lines depict the double-referenced sensograms obtained from duplicate injections of 
100, 50, 25, 12.5, 6.25 μM analyte loop 2 across 1200 RU immobilised ligand CD4D12. The ligand 
surface was regenerated with two 30 s injections of 10 mM glycine pH 1.75 between each binding 
cycle. The black lines depict the global fit of the data to a 1:1 Langmuir interaction model, yielding ka 
= 507.0 M-1∙s-1, kd = 1.508∙10-3 s-1, Kd = 2.974-6 M. 
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Figure 173 Replicate 2 of performed experiment to measure binding of loop 3 to the immobilised 
CD4D12 at 25C. 
The coloured lines depict the double-referenced sensograms obtained from duplicate injections of 
100, 50, 25, 12.5, 6.25 μM analyte loop 3 across 1200 RU immobilised ligand CD4D12. The ligand 
surface was regenerated with two 30 s injections of 10 mM glycine pH 1.75 between each binding 
cycle. The black lines depict the global fit of the data to a 1:1 Langmuir interaction model. 
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